PMID,month,crossoverrho1,Country,notes,funding,CochraneID,origin_data,r1,r2,b1,b2,b3,b4,b5,b6,b7,b8,b9,b10,b11,b12,b13,b14,b15,b16,b17,b18,b19,b20,b21,b22,a1,a2,a3,a4,a5,a6,a7,a8,a9,a10,a11,a12,sample_size,Title,Authors,Citation,First_Author,Publication_Year,numb_authors,nGroups,P_onesided,pubmed,notes_SS,CochraneID1,CochraneID2,CochraneID3,Cochrane_title,Cochrane_Citation,Cochrane_first_author,Cochrane_Publication_Year,xT,sT,nT,xC,sC,nC,LnCVR,var_LnCVR,placebo,lncvrsigma,sigma_lncvr,endpoint,effect,var_effect,effectsigma,SD_Available
-1512,12,0,China,Funding: no details on funding,not reported,33210751,published data only,1,1,,,,,2,2,,0,2,,,,,,,2,2,,0,2,,,,,,,2,2,,2,2,,,,263,Clinical intervention in patients with IGR.,"Zhang A, Li P, Cao W, Wei A, Huang L.",Acta Academiae Medicinae Weifang 2007; 29(5): 394-7.,Zhang A,2007,5,5,1,0,Characteristics of included studies in Cochrane review does not report on number randomized;Zhang reports This study involved 263 patients…,33210751,,,Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Nov 19;11(11):CD013516. doi: 10.1002/14651858.CD013516.pub2.,Ipsen EØ,2020,6.08,1.59,52,6.02,1.27,56,0.215252475,0.0213634524,0,0,,dif,-0.39,0.0924715724,0,1
-1511,6,0,China,Funding: non-commercial funding: Science and Technology Project of Wuhan Municipal Health Bureau,non-commercial,33210751,published data only,1,1,,,,,2,2,,,,,,,,,,2,2,,,,,,,,,,1,1,,,,,,,67,Effects of pioglitazone on ambulatory pulse pressure index in patients with elderly essential hypertension and impaired glucose tolerance,"Wu Y, Wu T, Li X, Wang W, Zhang Q, Xiong H, Hong YE.",Journal of Clinical Cardiology 2013; 29(6): 443-5,Wu Y,2013,7,2,0.081634827,0,Characteristics of included studies in Cochrane review does not report on number randomized; Wu reports: (n=34) and(n=33),33210751,,,Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Nov 19;11(11):CD013516. doi: 10.1002/14651858.CD013516.pub2.,Ipsen EØ,2020,5.1,0.5,34,5.9,0.8,33,-0.324628083,0.0325639621,0,0,,dif,-0.9,0.0445110752,0,1
-1510,10,0,China,Funding: not reported,not reported,33210751,published data only,1,1,,,,,2,2,,,,,,,,,,2,2,,,,,,,,,,1,1,,,,,,,80,Intervention of pioglitazone in the development of pre-diabetes.,"Shi J,",Chinese Journal of Trauma and Disability Medicine 2014; 22(23): 117.,Shi J,2014,1,2,0.0234668087,0,Characteristics of included studies in Cochrane review does not report on number randomized: Shi reports (Google translate): 80 patients were selected from our internal medicine outpatient clinic,33210751,,,Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Nov 19;11(11):CD013516. doi: 10.1002/14651858.CD013516.pub2.,Ipsen EØ,2020,6.06,0.3,40,6.1,0.36,40,-0.175729683,0.0264468354,0,0,,dif,-0.06,0.009714125,0,1
-1509,12,0,China,Funding: not reported,not reported,33210751,published data only,1,1,,,,1,2,2,,0,,,,,,,1,2,2,,0,,,,,,,1,1,1,,1,,,,,60,Observation on the interventive effect of pioglitazone hydrochloride on the IGT population of diabetes mellitus,"Liang Z, Tang L.",Journal of Guangxi Medical University 2004; 21(2): 165-7.,Liang Z,2004,2,2,0.9739907162,0,Characteristics of included studies in Cochrane review does not report on number randomized; Liang reports: 60  cases of IGT,33210751,,,Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Nov 19;11(11):CD013516. doi: 10.1002/14651858.CD013516.pub2.,Ipsen EØ,2020,5.45,0.85,29,5.97,1.03,30,-0.100253932,0.0381626414,0,0,,dif,-0.44,0.0823779097,0,1
-1508,6,0,China,Funding: not specified,not reported,33210751,published data only,2,1,,,,,2,2,,0,,,,,,,,2,2,,0,,,,,,,,1,2,,1,,,,,150,The value of pioglitazone in the treatment of patients with impaired glucose tolerance,"Li Y,",The Journal of Medical Theory and Practice 2017; 30(11): 1609-11.,Li Y,2017,1,2,0.4733492633,0,Characteristics of included studies in Cochrane review does not report on number randomized; Li shows 150 patients in Table 2; so does Ipsen in analysis 3.16,33210751,,,Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Nov 19;11(11):CD013516. doi: 10.1002/14651858.CD013516.pub2.,Ipsen EØ,2020,5.02,0.43,75,6.79,0.45,75,0.2565390008,0.0138525273,0,0,,dif,-1.95,0.0110632641,0,1
-1507,12,0,China,Funding: not specified,not reported,33210751,published data only,1,1,,,,,2,2,,0,,,,,,,,2,2,,0,,,,,,,,1,1,,1,,,,,62,Results of intervention of subsidence of glucose tolerance by using rosiglitazone.,"Ke X, Tang L, Tan M, Huang Y.",China Tropical Medicine 2006; 6(9): 1622-31.,Ke X,2006,4,2,0.6597626935,0,Characteristics of included studies in Cochrane review does not report on number randomized; Ke in Table 1 reports 62 patients; so does Ipsen in analysis 3.16,33210751,,,Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Nov 19;11(11):CD013516. doi: 10.1002/14651858.CD013516.pub2.,Ipsen EØ,2020,5.56,0.75,30,5.79,0.98,32,-0.225688474,0.0359875986,0,0,,dif,-0.16,0.1010694207,0,1
-1506,12,0,China,Funding: not reported,not reported,33210751,published data only,1,1,,,,,,2,,,,,,,,,,,2,,,,,,,,,,,1,,,,,,,64,Effect of pioglitazone on carotid atherosclerosis in old-aged impaired glucose tolerance patients.,"Guo Y, Bao H, Li W, Su L, Zhang Q, Miao Y.",Chinese Pharmaceutical Journal 2010; 45(10): 764-7.,Guo Y,2010,6,2,0.0575598304,0,Characteristics of included studies in Cochrane review does not report on number randomized; Guo 2010 reports: in abstract ; 112 subjects were selected; Cochrane reports in forest plot (3.16) on 32 patients per group and so does table 2 in Guo 2010,33210751,,,Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Nov 19;11(11):CD013516. doi: 10.1002/14651858.CD013516.pub2.,Ipsen EØ,2020,5.65,0.85,32,6.04,0.97,32,-0.065261909,0.0348124729,0,0,,dif,-0.41,0.0870686332,0,1
-1505,6,0,China,Funding: not reported,not reported,33210751,published data only,1,1,,,,,,2,,,,,,,,,,,2,,,,,,,,,,,1,,,,,,,60,Effect of pioglitazone on endothelial function in elderly patients with impaired glucose tolerance.,"Guo Y, Li W, Bao H, Fan C, Zhang X.",Chinese Journal of New Drugs 2009; 18(24): 2323-6.,Guo Y,2009,5,2,0.123412584,0,Characteristics of included studies in Cochrane review does not report on number randomized; Guo2009 reports: in text - 30 subjects per group; same in Ipsen forest plot,33210751,,,Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Nov 19;11(11):CD013516. doi: 10.1002/14651858.CD013516.pub2.,Ipsen EØ,2020,5.65,1.02,30,6.16,0.98,30,0.1263052084,0.0376028103,0,0,,dif,-0.64,0.1056369501,0,1
-1504,12,0,China,Funding: non-commercial: Pudong New Area Health Bureau of Shanghai,non-commercial,33210751,published data only,1,1,2,,,,2,2,,0,2,,,2,,,,2,2,,0,2,,,1,,,,1,2,,1,1,,,,120,Efficacy and safety of pioglitazone for intervention therapy of impaired glucose regulation.,"Fang Q, Fang M, Yao Y, Feng S, Yang Y, Xue L, Xu G, Tang R, Yang Y",Journal of Clinical Research 2013; 30(2): 239-42.,Fang Q,2013,9,2,0.9999999999,0,"Characteristics of included studies in Cochrane review does not report on number randomized; Fang reports: totally, 120 patients were enrolled",33210751,,,Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Nov 19;11(11):CD013516. doi: 10.1002/14651858.CD013516.pub2.,Ipsen EØ,2020,6.04473,0.87812,55,6.20357,0.31722,56,1.0441256806,0.0191173924,0,1,6+,dif,-0.05551,0.0241570741,0,1
-1503,6,0,China,Funding: not specified,not reported,33210751,published data only,1,1,,,,,2,2,,,,,,,,,,2,2,,,,,,,,,,1,1,,,,,,,73,Clinical analysis of pioglitazone dispersible tablets in 38 patients with abnormal glucose tolerance in essential hypertension.,"Che C, Zhao Q.",Journal of Medical Theory and Practice 2014; 17: 2290-1.,CheC,2014,2,2,0.976103632,0,Characteristics of included studies in Cochrane review does not report on number randomized; Che reports (Google translate: 73 patients with hypertension and impaired glucose tolerance,33210751,,,Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Nov 19;11(11):CD013516. doi: 10.1002/14651858.CD013516.pub2.,Ipsen EØ,2020,5.4,0.37,38,5.88,0.47,35,-0.15523475,0.0293232695,0,0,,dif,-0.45,0.0162050137,0,1
-1502,3,0,Iran,Funding source: Not reported. Conflict of interests: Not reported,not reported,26545069,published data only,1,1,1,1,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,30,Effect of topical tetracycline gel with non surgical periodontal therapy on Hba1c and lipid profile in type 2 diabetic patients: a clinico-bioche,"Haerian Ardakani A, Asadi Y, Afkhami Ardakani M, Nooorelahi M, Sooratgar A.",Journal of Shahid Sadoughi University of Medical Sciences 2014; 22(4): 1387-95.,Haerian Ardakani,2014,5,2,0.1959373473,0,From Cochrane:Number randomised: 30; Number evaluated: 30,26545069,,,Treatment of periodontal disease for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2015 Nov 6;2015(11):CD004714. doi: 10.1002/14651858.CD004714.pub3.,Simpson TC,2015,6.15,0.43,15,6.12,0.28,15,0.4240124398,0.0769961309,0,0,,post,0.03,0.0175533333,0,1
-1501,12,0,Italy,COMMERCIAL FUNDING: No - NON-COMMERCIAL FUNDING: Yes - CNR Italy's National Research Council,non-commercial,20091571,published data only,1,2,0,,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,64,Frequency of hypoglycaemic and hyperglycaemicketotic episodes during conventional and subcutaneous continuous insulin infusion therapy in IDDM.,"Nosadini R,",Diabetes Nutrition and Metabolism 1988; 1988(1): 289-96.,Nosadini R.,1988,1,4,0.999999912,0,"From Cochrane: WHO PARTICIPATED: 64 participants were included in this study (25 female, 39 male), however the following groups are relevant to this review: MI (ICIT), CSII (CSII-fixed basal overnight insulin infusion rate (FBR) and CSII-higher programmable overnight insulin infusion rate (HOR)) there were 44 participants (16 female, 28 male).",20091571,,,Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2010 Jan 20;(1):CD005103. doi: 10.1002/14651858.CD005103.pub2.,Misso ML,2010,6.3,0.7,19,7.1,0.9,15,-0.139495064,0.0693080672,0,0,,post,-0.8,0.0797894737,0,1
-1500,8,0,Japan,Funding: commercial funding (Novo Nordisk),commercial,33166419,published and unpublished data,1,1,1,2,1,1,,0,,1,2,1,1,,0,,,,,,,,,,2,2,2,2,,2,,,,,,,363,Phase 3 clinical trial of insulin detemir for type 2 diabetes patients with insufficient blood sugar control in oral diabetes drug therapy.,"Kobayashi M, Iwamoto Y, Kaku K, Kawamori R, Tajima N.",Journal of the Japan Diabetes Society 2007; 50(9): 665-77.,Kobayashi M,2007,5,2,0.3109590677,0,"Characteristics of included studies in Cochrane review does not report on number randomized; Kobayashi reports: 371  type I and II diabetes randomized, 332 completed",33166419,,,(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Nov 9;11(11):CD005613. doi: 10.1002/14651858.CD005613.pub4.,Semlitsch T,2020,7.81,0.73,180,7.74,0.85,181,-0.161170526,0.0057172823,0,0,,dif,0.09,0.0058552149,0,1
-1450,2,0,China,(Non) commercial funding: not reported,not reported,23235661,published data only,1,1,1,1,1,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,48,Paroxetine for depression in diabetes: a randomized controlled trial.,"Xue H,",Zhongguo-xinli-weisheng-zazhi She 2004; 18(10): 735-7.,Xue H.,2004,1,2,0.204612211,0,Characteristics of included studies in Cochrane review does not report on number randomized; Xue reports: 48 patients with diabetes,23235661,,,Psychological and pharmacological interventions for depression in patients with diabetes mellitus and depression,Cochrane Database Syst Rev. 2012 Dec 12;12:CD008381. doi: 10.1002/14651858.CD008381.pub2.,Baumeister H,2012,8.3,1.1,24,8.6,1.6,24,-0.338831572,0.0475439919,1,0,,post,-0.3,0.1570833333,0,1
-1400,1,0,Japan,Funding: commercial funding (Novo Nordisk),commercial,33166419,published and unpublished data,1,1,1,2,,1,0,0,,1,2,,1,0,0,,,,,,,,,,2,2,,2,0,2,,,,,,,401,Phase 3 clinical trial of insulin detemir for patients with insulindependent diabetes during basal-bolus therapy – a study of efficacy and safety,"Kobayashi M, Iwamoto Y, Kaku K, Kawamori R, Tajima N.",Journal of the Japan Diabetes Society 2007; 50(9): 649-63.,Kobayashi M,2007,5,2,0.4555201492,0,"Characteristics of included studies in Cochrane review does not report on number randomized; Kobayashi reports: 401 type I and II diabetes randomized, 371 completed;  Cochrane only included Type II diabetics in study which is 67 and 35 in the groups; Analysis 2.14 in Cochrane reports shows those sample sizes.",33166419,,,(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Nov 9;11(11):CD005613. doi: 10.1002/14651858.CD005613.pub4.,Semlitsch T,2020,7.45,1.02,67,7.26,0.99,35,-0.002985611,0.0236401949,0,0,,dif,0.11,0.0491909168,0,1
-1300,3,0,China,(Non) commercial funding: not reported,not reported,23235661,published data only,1,1,0,1,0,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,59,Effect of health education and psychosocial intervention on depression in patients with type 2 diabetes.,"Huang X, Song L, Li T.",Zhongguo-xinli-weisheng-zazhi She 2002; 16(3): 149-51.,Huang X,2002,3,2,1,0,Characteristics of included studies in Cochrane review does not report on number randomized; Huang reports: randomly divided into an intervention group(30) and a control group (29),23235661,,,Psychological and pharmacological interventions for depression in patients with diabetes mellitus and depression,Cochrane Database Syst Rev. 2012 Dec 12;12:CD008381. doi: 10.1002/14651858.CD008381.pub2.,Baumeister H,2012,6.5,2.3,30,8.5,1.8,29,0.5114570735,0.0420606374,0,1,3,post,-2,0.2880574713,1,1
-1234,12,0,Pakistan,Funding: not reported,not reported,32501595,published data only,1,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,204,Monotherapy with metformin or glimepiride and changes in serum sialic acid in type 2 diabetes mellitus.,"Rahman I, Malik S, Bashir M, Khan R, Idrees M.",British Journal of Diabetes & Vascular Disease 2011; 11: 137-40,Rahman I,2011,5,2,0.0215163199,0,Characteristics of included studies in Cochrane review does not report on number randomized;Rahman reports: were assigned to 12 months of monotherapy with metformin (n=102) or glibenclamide (n=102) t,32501595,,,Metformin monotherapy for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Jun 5;6(6):CD012906. doi: 10.1002/14651858.CD012906.pub2.,Gnesin F,2020,8.3,1.8,102,8.5,1.8,102,0.0237999271,0.0108999657,0,0,,post,-0.2,0.0635294118,0,1
-1200,6,0,Japan,Funding: commercial (Novo Nordisk),commercial,27362975,published data only,1,1,0,0,1,1,,,,,,,,,,,,,,,,,,,0,0,,,,,,,,,,,205,Comparison between insulin aspart and soluble human insulin in type 1 diabetes (IDDM) patients treated with basalbolus insulin therapy - Phase II,"Iwamoto Y, Akanuma Y, Niimi H, Sasaki N, Tajima N.",Journal of the Japan Diabetes Society 2001; 44(10): 799-811.,Iwamoto Y,2001,5,2,0.0653507592,0,Characteristics of included studies in Cochrane review does not report on number randomized; From Iwamoto - Figure 211 randomized - 208 analyzed,27362975,,,Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus,Cochrane Database Syst Rev. 2016 Jun 30;2016(6):CD012161. doi: 10.1002/14651858.CD012161.,Fullerton B,2016,7.36,1.12,135,7.6,1.08,61,0.0639337262,0.0127340611,0,0,,post,-0.24,0.0284131633,0,1
-1100,6,0,Japan,Funding: commercial funding (Sanofi),commercial,33166419,published and unpublished data,2,1,1,2,,1,,0,,1,2,,1,,0,,,,,,,,,,2,2,,0,,2,,,,,,,275,Efficacy and safety of insulin glargine in concurrent use with oral hypoglycemic agents for the treatment of type 2 diabetes patients.,"Kawamori R, Iwamoto Y, Kadowaki T, Iwasaki M.",Rinshoiyaku 2003; 19(5): 445-64.,Kawamori R,2003,4,2,0.4693352176,0,Characteristics of included studies in Cochrane review does not report on number randomized; 275 patient in forest plot 1.15,33166419,,,(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Nov 9;11(11):CD005613. doi: 10.1002/14651858.CD005613.pub4.,Semlitsch T,2020,7.97,1.02,141,8.06,1.05,134,-0.017941199,0.0076274299,0,0,,dif,-0.05,0.0123138933,0,1
-1001,3,0,China,Funding source: 11th 5-year National Science and Technology Support Project (2007BAI18B02),non-commercial,35420698,published data only,1,2,0,0,2,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,71,Scaling and root planing with enhanced root planing on healthcare for type 2 diabetes mellitus: A randomized controlled clinical trial.,"Zhang H, Li C, Shang S, Luo Z.",Journal of Dental Sciences 2013; 8(3): 272-80.,Zhang H,2013,4,2,0.4654534901,0,"From Cochrane:Number randomised: 75; Gp A n = 50, Gp B n = 25; Number evaluated: 72 at 3 mths, 71 at 6 mths",26545069,35420698,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,7.54,1.13,49,7.42,0.99,22,0.1030073857,0.0368449659,0,0,,post,0.12,0.0706091837,0,1
-1001,6,0,China,Funding source: 11th 5-year National Science and Technology Support Project (2007BAI18B02),non-commercial,35420698,published data only,1,2,0,0,2,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,71,Scaling and root planing with enhanced root planing on healthcare for type 2 diabetes mellitus: A randomized controlled clinical trial.,"Zhang H, Li C, Shang S, Luo Z.",Journal of Dental Sciences 2013; 8(3): 272-80.,Zhang H,2013,4,2,0.4654534901,0,"From Cochrane:Number randomised: 75; Gp A n = 50, Gp B n = 25; Number evaluated: 72 at 3 mths, 71 at 6 mths",26545069,35420698,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,7.51,1.31,49,7.42,0.99,22,0.2547223103,0.0370076459,0,0,,post,0.09,0.079572449,0,1
-104,3,0,Brazil,Funding source: none declared,not reported,35420698,published data only,1,1,0,0,0,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,26,Effect of periodontal therapy on serum osteocalcin levels in patients with type 2 diabetes and severe chronic periodontitis [Thesis] [Efeito do t,"Rodrigues R,",www.bdtd.uerj.br:8443/bitstream/1/14058/1/.,Rodrigues R.,2015,1,2,0.9999636982,0,From Cochrane:Number randomised: 26; Number evaluated: 26 at 3 mths (13/13),35420698,,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,6.846,1.242,13,8.008,2.671,13,-0.605940496,0.1014070652,0,0,,post,-1.162,0.6674465385,0,1
-103,4,0,Chile,Funding source: not reported,not reported,35420698,published and unpublished data,1,1,0,0,1,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,24,Evaluation of influence of conventional therapy in diabetics type 2.,"Calbacho V, Carrasco E, Wilckens M, Barboza P, Grant C, Aguirre M.",Journal of Dental Research 2004; 84: (Spec Issue B Chilean section):65739.,Calbacho V,2004,6,2,0.8814297154,0,From Cochrane:Number randomised: 24 (12 per gp); Number evaluated: 24,26545069,35420698,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,9.6,3.2,12,10.6,2.2,12,0.4709495486,0.112071775,0,0,,post,-1,1.2566666667,0,1
-102,3,0,India,Funding source: unknown,not reported,35420698,published and unpublished data,1,1,0,0,1,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,50,Effect of noninvasive periodontal therapy on glycaemic control in type 2 diabetes mellitus patients - a randomized control trial.,"Kothiwale S, Kothiwale V, Bhargava P.",Diabetes 2013; 62: Suppl 1):Abstract No A229,Kothiwale S,2013,3,2,0.2168882938,0,"From Cochrane:Number randomised: 50 (Gp A 25, Gp B 25) ; Number evaluated: not reported",26545069,35420698,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,7.53,0.4,25,7.97,0.64,25,-0.413141649,0.0437736213,0,0,,post,-0.44,0.022784,0,1
-101,3,0,Slovenia,Funding source: Slovenian Human Resources Development and Scholarship Fund (SHRDSF) for scholarship for Dr Dashnor Bukleta,non-commercial,35420698,published data only,1,1,0,0,0,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,100,Impact of combined non-surgical and surgical periodontal treatment in patients with type 2 diabetes mellitus - a preliminary report randomized cl,"Bukleta D, Krasniqi S, Beretta G, Daci A, Nila A, Komoni T.",Biomedical Research 2018; 29(3): 633-9,"Bukleta D,",2018,6,2,0.9761014523,0,From Cochrane:Number randomised: 100 diabetic participants;Number evaluated: 100 (50 in each gp) at 3 mths,35420698,,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,8.03,1.67,50,7.69,2.09,50,-0.267298048,0.0231684571,0,0,,post,0.34,0.14314,0,1
-100,3,0,Brazil,Funding source: none declared,not reported,35420698,published data only,1,1,0,0,0,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,41,"Effect of non-surgical periodontal treatment on glycemic control, inflammatory mediators and adipokines in patients with type 2 diabetes and seve","Felipe M,",pesquisa.bvsalud.org/portal/resource/pt/biblio-910208.,Felipe M.,2015,1,2,0.9999999992,0,"From Cochrane: Number randomised: 41 (initially 42 (21 per group), but 1 participant did not attend baseline exam and was excluded from study)",35420698,,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,6.7294118,1.7272683,17,7.2052632,2.3181587,19,-0.221649548,0.0718698105,0,0,,post,-0.4758514,0.458332123,0,1
-66,6,0,Spain,Funding: commercial funding (Novo Nordisk),commercial,33166419,published data only,1,1,1,2,1,1,,0,,1,2,1,1,,0,,,,,,,,,,2,2,2,2,,2,,,,,,,59,"A multi-centre, open-labelled, randomised, two-group parallel trial comparing the change in fat distribution in overweight and obese subjects wit","NN304-3614 Novo Nordisk A/S,",http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&studyid=1461&filename=3614-ctrsy,NN304-3614,2008,,2,0.9421900792,0,Characteristics of included studies in Cochrane review does not report on number randomized; 54 patients in forest plot 2.14 Cochrane report,33166419,,,(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Nov 9;11(11):CD005613. doi: 10.1002/14651858.CD005613.pub4.,Semlitsch T,2020,,,,,,,,,0,,,dif,-0.13,0.0804758523,0,0
-57,3,0,USA,Funding source: Biomedical Development Corporation (manufacturer of an iodine mouthrinse product: www.biodevcorp.com/products/icleanmouths/); Methodist Healthcare Ministries of South Texas; Foundation Of Collaborative Unique Science (FOCUS).Conflict of interests: Unknown,both,26545069,published and unpublished data,2,1,2,1,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,30,Exploratory study of iocide oral rinse in a diabetic population (diabetes).,"NCT00801164,",clinicaltrials.gov/show/NCT00801164.,NCT00801164,2012,,2,0.9608413024,0,From Cochrane:Number randomised: 30; Number evaluated: 27,26545069,,,Treatment of periodontal disease for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2015 Nov 6;2015(11):CD004714. doi: 10.1002/14651858.CD004714.pub3.,Simpson TC,2015,8.714,0.468,14,8.662,0.486,13,-0.046912678,0.0870072415,0,0,,post,0.052,0.0338134945,0,1
-57,6,0,USA,Funding source: Biomedical Development Corporation (manufacturer of an iodine mouthrinse product: www.biodevcorp.com/products/icleanmouths/); Methodist Healthcare Ministries of South Texas; Foundation Of Collaborative Unique Science (FOCUS).Conflict of interests: Unknown,both,26545069,published and unpublished data,2,1,2,1,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,30,Exploratory study of iocide oral rinse in a diabetic population (diabetes).,"NCT00801164,",clinicaltrials.gov/show/NCT00801164.,NCT00801164,2012,,2,0.9608413024,0,From Cochrane:Number randomised: 30; Number evaluated: 27,26545069,,,Treatment of periodontal disease for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2015 Nov 6;2015(11):CD004714. doi: 10.1002/14651858.CD004714.pub3.,Simpson TC,2015,9.136,0.468,14,8.8,0.485,13,-0.076333545,0.0869801423,0,0,,post,0.336,0.0337388022,0,1
-55,6,0,USA,Funding: commercial funding (Novo Nordisk),commercial,33166419,published and unpublished data,2,2,1,2,1,2,,0,,1,2,1,2,,0,,,,,,,,,,2,2,2,2,,2,,,,,,,467,"Cologne:Institute for Quality and Efficiency in Health Care (IQWiG), 2009.","NN304-1337. Institute for Quality and Efficiency in Health Care (IQWiG). Longacting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports Commission No. A05-03),",Listed as another study identifier under https://www.clinicaltrials.gov/study/NCT00700830,NN304-1337,2009,,2,0.5964510397,0,Characteristics of included studies in Cochrane review does not report on number randomized; 467 patients in forest plot 2.14 in Cochrane report,33166419,,,(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Nov 9;11(11):CD005613. doi: 10.1002/14651858.CD005613.pub4.,Semlitsch T,2020,8.5,1.3,290,8,1.2,144,0.0176894819,0.005493969,0,0,,dif,0.6,0.0178666667,0,1
-1,6,0,USA,Funding: non-commercial funding (US NIH grant U54RR014616),non-commercial,33166419,published data only,1,1,1,2,,1,,0,,1,2,,1,,0,,,,,,,,,,0,0,,0,,0,,,,,,,24,The utility of insulin glargine (Lantus) compared to NPH in ethnic minority type 2 diabetic subjects on combination insulin-oral agent therapy.,"NCT00687453,",clinicaltrials.gov/ct2/show/NCT00687453.,NCT00687453,2008,,2,0.4326202162,0,Characteristics of included studies in Cochrane review does not report on number randomized; 24 patients in cochrane report analysis 1.15,33166419,,,(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Nov 9;11(11):CD005613. doi: 10.1002/14651858.CD005613.pub4.,Semlitsch T,2020,,,,,,,,,0,,,dif,0.2,0.1844055944,0,0
1,12,0,Multi-countr,Funding: commercial (Eli Lilly),commercial,27362975,published and unpublished data,2,2,0,0,1,1,,,,,,,,,,,,,,,,,,,2,2,,,,,,,,,,,98,Kurzwirksame Ins+F9ulinanaloga zur Behandlung des Diabetes mellitus Typ 1,"Z015,",IQWiG-Berichte - Jahr: 2007 Nr. 22,Z015,1996,,2,0.537005,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Garg reports: in 39 subjects (20 females, 19 males) with Type 1 diabetes (PMID =1)- Garg included in Z015 - n=98 in IQWig report",27362975,,,Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus,Cochrane Database Syst Rev. 2016 Jun 30;2016(6):CD012161. doi: 10.1002/14651858.CD012161.,Fullerton B,2016,7.77,2.24,50,7.84,2.35,46,-0.039732325,0.0253890403,0,0,,post,-0.07,0.2204063478,0,1
1936479,24,0,Germany,Funding: not reported,not reported,32501595,published data only,1,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100,Prospective randomized two-years clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes,"Teupe B, Bergis K.",Diabete Metab. 1991 May;17(1 Pt 2):213-7.,Teupe B,1991,2,2,0.7251840519,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Teuper reports: After a 2 weeks hospital treatment with a strong dietary regime 100 patients not sufficiently controlled (blood glucose fasting 120-180, pp 180-250 mg/100 ml), were randomly allocated",32501595,,,Metformin monotherapy for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Jun 5;6(6):CD012906. doi: 10.1002/14651858.CD012906.pub2.,Gnesin F,2020,8.1,1.7,25,8,1.2,29,0.3383673325,0.0427359286,0,0,,post,0.1,0.1652551724,0,1
2170088,6,0,USA,Funding: the Veterans Administration Health Services Research and Development Service and additionalfunds from the A.W. Mellon Foundation,non-commercial,22258959,published data only,2,1,0,0,1,,,,,,,,,,,,,,,,,,,,2,0,,,,,,,,,,,54,Impact of glucose self-monitoring on non-insulin-treated patients with type II diabetes mellitus. Randomized controlled trial comparing blood and,"Allen BT, DeLong ER, Feussner JR.",Diabetes Care. 1990 Oct;13(10):1044-50. doi: 10.2337/diacare.13.10.1044.,Allen BT,1990,3,2,0.2102303819,1,From Cochrane:Number of participants: 54,22258959,,,Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin,Cochrane Database Syst Rev. 2012 Jan 18;1:CD005060. doi: 10.1002/14651858.CD005060.pub3.,Malanda UL,2012,10.4,2.9,27,9.7,2.6,27,0.0394099441,0.0454893037,0,0,,dif,0,0.6414814815,0,1
2499443,3,0.03,Australia,Funding source: none,not reported,27640062,published data only,1,1,,2,,2,2,,1,,1,1,,,,,,,,,,,,,,2,,2,2,,,,,,,,31,Effects of combined insulin-sulfonylurea therapy in type II patients,"Lewitt MS, Yu VK, Rennie GC, Carter JN, Marel GM, Yue DK, Hooper MJ.",Diabetes Care. 1989 Jun;12(6):379-83. doi: 10.2337/diacare.12.6.379.,Lewitt MS,1989,7,2,,1,Characteristics of included studies in Cochrane review does not report on number randomized; Lewitt reports: Glyburide (15 mg/day) or placebo was added to the treatment regimen of 31 insulin-treated type II (noninsulin- dependent) diabetic subjects.,27640062,,,Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control,Cochrane Database Syst Rev. 2016 Sep 18;9(9):CD006992. doi: 10.1002/14651858.CD006992.pub2.,Vos RC,2016,9.1,1.3,31,10.3,1.6,31,-0.083709846,0.021911041,0,0,,dif,-1.2,0.120523871,0,1
2630378,6.01,0,France,"Funding: Ames Division, Miles Laboratories",commercial,22258959,published data only,1,1,0,0,1,,,,,,,,,,,,,,,,,,,,0,0,,,,,,,,,,,208,Is glucose self-monitoring beneficial in non-insulin-treated diabetic patients? Results of a randomized comparative trial,"Fontbonne A, Billault B, Acosta M, Percheron C, Varenne P, Besse A, Eschwege E, Monnier L, Slama G, Passa P.",Diabete Metab. 1989 Sep-Oct;15(5):255-60.,Fontbonne A,1989,10,3,0.2710769567,1,From Cochrane:Number of participants: 208,22258959,,,Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin,Cochrane Database Syst Rev. 2012 Jan 18;1:CD005060. doi: 10.1002/14651858.CD005060.pub3.,Malanda UL,2012,,,,,,,,,0,,,dif,-0.23,0.1737171296,0,0
2630378,6.02,0,France,"Funding: Ames Division, Miles Laboratories",commercial,22258959,published data only,1,1,0,0,1,,,,,,,,,,,,,,,,,,,,0,0,,,,,,,,,,,208,Is glucose self-monitoring beneficial in non-insulin-treated diabetic patients? Results of a randomized comparative trial,"Fontbonne A, Billault B, Acosta M, Percheron C, Varenne P, Besse A, Eschwege E, Monnier L, Slama G, Passa P.",Diabete Metab. 1989 Sep-Oct;15(5):255-60.,Fontbonne A,1989,10,3,0.2710769567,1,From Cochrane:Number of participants: 208,22258959,,,Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin,Cochrane Database Syst Rev. 2012 Jan 18;1:CD005060. doi: 10.1002/14651858.CD005060.pub3.,Malanda UL,2012,,,,,,,,,0,,,dif,0.14,0.1280060185,0,0
2651031,6,0.86728,Denmark,COMMERCIAL FUNDING: Not reported NON-COMMERCIAL FUNDING: Not reported,not reported,20091571,published data only,1,1,0,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,10,Effect of pump versus pen treatment on glycaemic control and kidney function in long-term uncomplicated insulin-dependent diabetes mellitus (IDDM,"Schmitz A, Christiansen JS, Christensen CK, Hermansen K, Mogensen CE.",Dan Med Bull. 1989 Apr;36(2):176-8.,Schmitz A,1989,5,2,,1,"From Cochrane: WHO PARTICIPATED: Ten participants were included in this study. The participants were randomised to either CSII or MI for six months, after which they were crossed over for another six months serving as their own control. All participants completed the study.",20091571,,,Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2010 Jan 20;(1):CD005103. doi: 10.1002/14651858.CD005103.pub2.,Misso ML,2010,7,1,10,7.7,1,10,0.0951330842,0.0726122074,0,0,,post,-0.7,0.026544,0,1
2964981,5,0.68,Denmark,COMMERCIAL FUNDING: Yes - NON-COMMERCIAL FUNDING: No,commercial,20091571,published data only,1,1,0,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,21,Comparison of continuous subcutaneous insulin infusion with multiple insulin injections using the NovoPen,"Saurbrey N, Arnold-Larsen S, Møller-Jensen B, Kühl C.",Diabet Med. 1988 Mar;5(2):150-3. doi: 10.1111/j.1464-5491.1988.tb00962.x.,Saurbrey N,1988,4,2,,1,"From Cochrane: WHO PARTICIPATED: 21 participants were included in this study. Of the 21 participants randomised, 19 completed the study (13 in CSII and 6 in MI) (8 female, 11 male).",20091571,,,Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2010 Jan 20;(1):CD005103. doi: 10.1002/14651858.CD005103.pub2.,Misso ML,2010,7.6,0.87,19,7.6,0.87,19,0,0.0361073124,0,0,,post,0,0.0254955789,0,1
3106656,4,0.03,USA,"Funding source: Upjohn, NIH",both,27640062,published data only,1,1,,2,,2,2,,1,,1,1,,,,,,,,,,,,,,2,,2,2,,,,,,,,16,"Addition of sulfonylurea to insulin treatment in poorly controlled type II diabetes. A double-blind, randomized clinical trial","Schade DS, Mitchell WJ, Griego G.",JAMA. 1987 May 8;257(18):2441-5.,Schade DS,1987,3,2,,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Schade reports: A randomized, double-blind, crossover experimental design was utilized in 16 type II diabetic patients for a period of eight months.",27640062,,,Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control,Cochrane Database Syst Rev. 2016 Sep 18;9(9):CD006992. doi: 10.1002/14651858.CD006992.pub2.,Vos RC,2016,10.2,1.936491,15,10.9,1.161895,15,0.5763776443,0.0472557223,0,1,3,dif,-0.7,0.3491190667,0,1
3133266,4,0.03,Finland,"Funding source: Sigrid Juselius Foundation, Finnish Medical Association, Signe and Ane Gyllenberg foundation",non-commercial,27640062,published data only,2,1,,2,,2,2,,1,,1,1,,,,,,,,,,,,,,2,,2,2,,,,,,,,15,Effects of the combination of insulin and glibenclamide in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral hypogl,"Stenman S, Groop PH, Saloranta C, Tötterman KJ, Fyhrqvist F, Groop L.",Diabetologia. 1988 Apr;31(4):206-13. doi: 10.1007/BF00290586.,Stenman S,1988,6,2,,1,Characteristics of included studies in Cochrane review does not report on number randomized; Stenman reports: The effects of combined insulin and Sulfonylureatherapy on glycaemic control and B-cell functionwas studied in 15 Type 2 (non-insulin-dependent) diabetic patients who had failed on treatment with oral hypoglycaemic agents.,27640062,,,Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control,Cochrane Database Syst Rev. 2016 Sep 18;9(9):CD006992. doi: 10.1002/14651858.CD006992.pub2.,Vos RC,2016,8.3,0.77,15,9.1,1.16,15,-0.317511111,0.0464252725,0,0,,dif,-0.8,0.1057450667,0,1
3141099,12,0,USA,Funding source: Upjohn Company and an intramural grant from Texas Tech Health Sciences Center,both,27640062,published data only,1,1,,0,,2,0,,1,,1,1,,,,,,,,,,,,,,2,,2,2,,,,,,,,63,"Insulin-glyburide combination therapy for non-insulin-dependent diabetes mellitus: a long-term double-blind, placebo-controlled trial","Casner PR,C231",Clin Pharmacol Ther. 1988 Nov;44(5):594-603. doi: 10.1038/clpt.1988.199.,Casner PR,1988,2,2,0.1795388317,1,Characteristics of included studies in Cochrane review does not report on number randomized; Casner reports :Sixty-four patients with non-insulin-dependent diabetes mellitus were treated,27640062,,,Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control,Cochrane Database Syst Rev. 2016 Sep 18;9(9):CD006992. doi: 10.1002/14651858.CD006992.pub2.,Vos RC,2016,12.93,2.23,22,14.41,2.67,18,-0.077029275,0.0593472669,0,0,,dif,-0.95,0.7545636364,0,1
3289293,48,0,Norway,"COMMERCIAL FUNDING: Yes - Nordisk Gentofte, Boehringer Mannheim - NON-COMMERCIAL FUNDING: Yes - Norwegian Council for Science and the Humanities, Norwegian Diabetes Association, Norwegian Council on Cardiovascular Disease, University of Oslo, Jahres Medical Foundation.",both,20091571,published data only,2,1,0,,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,43,Reduction of urinary albumin excretion after 4 years of continuous subcutaneous insulin infusion in insulin-dependent diabetes mellitus. The Oslo,"Dahl-Jørgensen K, Hanssen KF, Kierulf P, Bjøro T, Sandvik L, Aagenaes O.",Acta Endocrinol (Copenh). 1988 Jan;117(1):19-25. doi: 10.1530/acta.0.1170019.,Dahl-Jørgensen K,1988,6,3,0.5505580985,1,"From Cochrane: WHO PARTICIPATED: 15 participants randomised to CSII and 15 randomised to MI. It is unclear how many participants completed the study.from Dahl:""45 patients agreed to participate."" ""comparing continuous sc insulin infusion (CSII), multiple insulin injections, and conventional treatment with twice daily injections"".  First variable in baseline (Mean 24-h urinary albumin excretion) is on 43 patients",20091571,,,Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2010 Jan 20;(1):CD005103. doi: 10.1002/14651858.CD005103.pub2.,Misso ML,2010,9,1.44,13,9.4,1.55,15,-0.02425261,0.0871896679,0,0,,post,-0.4,0.319674359,0,1
3545931,12,0,Italy,Funding source: none,not reported,27640062,published data only,2,1,,1,,1,1,,1,,1,1,,,,,,,,,,,,,,2,,2,2,,,,,,,,30,Combined insulin and sulfonylurea therapy in non-insulin-dependent diabetics with secondary failure to oral drugs: a one year follow-up,"Quatraro A, Consoli G, Ceriello A, Giugliano D.",Diabete Metab. 1986 Dec;12(6):315-8.,Quatraro A,1986,4,2,0.0347529873,1,"Characteristics of included studies in Cochrane review does not report on number randomized; quatraro reports: The remaining 30 diabetics who had little or no improvementin their control entered the study.They were allocated at random into two groups, each consisting of 15subjects;",27640062,,,Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control,Cochrane Database Syst Rev. 2016 Sep 18;9(9):CD006992. doi: 10.1002/14651858.CD006992.pub2.,Vos RC,2016,9,1.16,15,11.5,1.55,15,-0.044660668,0.0788505387,0,0,,dif,-2.9,0.4295066667,1,1
3605188,3,0.03,USA,"Funding source: NIH, Abe Goodman Fund for Diabetes Research, Eli Lilly, Upjohn Company",both,27640062,published data only,1,1,,1,,1,1,,1,,1,1,,,,,,,,,,,,,,2,,2,2,,,,,,,,12,Combined therapy of insulin and tolazamide decreases insulin requirement and serum triglycerides in obese patients with noninsulin-dependent diab,"Kitabchi AE, Soria AG, Radparvar A, Lawson-Grant V.",Am J Med Sci. 1987 Jul;294(1):10-4. doi: 10.1097/00000441-198707000-00002.,Kitabchi AE,1987,4,2,,1,Characteristics of included studies in Cochrane review does not report on number randomized; Kibayashi reports: 12 obese patients,27640062,,,Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control,Cochrane Database Syst Rev. 2016 Sep 18;9(9):CD006992. doi: 10.1002/14651858.CD006992.pub2.,Vos RC,2016,8.8,1.42,12,9.2,1.91,12,-0.251283643,0.0605934016,0,0,,dif,-0.4,0.8601793333,0,1
3884404,12,0,Italy,Funding source: government,non-commercial,28594069,published data only,1,1,1,1,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,10,Effect of long-term near-normoglycemia on the progression of diabetic nephropathy,"Ciavarella A, Vannini P, Flammini M, Bacci L, Forlani G, Borgnino LC.",Diabete Metab. 1985 Feb;11(1):3-8.,Ciavarella A,1985,6,2,0.0553260536,1,From Cochrane:Number: treatment group (5); control group (5),28594069,,,Glucose targets for preventing diabetic kidney disease and its progression,Cochrane Database Syst Rev. 2017 Jun 8;6(6):CD010137. doi: 10.1002/14651858.CD010137.pub2.,Ruospo M,2017,8.98,0.66,5,11.42,0.76,5,0.0991904368,0.3144671058,0,0,,post,-2.44,0.20264,1,1
3931537,2,0.03,Finland,Funding source: none,not reported,27640062,published data only,1,1,,2,,2,,,1,,1,,,,,,,,,,,,,,,2,,2,,,,,,,,,9,Combination of insulin and glibenclamide in the treatment of elderly non-insulin dependent (type 2) diabetic patients,"Kyllästinen M, Groop L.",Ann Clin Res. 1985;17(3):100-4.,Kyllästinen M,1985,2,2,,1,Characteristics of included studies in Cochrane review does not report on number randomized; Kyllastinen reports: Nine elderly outpatients with non-insulin dependent (type 2) diabetes participated in the study.,27640062,,,Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control,Cochrane Database Syst Rev. 2016 Sep 18;9(9):CD006992. doi: 10.1002/14651858.CD006992.pub2.,Vos RC,2016,12.4,1.8,9,14.1,1.2,9,0.5331751716,0.0814988793,0,0,,dif,-2,0.8157511111,0,1
6381006,3,0.68,Canada,"COMMERCIAL FUNDING: No NON-COMMERCIAL FUNDING: Yes - medical research councils, NIH etc.",non-commercial,20091571,published data only,1,1,0,,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,12,Continuous subcutaneous insulin infusion (Mill-Hill Infuser) versus multiple injections (Medi-Jector) in the treatment of insulin-dependent diabe,"Chiasson JL, Ducros F, Poliquin-Hamet M, Lopez D, Lecavalier L, Hamet P.",Diabetes Care. 1984 Jul-Aug;7(4):331-7. doi: 10.2337/diacare.7.4.331.,Chiasson JL,1984,6,2,,1,From Cochrane:WHO PARTCIPATED: 12 participants were included in this study. Half,20091571,,,Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2010 Jan 20;(1):CD005103. doi: 10.1002/14651858.CD005103.pub2.,Misso ML,2010,9.1,1.04,12,8.7,1.39,12,-0.334515036,0.0595715169,0,0,,post,0.4,0.087307,0,1
6439036,4,0,USA,"Funding source: UpJohn, Core Laboratory, Central Ohio Diabetes Association",both,27640062,published data only,2,1,,2,,2,2,,1,,1,1,,,,,,,,,,,,,,2,,2,2,,,,,,,,22,Concomitant insulin and sulfonylurea therapy in patients with type II diabetes. Effects on glucoregulation and lipid metabolism,"Osei K, O'Dorisio TM, Falko JM.",Am J Med. 1984 Dec;77(6):1002-9. doi: 10.1016/0002-9343(84)90179-7.,Osei K,1984,3,2,0.0906266542,1,Characteristics of included studies in Cochrane review does not report on number randomized; Osei reports: after addition of either glyburide (n = 10) or placebo (n =12),27640062,,,Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control,Cochrane Database Syst Rev. 2016 Sep 18;9(9):CD006992. doi: 10.1002/14651858.CD006992.pub2.,Vos RC,2016,9.62,0.73485,6,10.45,2.12264,11,-0.926602607,0.1797308519,0,1,5,dif,-1.38,0.7269090909,0,1
6624767,4,0,USA,Funding: Research Fellowship from the Iowa Affiliate of the American Diabetes Association.,non-commercial,31120549,published data only,2,1,2,2,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,30,Efficacy of home glucose monitoring in diabetic pregnancy,"Varner MW,C202",Am J Med. 1983 Oct;75(4):592-6. doi: 10.1016/0002-9343(83)90438-2.,Varner MW,1983,2,2,0.2467130281,1,from cochrane: Number randomised: 30.,28602020,31120549,,Techniques of monitoring blood glucose during pregnancy for women with pre-existing diabetes,Cochrane Database Syst Rev. 2019 May 23;5(5):CD009613. doi: 10.1002/14651858.CD009613.pub4.,Jones LV,2019,7.21,2.01,14,7.59,2.4,14,-0.125176091,0.0955742862,0,0,,post,-0.38,0.7000071429,0,1
6758461,0.2,0,Italy,COMMERCIAL FUNDING: No- NON-COMMERCIAL FUNDING: Yes - Consiglio Nazionale delle Ricerche,non-commercial,20091571,published data only,1,1,0,,,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,16,Short-term subcutaneous insulin infusion in diabetic children. Comparison with three daily insulin injections,"Meschi F, Beccaria L, Vanini R, Szulc M, Chiumello G.",Acta Diabetol Lat. 1982 Oct-Dec;19(4):371-5. doi: 10.1007/BF02629260.,Meschi F,1982,5,2,0.0017304794,1,From Cochrane: WHO PARTICIPATED: 16 participants were included in this study.,20091571,,,Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2010 Jan 20;(1):CD005103. doi: 10.1002/14651858.CD005103.pub2.,Misso ML,2010,10.7,1.05,8,10.5,2.9,8,-1.030623337,0.1740503452,0,1,5,post,0.2,1.1890625,0,1
6765222,2,0.51,England,COMMERCIAL FUNDING: No - NON-COMMERCIAL FUNDING: Yes,non-commercial,20091571,published data only,1,1,0,,,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,10,A crossover comparison of continuous subcutaneous insulin infusion (CSII) against multiple insulin injections in insulin-dependent diabetic subje,"Home PD, Capaldo B, Burrin JM, Worth R, Alberti KG.",Diabetes Care. 1982 Sep-Oct;5(5):466-71. doi: 10.2337/diacare.5.5.466.,Home PD,1982,5,2,,1,From Cochrane: WHO PARTCIPATED: 10 participants were included in this study,20091571,,,Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2010 Jan 20;(1):CD005103. doi: 10.1002/14651858.CD005103.pub2.,Misso ML,2010,10,2.21,10,11.7,1.89,10,0.312282119,0.0743206786,0,0,,post,-1.7,0.4195762,1,1
7046554,3,0.88705,USA,COMMERCIAL FUNDING: Yes - NON-COMMERCIAL FUNDING: No,commercial,20091571,published data only,1,1,1,,,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,5,Intensive conventional and insulin pump therapies in adult type I diabetes. A crossover study,"Nathan DM, Lou P, Avruch J.",Ann Intern Med. 1982 Jul;97(1):31-6. doi: 10.7326/0003-4819-97-1-31.,Nathan DM,1982,3,2,,1,From Cochrane: WHO PARTICIPATED: Five participants were included in this study.,20091571,,,Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2010 Jan 20;(1):CD005103. doi: 10.1002/14651858.CD005103.pub2.,Misso ML,2010,5.45,0.3696846,4,7.875,1.36717,4,-0.936578046,0.2184857679,0,0,,post,-2.425,0.277287971,1,1
7555551,8,0,USA,Funding source: Miles pharmaceutical division,commercial,27640062,published data only,1,1,,1,,1,2,,1,,1,1,,,,,,,,,,,,,,2,,2,2,,,,,,,,207,A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type,"Coniff RF, Shapiro JA, Seaton TB, Hoogwerf BJ, Hunt JA.",Diabetes Care. 1995 Jul;18(7):928-32. doi: 10.2337/diacare.18.7.928.,Coniff RF,1995,5,2,1,1,Characteristics of included studies in Cochrane review does not report on number randomized; Coniff reports: The study population consisted of 219 men and women with a primary diagnosis of type II diabetes of at least 6 months duration.,27640062,,,Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control,Cochrane Database Syst Rev. 2016 Sep 18;9(9):CD006992. doi: 10.1002/14651858.CD006992.pub2.,Vos RC,2016,,,,,,,,,0,,,dif,-0.4,0.0128352875,0,0
7843470,12,0,UK,Funding: not reported,not reported,32501595,published data only,1,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,48,One year comparative trial of metformin and glipizide in type 2 diabetes mellitus,"Campbell IW, Menzies DG, Chalmers J, McBain AM, Brown IR.",Diabete Metab. 1994 Jul-Aug;20(4):394-400.,Campbell IW,1994,5,2,0.1205171152,1,Characteristics of included studies in Cochrane review does not report on number randomized; Campbell reports: 48 diabetic subjects with diet failed type 2 diabetes mellitus,32501595,,,Metformin monotherapy for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Jun 5;6(6):CD012906. doi: 10.1002/14651858.CD012906.pub2.,Gnesin F,2020,8.64,1.21,24,9.72,1.91,24,-0.338304012,0.0477963325,0,0,,post,-1.08,0.2130083333,0,1
7888692,6,0,USA,"Funding: Department of Academic Affairs, Scripps Clinic and Research Foundation",non-commercial,22258959,published data only,0,0,0,0,1,,,,,,,,,,,,,,,,,,,,0,1,,,,,,,,,,,23,Self-monitoring of blood glucose in overweight type 2 diabetic patients,"Muchmore DB, Springer J, Miller M.",Acta Diabetol. 1994 Dec;31(4):215-9. doi: 10.1007/BF00571954.,Muchmore DB,1994,3,2,0.3177014494,1,From Cochrane:Number of participants: 23,22258959,,,Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin,Cochrane Database Syst Rev. 2012 Jan 18;1:CD005060. doi: 10.1002/14651858.CD005060.pub3.,Malanda UL,2012,8.75,1.66,12,9.6,2.09,11,-0.141527761,0.1119086609,0,0,,dif,-1.7,0.5759540726,1,1
8147960,,0,Sweden,"Funding source: Novo-Nordisk, Boehringer-Mannheim Scandinavia and the Swedish Medical Research Council (06615)",both,28594069,published data only,1,2,1,1,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,102,The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus,"Reichard P, Nilsson BY, Rosenqvist U.",N Engl J Med. 1993 Jul 29;329(5):304-9. doi: 10.1056/NEJM199307293290502.,Reichard P,1993,3,2,0.6364909843,1,From Cochrane: Number: treatment group (48); control group (54),28594069,,,Glucose targets for preventing diabetic kidney disease and its progression,Cochrane Database Syst Rev. 2017 Jun 8;6(6):CD010137. doi: 10.1002/14651858.CD010137.pub2.,Ruospo M,2017,7.1,0.7,48,8.5,0.7,54,0.1811372584,0.0208047334,0,0,,post,-1.4,0.0192824074,0,1
8190431,3,0,USA,"Cochrane provide no info: Manuscript reports:""Supported in part by National Institutes of Health (NIH) HD 20748 (Perinatal Emphasis Research Center), NIH HD 11725 (Diabetes in Pregnancy), and NIH HD 07200 (Research Training in Perinatology).",non-commercial,27142841,published data only,1,1,0,1,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,137,Impact of metabolic control of diabetes during pregnancy on neonatal hypocalcemia: a randomized study,"Demarini S, Mimouni F, Tsang RC, Khoury J, Hertzberg V.",Obstet Gynecol. 1994 Jun;83(6):918-22. doi: 10.1097/00006250-199406000-00003.,Demarini S,1994,5,2,0.8840480491,1,From Cochrane: 137 pregnant women and their infants,20824880,22895976,27142841,Different intensities of glycaemic control for pregnant women with pre-existing diabetes,Cochrane Database Syst Rev. 2016 May 4;2016(5):CD008540. doi: 10.1002/14651858.CD008540.pub4.,Middleton P,2016,9.4,1.9,68,9.4,1.8,69,0.0541422693,0.0161677047,0,0,,post,0,0.100044757,0,1
8190431,6,0,USA,"Cochrane provide no info: Manuscript reports:""Supported in part by National Institutes of Health (NIH) HD 20748 (Perinatal Emphasis Research Center), NIH HD 11725 (Diabetes in Pregnancy), and NIH HD 07200 (Research Training in Perinatology).",non-commercial,27142841,published data only,1,1,0,1,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,137,Impact of metabolic control of diabetes during pregnancy on neonatal hypocalcemia: a randomized study,"Demarini S, Mimouni F, Tsang RC, Khoury J, Hertzberg V.",Obstet Gynecol. 1994 Jun;83(6):918-22. doi: 10.1097/00006250-199406000-00003.,Demarini S,1994,5,2,0.8840480491,1,From Cochrane: 137 pregnant women and their infants,20824880,22895976,27142841,Different intensities of glycaemic control for pregnant women with pre-existing diabetes,Cochrane Database Syst Rev. 2016 May 4;2016(5):CD008540. doi: 10.1002/14651858.CD008540.pub4.,Middleton P,2016,7.8,1.4,68,7.7,1.4,69,-0.01279099,0.0159882284,0,0,,post,0.1,0.0572293265,0,1
8190431,9,0,USA,"Cochrane provide no info: Manuscript reports:""Supported in part by National Institutes of Health (NIH) HD 20748 (Perinatal Emphasis Research Center), NIH HD 11725 (Diabetes in Pregnancy), and NIH HD 07200 (Research Training in Perinatology).",non-commercial,27142841,published data only,1,1,0,1,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,137,Impact of metabolic control of diabetes during pregnancy on neonatal hypocalcemia: a randomized study,"Demarini S, Mimouni F, Tsang RC, Khoury J, Hertzberg V.",Obstet Gynecol. 1994 Jun;83(6):918-22. doi: 10.1097/00006250-199406000-00003.,Demarini S,1994,5,2,0.8840480491,1,From Cochrane: 137 pregnant women and their infants,20824880,22895976,27142841,Different intensities of glycaemic control for pregnant women with pre-existing diabetes,Cochrane Database Syst Rev. 2016 May 4;2016(5):CD008540. doi: 10.1002/14651858.CD008540.pub4.,Middleton P,2016,7.5,1.2,68,7.6,1.1,69,0.1003299164,0.0157153353,0,0,,post,-0.1,0.0387127025,0,1
8453955,6,0,Italy,Funding source: not reported,not reported,27640062,published data only,2,1,,,,2,2,,,,1,1,,,,,,,,,,,,,,,,2,2,,,,,,,,50,"Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors","Giugliano D, Quatraro A, Consoli G, Minei A, Ceriello A, De Rosa N, D'Onofrio F.",Eur J Clin Pharmacol. 1993;44(2):107-12. doi: 10.1007/BF00315466.,Giugliano D,1993,7,2,0.4370078563,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Guigliano reports: Fifty insulin-treated, obese diabetics participated in this prospective, nrandomised double-blind six-month trial.",27640062,,,Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control,Cochrane Database Syst Rev. 2016 Sep 18;9(9):CD006992. doi: 10.1002/14651858.CD006992.pub2.,Vos RC,2016,9.8,1.5,27,11.3,1.1,23,0.4488509195,0.0450109034,0,0,,dif,-1.7,0.1311333333,1,1
8741812,12,0,Multi-countr,Funding: commercial (Eli Lilly),commercial,27362975,published and unpublished data,2,2,0,0,1,1,,,,,,,,,,,,,,,,,,,2,2,,,,,,,,,,,169,Pre-meal insulin analogue insulin lispro vs Humulin R insulin treatment in young subjects with type 1 diabetes,"Garg SK, Carmain JA, Braddy KC, Anderson JH, Vignati L, Jennings MK, Chase HP.",Diabet Med. 1996 Jan;13(1):47-52. doi: 10.1002/(SICI)1096-9136(199601)13:1<47::AID-DIA999>3.0.CO;2-M.,Garg SK,1996,7,2,0.4295462802,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Garg SK reports: in 39 subjects (20 females, 19 males) with Type 1 diabetes (PMID=8741812) Garg included in Z013 n=169 in IQWIG report",27362975,,,Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus,Cochrane Database Syst Rev. 2016 Jun 30;2016(6):CD012161. doi: 10.1002/14651858.CD012161.,Fullerton B,2016,8.08,1.43,80,8.22,1.44,88,0.010770261,0.0129628145,0,0,,post,-0.14,0.0491248864,0,1
9083709,12,0,Multi-countr,Funding: commercial (Eli Lilly),commercial,27362975,published and unpublished data,2,2,0,0,1,1,,,,,,,,,,,,,,,,,,,2,2,,,,,,,,,,,167,Improved mealtime treatment of diabetes mellitus using an insulin analogue. Multicenter Insulin Lispro Study Group,"Anderson JH Jr, Brunelle RL, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R.",Clin Ther. 1997 Jan-Feb;19(1):62-72. doi: 10.1016/s0149-2918(97)80073-2.,Anderson JH Jr,1997,6,2,0.471765,1,Characteristics of included studies in Cochrane review does not report on number randomized; Z011 2007 study with 167 patients on page 50. Anderson reports: A 1Zmonth study was performed in 336 patients with insulin-dependent diabetes mellitus (IDDM) and 295 patients with non-insulin-dependent diabetes mellitus (NIDDM).,27362975,,,Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus,Cochrane Database Syst Rev. 2016 Jun 30;2016(6):CD012161. doi: 10.1002/14651858.CD012161.,Fullerton B,2016,8.14,1.3,81,8.38,1.37,84,-0.02316119,0.0130579674,0,0,,post,-0.24,0.0432082451,0,1
9219407,6,0,UK,Funding: Central Manchester Hospitals Trust Research Grant,non-commercial,25188210,published data only,2,2,0,0,2,0,,,,,,,,,,,,,,,,,,,2,2,,,,,,,,,,,201,One-to-one teaching with pictures--flashcard health education for British Asians with diabetes,"Hawthorne K, Tomlinson S.",Br J Gen Pract. 1997 May;47(418):301-4.,Hawthorne K,1997,2,2,0.5955224453,1,Characteristics of included studies in Cochrane review does not report on number randomized; Hawthorne reports: A randomized controlled trial of pictorial flashcard one-to-one education in 201 patients attending a hospital outpatient clinic or diabetic clinics in ten general practices in Manchester.,25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,8.3,2.31,106,8.64,1.99,86,0.1880825619,0.0121068599,0,0,,post,-0.34,0.0963882405,0,1
9287060,3.01,0,USA,Funding source: Grants from 'USPHS' and National Institute of Dental Research and equipment donated by Eastman Kodak. Conflict of interests: Not reported,both,26545069,published and unpublished data,1,1,1,0,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,112,Treatment of periodontal disease in diabetics reduces glycated hemoglobin,"Grossi SG, Skrepcinski FB, DeCaro T, Robertson DC, Ho AW, Dunford RG, Genco RJ.",J Periodontol. 1997 Aug;68(8):713-9. doi: 10.1902/jop.1997.68.8.713.,Grossi SG,1997,7,5,0.7867580784,1,From Cochrane:Number randomised: 113; Number evaluated: 106/7,26545069,,,Treatment of periodontal disease for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2015 Nov 6;2015(11):CD004714. doi: 10.1002/14651858.CD004714.pub3.,Simpson TC,2015,9.4,2.3,18,10.5,2.2,26,0.1637103103,0.0569633354,0,0,,post,-1.1,0.480042735,0,1
9287060,3.02,0,USA,Funding source: Grants from 'USPHS' and National Institute of Dental Research and equipment donated by Eastman Kodak. Conflict of interests: Not reported,both,26545069,published and unpublished data,1,1,1,0,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,112,Treatment of periodontal disease in diabetics reduces glycated hemoglobin,"Grossi SG, Skrepcinski FB, DeCaro T, Robertson DC, Ho AW, Dunford RG, Genco RJ.",J Periodontol. 1997 Aug;68(8):713-9. doi: 10.1902/jop.1997.68.8.713.,Grossi SG,1997,7,5,0.7867580784,1,From Cochrane:Number randomised: 113; Number evaluated: 106/7,26545069,,,Treatment of periodontal disease for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2015 Nov 6;2015(11):CD004714. doi: 10.1002/14651858.CD004714.pub3.,Simpson TC,2015,9.9,2.1,39,10.1,2.3,44,-0.069428696,0.0277361502,0,0,,post,-0.2,0.2333041958,0,1
9287060,6.01,0,USA,Funding source: Grants from 'USPHS' and National Institute of Dental Research and equipment donated by Eastman Kodak. Conflict of interests: Not reported,both,26545069,published and unpublished data,1,1,1,0,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,112,Treatment of periodontal disease in diabetics reduces glycated hemoglobin,"Grossi SG, Skrepcinski FB, DeCaro T, Robertson DC, Ho AW, Dunford RG, Genco RJ.",J Periodontol. 1997 Aug;68(8):713-9. doi: 10.1902/jop.1997.68.8.713.,Grossi SG,1997,7,5,0.7867580784,1,From Cochrane:Number randomised: 113; Number evaluated: 106/7,26545069,,,Treatment of periodontal disease for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2015 Nov 6;2015(11):CD004714. doi: 10.1002/14651858.CD004714.pub3.,Simpson TC,2015,10.3,2.2,17,10.3,2.1,26,0.0572275965,0.0582904177,0,0,,post,0,0.454321267,0,1
9287060,6.02,0,USA,Funding source: Grants from 'USPHS' and National Institute of Dental Research and equipment donated by Eastman Kodak. Conflict of interests: Not reported,both,26545069,published and unpublished data,1,1,1,0,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,112,Treatment of periodontal disease in diabetics reduces glycated hemoglobin,"Grossi SG, Skrepcinski FB, DeCaro T, Robertson DC, Ho AW, Dunford RG, Genco RJ.",J Periodontol. 1997 Aug;68(8):713-9. doi: 10.1902/jop.1997.68.8.713.,Grossi SG,1997,7,5,0.7867580784,1,From Cochrane:Number randomised: 113; Number evaluated: 106/7,26545069,,,Treatment of periodontal disease for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2015 Nov 6;2015(11):CD004714. doi: 10.1002/14651858.CD004714.pub3.,Simpson TC,2015,10.2,2.2,41,10.3,2.1,43,0.0567874591,0.0271031764,0,0,,post,-0.1,0.22060692,0,1
9314625,3,0,USA,"Funding: dissertation research grant, partially funded by the National Institute of Aging and the National Institutes of Health",non-commercial,25188210,published data only,1,1,0,0,1,0,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,64,A randomized controlled trial of weight reduction and exercise for diabetes management in older African-American subjects,"Agurs-Collins TD, Kumanyika SK, Ten Have TR, Adams-Campbell LL.",Diabetes Care. 1997 Oct;20(10):1503-11. doi: 10.2337/diacare.20.10.1503.,Agurs-Collins TD,1997,4,2,0.9468631866,1,Characteristics of included studies in Cochrane review does not report on number randomized; Agurs reports: Overweight African-Americans (n = 64) ages 55-79 years with NIDDM were randomized,25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,9.5,1.8,31,10.3,1.9,27,0.0242718789,0.0396124602,0,0,,post,-0.8,0.2382198327,0,1
9314625,6,0,USA,"Funding: dissertation research grant, partially funded by the National Institute of Aging and the National Institutes of Health",non-commercial,25188210,published data only,1,1,0,0,1,0,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,64,A randomized controlled trial of weight reduction and exercise for diabetes management in older African-American subjects,"Agurs-Collins TD, Kumanyika SK, Ten Have TR, Adams-Campbell LL.",Diabetes Care. 1997 Oct;20(10):1503-11. doi: 10.2337/diacare.20.10.1503.,Agurs-Collins TD,1997,4,2,0.9468631866,1,Characteristics of included studies in Cochrane review does not report on number randomized; Agurs reports: Overweight African-Americans (n = 64) ages 55-79 years with NIDDM were randomized,25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,9.9,2,30,11.5,4.4,25,-0.639989451,0.0467713497,0,1,3,post,-1.6,0.9077333333,0,1
9542261,5,0,Italy,Funding: not mentioned.,not reported,31120549,published data only,1,1,2,2,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,20,Telemedicine in the treatment of diabetic pregnancy,"di Biase N, Napoli A, Sabbatini A, Borrello E, Buongiorno AM, Fallucca F.",Ann Ist Super Sanita. 1997;33(3):347-51.,di Biase N,1997,6,2,0.4104725378,1,from Cochrane: Number randomised: 20.,24782359,28602020,31120549,Techniques of monitoring blood glucose during pregnancy for women with pre-existing diabetes,Cochrane Database Syst Rev. 2019 May 23;5(5):CD009613. doi: 10.1002/14651858.CD009613.pub4.,Jones LV,2019,5,0.4,10,5.7,0.3,10,0.418528839,0.1243740416,0,0,,post,-0.7,0.025,0,1
9589227,3,-0.12,UK,Funding source: Lipha Pharmaceuticals,commercial,27640062,published data only,1,1,,2,,2,2,,1,,1,1,,,,,,,,,,,,,,2,,2,2,,,,,,,,19,The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control,"Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS.",Diabetes Care. 1998 May;21(5):701-5. doi: 10.2337/diacare.21.5.701.,Robinson AC,1998,5,2,,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Robinson reports :Two randomized double-blind placebo-controlled crossover studies were run. In study 1 (n = 19), insulin-treated subjects with suboptimal glycemic control received 12 weeks of metformin 1 g b.i.d. and 12 weeks of placebo. In study 2 (n = 14), subjects already established on adjunctive metformin/i",27640062,,,Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control,Cochrane Database Syst Rev. 2016 Sep 18;9(9):CD006992. doi: 10.1002/14651858.CD006992.pub2.,Vos RC,2016,,,,,,,,,0,,,dif,-1.6,0.1463578947,1,0
9786808,3,0,USA,"Commercial funding: Sandoz Corporation. Non-commercial funding: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, American Diabetes Association",both,23235661,published data only,2,2,0,2,0,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,42,"Cognitive behavior therapy for depression in type 2 diabetes mellitus. A randomized, controlled trial","Lustman PJ, Griffith LS, Freedland KE, Kissel SS, Clouse RE.",Ann Intern Med. 1998 Oct 15;129(8):613-21. doi: 10.7326/0003-4819-129-8-199810150-00005.,Lustman PJ,1998,5,2,0.7245519363,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Lustman reports: 51 patients with type 2 diabetes and major depression, 42 subjects in table.",23235661,,,Psychological and pharmacological interventions for depression in patients with diabetes mellitus and depression,Cochrane Database Syst Rev. 2012 Dec 12;12:CD008381. doi: 10.1002/14651858.CD008381.pub2.,Baumeister H,2012,10.2,0.7,20,9.9,0.7,22,,,0,,,post,0.3,0.0467727273,0,0
9786808,6,0,USA,"Commercial funding: Sandoz Corporation. Non-commercial funding: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, American Diabetes Association",both,23235661,published data only,2,2,0,2,0,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,42,"Cognitive behavior therapy for depression in type 2 diabetes mellitus. A randomized, controlled trial","Lustman PJ, Griffith LS, Freedland KE, Kissel SS, Clouse RE.",Ann Intern Med. 1998 Oct 15;129(8):613-21. doi: 10.7326/0003-4819-129-8-199810150-00005.,Lustman PJ,1998,5,2,0.7245519363,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Lustman reports: 51 patients with type 2 diabetes and major depression, 42 subjects in table.",23235661,,,Psychological and pharmacological interventions for depression in patients with diabetes mellitus and depression,Cochrane Database Syst Rev. 2012 Dec 12;12:CD008381. doi: 10.1002/14651858.CD008381.pub2.,Baumeister H,2012,9.5,2,20,10.9,2,21,,,0,,,post,-1.4,0.3904761905,1,0
9868971,4,0,Spain,Funding source: Novo Nordisk,commercial,27640062,published data only,2,1,,0,,0,0,,0,,0,0,,,,,,,,,,,,,,1,,2,2,,,,,,,,47,Adding metformin versus insulin dose increase in insulin-treated but poorly controlled Type 2 diabetes mellitus: an open-label randomized trial,"Relimpio F, Pumar A, Losada F, Mangas MA, Acosta D, Astorga R.",Diabet Med. 1998 Dec;15(12):997-1002. doi: 10.1002/(SICI)1096-9136(1998120)15:12<997::AID-DIA716>3.0.CO;2,Relimpio F,1998,6,2,0.3425560928,1,Characteristics of included studies in Cochrane review does not report on number randomized; Relimpio reports: 47 consecutive such patients (baseline daily dose .0.5 IU kg21 and HbA1c .8%) wereopenly randomized either,27640062,,,Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control,Cochrane Database Syst Rev. 2016 Sep 18;9(9):CD006992. doi: 10.1002/14651858.CD006992.pub2.,Vos RC,2016,7.76,1.58,24,9.6,1.79,23,0.0868939739,0.0496862176,0,0,,dif,-1.9,0.3171130435,1,1
10332695,5,0,USA,Funding source: Bristol-Myers-Squibb,commercial,27640062,published data only,1,1,,2,,2,2,,,,1,1,,,,,,,,,,,,,,2,,2,2,,,,,,,,50,Metformin added to insulin therapy in poorly controlled type 2 diabetes,"Hirsch IB,C255",Diabetes Care. 1999 May;22(5):854. doi: 10.2337/diacare.22.5.854b.,Hirsch IB,1999,2,2,0.6609917094,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Hirsch reports: T h e re were 50 patients included in the data analysis: 25 subjects re c e i v e d m e t f o rmin, and 25 received the placebo.",27640062,,,Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control,Cochrane Database Syst Rev. 2016 Sep 18;9(9):CD006992. doi: 10.1002/14651858.CD006992.pub2.,Vos RC,2016,7.4,1.31,22,8.2,1.9,25,-0.265834879,0.0502200317,0,0,,dif,-0.4,0.2224567273,0,1
10428734,6,0,USA,Funding source: Bristol-Myers-Squibb,commercial,27640062,published data only,1,1,,2,,2,2,,1,,1,1,,,,,,,,,,,,,,2,,2,2,,,,,,,,43,"Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled","Avilés-Santa L, Sinding J, Raskin P.",Ann Intern Med. 1999 Aug 3;131(3):182-8. doi: 10.7326/0003-4819-131-3-199908030-00004.,Avilés-Santa L,1999,3,2,0.2772998468,1,Characteristics of included studies in Cochrane review does not report on number randomized; Aviles reports: 43 patients with poorly controlled type 2 diabetes who were receiving insulin therapy.,27640062,,,Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control,Cochrane Database Syst Rev. 2016 Sep 18;9(9):CD006992. doi: 10.1002/14651858.CD006992.pub2.,Vos RC,2016,,,,,,,,,0,,,dif,-0.9,0.1175469697,0,0
10834413,12,0,Multi-countr,Funding: commercial (Novo Nordisk),commercial,27362975,published data only,1,1,0,0,1,1,,,,,,,,,,,,,,,,,,,2,2,,,,,,,,,,,882,"Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes","Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L.",Diabetes Care. 2000 May;23(5):583-8. doi: 10.2337/diacare.23.5.583.,Raskin P,2000,5,2,0.3008359216,1,Characteristics of included studies in Cochrane review does not report on number randomized; From Raskin - This was a multicenter randomized openlabel 6-month study (882 subjects) with a 6-month extension period (714 subjects) that enrolled subjects with type 1 diabetes.,27362975,,,Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus,Cochrane Database Syst Rev. 2016 Jun 30;2016(6):CD012161. doi: 10.1002/14651858.CD012161.,Fullerton B,2016,7.78,0.86,467,7.93,0.87,208,,,0,,,post,-0.15,0.0052226682,0,0
10834419,2,0,USA,"Commercial funding: Eli Lilly Non-commercial funding: National Institute of Diabetes and Digestive and Kidney diseases, National Institute of Health",both,23235661,published data only,2,2,2,2,2,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,54,Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial,"Lustman PJ, Freedland KE, Griffith LS, Clouse RE.",Diabetes Care. 2000 May;23(5):618-23. doi: 10.2337/diacare.23.5.618.,Lustman PJ,2000,4,2,0.6331953412,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Lustman reports: Sixty patients with diabetes (type 1, n = 26; type 2, n = 34) and major depressive disorder entered an 8-week randomized placebo-controlled double-blind trial.",23235661,,,Psychological and pharmacological interventions for depression in patients with diabetes mellitus and depression,Cochrane Database Syst Rev. 2012 Dec 12;12:CD008381. doi: 10.1002/14651858.CD008381.pub2.,Baumeister H,2012,,,,,,,,,1,,,dif,-0.33,0.0465198462,0,0
10928231,2,-0.02,Germany,Funding source: Lipha Pharmaceuticals (medication),commercial,27640062,published data only,2,1,,,,2,2,,,,1,1,,,,,,,,,,,,,,,,2,2,,,,,,,,13,Intensive insulin therapy combined with metformin in obese type 2 diabetic patients,"Fritsche A, Schmülling RM, Häring HU, Stumvoll M.",Acta Diabetol. 2000 Mar;37(1):13-8. doi: 10.1007/s005920070030.,Fritsche A,2000,4,2,,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Fritsche reports: We studied 13 severely obese patients (9 females, 4 males) with type 2 diabetes",27640062,,,Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control,Cochrane Database Syst Rev. 2016 Sep 18;9(9):CD006992. doi: 10.1002/14651858.CD006992.pub2.,Vos RC,2016,7.4,1.08,13,7.6,1.08,13,0.0266256966,0.0546107564,0,0,,dif,-0.6,0.254016,0,1
10977011,4,0.68,France,COMMERCIAL FUNDING: Yes -NON-COMMERCIAL FUNDING: No,commercial,20091571,published and unpublished data,1,2,0,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,41,Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on,"Hanaire-Broutin H, Melki V, Bessières-Lacombe S, Tauber JP.",Diabetes Care. 2000 Sep;23(9):1232-5. doi: 10.2337/diacare.23.9.1232.,Hanaire-Broutin,2000,4,2,,1,From Cochrane:WHO PARTICIPATED: 41 participants were included in this study,20091571,,,Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2010 Jan 20;(1):CD005103. doi: 10.1002/14651858.CD005103.pub2.,Misso ML,2010,7.89,0.77,40,8.24,0.77,40,0.0433943102,0.0165930786,0,0,,post,-0.35,0.0094864,0,1
11023140,,0,USA,Funding source: Roerig/Pfizer,commercial,28594069,published data only,2,2,1,2,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,153,Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complicat,"Levin SR, Coburn JW, Abraira C, Henderson WG, Colwell JA, Emanuele NV, Nuttall FQ, Sawin CT, Comstock JP, Silbert CK.",Diabetes Care. 2000 Oct;23(10):1478-85. doi: 10.2337/diacare.23.10.1478.,Levin SR,2000,10,2,0.3654402416,1,From Cochrane:Number: treatment group (75); control group (78),28594069,,,Glucose targets for preventing diabetic kidney disease and its progression,Cochrane Database Syst Rev. 2017 Jun 8;6(6):CD010137. doi: 10.1002/14651858.CD010137.pub2.,Ruospo M,2017,7.1,0.87,75,9.1,0.88,78,,,0,,,post,-2,0.0200202051,0,0
11131100,6,0,Multi-countr,"Funding: commercial (Novo Nordisk) Cochrane lists ""Cross-over randomised controlled clinical trial""?",commercial,27362975,published and unpublished data,1,1,0,0,1,1,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,1065,Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial,"Home PD, Lindholm A, Riis A; European Insulin Aspart Study Group.",Diabet Med. 2000 Nov;17(11):762-70. doi: 10.1046/j.1464-5491.2000.00380.x.,Home PD,2000,3,2,0.14265205,1,Characteristics of included studies in Cochrane review does not report on number randomized; from Home: 1070 adult subjects with Type 1 diabetes,27362975,,,Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus,Cochrane Database Syst Rev. 2016 Jun 30;2016(6):CD012161. doi: 10.1002/14651858.CD012161.,Fullerton B,2016,7.88,0.76,649,8,0.74,344,,,0,,,post,-0.12,0.0024818451,0,0
11158450,3,0,USA,"COMMERCIAL FUNDING: Minimed proved the equipment for CGM NON-COMMERCIAL FUNDING: Children's Diabetes Foundation, Denver",both,22258980,published data only,1,1,2,2,,,,,,,,,,,,,,,,,,,,,2,1,,,,,,,,,,,11,Continuous subcutaneous glucose monitoring in children with type 1 diabetes,"Chase HP, Kim LM, Owen SL, MacKenzie TA, Klingensmith GJ, Murtfeldt R, Garg SK.",Pediatrics. 2001 Feb;107(2):222-6. doi: 10.1542/peds.107.2.222.,Chase HP,2001,7,2,0.9365301577,1,"From Cochrane: WHO PARTICIPATED: 12 children with type 1 diabetes were included in the study, randomised 1:1 to CGM or SMBG. 1 dropout in CGM group.",22258980,,,Continuous glucose monitoring systems for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008101. doi: 10.1002/14651858.CD008101.pub2.,Langendam M,2012,8.82,0.19,5,8.4,0.43,6,-0.840379334,0.2767796549,0,0,,dif,-0.42,0.3762111147,0,1
11194427,2,0,Australia,"Cochrane does not appear to report on funding sources or conflict of interest-Supported by a grant from the Foundation for Women’s and Infants’ Health, Western Australia.",non-commercial,28236296,published data only,1,1,2,1,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,124,A randomised controlled trial of dietary energy restriction in the management of obese women with gestational diabetes,"Rae A, Bond D, Evans S, North F, Roberman B, Walters B.",Aust N Z J Obstet Gynaecol. 2000 Nov;40(4):416-22. doi: 10.1111/j.1479-828x.2000.tb01172.x.,Rae A,2000,6,2,0.3937346573,1,From Cochrane:N = 125; N = 117 women involved in analysis (8 withdraw).,28236296,,,Different types of dietary advice for women with gestational diabetes mellitus,Cochrane Database Syst Rev. 2017 Feb 25;2(2):CD009275. doi: 10.1002/14651858.CD009275.pub3.,Han S,2017,5.3,0.79,63,5.5,1.47,54,,,0,,,post,-0.2,0.0499230159,0,0
11288794,6,0,Mexico,"Funding source: Grant from Consejo Nacional de Ciencia y Tecnologia (CONACYT) SIHGO 19980202026. Conflict of interests: Not reported, however does state ""the companies producing or marketing the medications under study were unaware of this work""",non-commercial,26545069,published data only,0,0,2,1,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,40,"Clinical and radiological improvement of periodontal disease in patients with type 2 diabetes mellitus treated with alendronate: a randomized, pl","Rocha M, Nava LE, Vázquez de la Torre C, Sánchez-Márin F, Garay-Sevilla ME, Malacara JM.",J Periodontol. 2001 Feb;72(2):204-9. doi: 10.1902/jop.2001.72.2.204.,Rocha M,2001,6,2,0.2985305689,1,From Cochrane:Number randomised: 40; Number evaluated: 40,26545069,,,Treatment of periodontal disease for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2015 Nov 6;2015(11):CD004714. doi: 10.1002/14651858.CD004714.pub3.,Simpson TC,2015,9.4,1.5,20,10.8,2.4,20,-0.330569217,0.0591478572,0,0,,post,-1.4,0.4005,1,1
11315821,6,0,Multi-countr,Funding: commercial funding (Sanofi),commercial,33166419,published and unpublished data,2,2,1,2,1,2,0,0,,1,2,1,2,0,0,,,,,,,,,,2,2,2,2,2,2,,,,,,,518,Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin,"Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB.",Diabetes Care. 2001 Apr;24(4):631-6. doi: 10.2337/diacare.24.4.631.,Rosenstock J,2001,6,2,0.4537187592,1,Characteristics of included studies in Cochrane review does not report on number randomized; Rosenstock reports: A total of 518 subjects with type 2 diabetes who were receiving NPH insulin with or without regular insulin for postprandial control were randomized,33166419,,,(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Nov 9;11(11):CD005613. doi: 10.1002/14651858.CD005613.pub4.,Semlitsch T,2020,,,,,,,,,0,,,dif,0.18,0.0083092683,0,0
11423920,1,0,Denmark,"Cochrane does not appear to report on funding sources or conflict of interest-Lauszus repportsSources of support were grants from the Mimi and Victor Larsens Foundation, Nordisk Insulin Foundation, Novo Nordisk Foundation, and the Institute of Experimental Clinical Research, Aarhus University, Denmark. Aarhus Olie Fabrik AS, Aarhus, Denmark provided the hybrid sunflower oil. The Danish Medical Research Council provided the statistical assistance.",both,28236296,published and unpublished data,2,2,0,1,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,27,Effect of a high monounsaturated fatty acid diet on blood pressure and glucose metabolism in women with gestational diabetes mellitus,"Lauszus FF, Rasmussen OW, Henriksen JE, Klebe JG, Jensen L, Lauszus KS, Hermansen K.",Eur J Clin Nutr. 2001 Jun;55(6):436-43. doi: 10.1038/sj.ejcn.1601193.,Lauszus FF,2001,7,2,0.9597761043,1,"From Cochrane:""N = 27.""",28236296,,,Different types of dietary advice for women with gestational diabetes mellitus,Cochrane Database Syst Rev. 2017 Feb 25;2(2):CD009275. doi: 10.1002/14651858.CD009275.pub3.,Han S,2017,5.7,0.35,12,5.3,0.36,13,-0.097122,0.0953948805,0,0,,post,0.4,0.0201775641,0,1
11476360,6,0.67,Italy,Funding: -,not reported,27362975,published data only,2,1,0,0,1,1,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,12,"Lispro insulin in type 1 diabetic patients on a Mediterranean or normal diet: a randomized, cross-over comparative study with regular insulin","Provenzano C, Vero R, Oliva A, Leto G, Puccio L, Vecci E, Mattioli PL, Di Mario U.",Diabetes Nutr Metab. 2001 Jun;14(3):133-9.,Provenzano C,2001,8,2,,1,Characteristics of included studies in Cochrane review does not report on number randomized; From Provenzano - 12 recruited and randomized,27362975,,,Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus,Cochrane Database Syst Rev. 2016 Jun 30;2016(6):CD012161. doi: 10.1002/14651858.CD012161.,Fullerton B,2016,7.62,0.49,12,7.84,0.49,12,0.0284529308,0.0584500248,0,0,,post,-0.22,0.0132055,0,1
11544612,6,0.67,Scotland,Funding: commercial (Eli Lilly),commercial,27362975,published and unpublished data,1,1,0,0,1,1,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,33,Severe hypoglycaemia in patients with type 1 diabetes and impaired awareness of hypoglycaemia: a comparative study of insulin lispro and regular,"Ferguson SC, Strachan MW, Janes JM, Frier BM.",Diabetes Metab Res Rev. 2001 Jul-Aug;17(4):285-91. doi: 10.1002/dmrr.202.,Ferguson SC,2001,4,2,,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Ferguson reports: An open-label, randomised, 12-month comparative crossover study of insulin lispro and regular human insulin was performed in 33 patients with type 1 diabetes",27362975,,,Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus,Cochrane Database Syst Rev. 2016 Jun 30;2016(6):CD012161. doi: 10.1002/14651858.CD012161.,Fullerton B,2016,9.1,0.83,33,9.3,1,33,-0.164540455,0.0202458242,0,0,,post,-0.2,0.0174757576,0,1
11574432,9,0,Canada,COMMERCIAL FUNDING: Yes - NON-COMMERCIAL FUNDING: No,commercial,20091571,published and unpublished data,2,2,0,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,27,Intensive insulin therapy with insulin lispro: a randomized trial of continuous subcutaneous insulin infusion versus multiple daily insulin injec,"Tsui E, Barnie A, Ross S, Parkes R, Zinman B.",Diabetes Care. 2001 Oct;24(10):1722-7. doi: 10.2337/diacare.24.10.1722.,Tsui E,2001,5,2,0.3070432082,1,"From Cochrane: WHO PARTICIPATED: 27 participants were included in this study. 13 participants (five female, eightmale) were randomised to and 12 completed CSII. 14 participants were randomised to and completed,MI (four female, ten male).",20091571,,,Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2010 Jan 20;(1):CD005103. doi: 10.1002/14651858.CD005103.pub2.,Misso ML,2010,7.38,0.56,12,7.56,0.59,14,,,0,,,post,-0.18,0.050997619,0,0
11679471,6,0,Netherlands,Funding: not stated,not reported,25188210,published data only,0,1,1,1,2,1,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,113,Effectiveness of culture-specific diabetes care for Surinam South Asian patients in the Hague: a randomized controlled trial/controlled before-an,"Middelkoop BJ, Geelhoed-Duijvestijn PH, van der Wal G.",Diabetes Care. 2001 Nov;24(11):1997-8. doi: 10.2337/diacare.24.11.1997.,Middelkoop BJ,2001,3,2,,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Middelkoop reports: The first part of the study was a randomized controlled trial (RCT), in which the patients were randomized based on date of birth: odd numbers (intervention patients, n  53) and even numbers (waiting-list control patients, n  60).",25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,,,,,,,,,0,,,dif,-0.5,0.0323679245,0,0
11815493,3,0,USA,"Funding: National Institute for Diabetes and Kidney Disease and the Office of Research on Minority Health, National Institute of Health and the State of Texas",non-commercial,25188210,published data only,1,1,0,0,2,0,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,252,Culturally competent diabetes self-management education for Mexican Americans: the Starr County border health initiative,"Brown SA, Garcia AA, Kouzekanani K, Hanis CL.",Diabetes Care. 2002 Feb;25(2):259-68. doi: 10.2337/diacare.25.2.259.,Brown SA,2002,4,2,0.4674738942,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Brown reports: A total of 256 randomly selected individuals with type 2 diabetes between 35 and 70 years of age, diagnosed with type 2 diabetes after 35 years of age, and accompanied by a family member or friend were included.",25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,10.6,2.64,108,11.22,2.77,99,0.0083670085,0.0110610271,0,0,,post,-0.62,0.1420373737,0,1
11815493,6,0,USA,"Funding: National Institute for Diabetes and Kidney Disease and the Office of Research on Minority Health, National Institute of Health and the State of Texas",non-commercial,25188210,published data only,1,1,0,0,2,0,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,252,Culturally competent diabetes self-management education for Mexican Americans: the Starr County border health initiative,"Brown SA, Garcia AA, Kouzekanani K, Hanis CL.",Diabetes Care. 2002 Feb;25(2):259-68. doi: 10.2337/diacare.25.2.259.,Brown SA,2002,4,2,0.4674738942,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Brown reports: A total of 256 randomly selected individuals with type 2 diabetes between 35 and 70 years of age, diagnosed with type 2 diabetes after 35 years of age, and accompanied by a family member or friend were included.",25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,10.8,2.8,117,12.2,2.95,109,0.0693657401,0.01013121,0,0,,post,-1.4,0.1468479965,1,1
11815493,12,0,USA,"Funding: National Institute for Diabetes and Kidney Disease and the Office of Research on Minority Health, National Institute of Health and the State of Texas",non-commercial,25188210,published data only,1,1,0,0,2,0,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,252,Culturally competent diabetes self-management education for Mexican Americans: the Starr County border health initiative,"Brown SA, Garcia AA, Kouzekanani K, Hanis CL.",Diabetes Care. 2002 Feb;25(2):259-68. doi: 10.2337/diacare.25.2.259.,Brown SA,2002,4,2,0.4674738942,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Brown reports: A total of 256 randomly selected individuals with type 2 diabetes between 35 and 70 years of age, diagnosed with type 2 diabetes after 35 years of age, and accompanied by a family member or friend were included.",25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,10.89,2.56,112,11.64,2.85,112,-0.040688304,0.0101191054,0,0,,post,-0.75,0.1310366071,0,1
11832527,34,0,USA,"Funding: commercial funding (Lipha (Merck-Sante) provided medicines, and LifeScan donated materials)/non-commercial funding (the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Child Health and Human Development, the National Institute on Aging,the National Eye Institute, the National Heart Lung and Blood Institute, the Office of Women’s Health,the National Center for Minority Health and Human Disease, the Centers for Disease Control and Prevention,and the American Diabetes Association)",both,29205264,published data only,2,2,2,,,2,2,,,,,2,0,2,,,2,2,,,,,2,0,2,,,2,2,,,,2,2,2,,3234,Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin,"Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group.",N Engl J Med. 2002 Feb 7;346(6):393-403. doi: 10.1056/NEJMoa012512.,Knowler WC,2002,7,3,0.4290572146,1,from cochrane - no info on # randomized found; lancet article: 3234 randomly assigned in DPP,29205264,,,"Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus",Cochrane Database Syst Rev. 2017 Dec 4;12(12):CD003054. doi: 10.1002/14651858.CD003054.pub4.,Hemmingsen B,2017,5.9,0.5,915,6.1,0.7,935,-0.303120985,0.0011054826,0,0,,post,-0.2,0.0007972882,0,1
11911170,6,0,Poland,Funding: not mentioned.,not reported,31120549,published data only,1,0,2,2,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,30,What we can really expect from telemedicine in intensive diabetes treatment: results from 3-year study on type 1 pregnant diabetic women,"Wojcicki JM, Ladyzynski P, Krzymien J, Jozwicka E, Blachowicz J, Janczewska E, Czajkowski K, Karnafel W.",Diabetes Technol Ther. 2001 Winter;3(4):581-9. doi: 10.1089/15209150152811207.,Wojcicki JM,2001,8,2,0.255959692,1,from Cochrane: Number randomised: 32.,24782359,28602020,31120549,Techniques of monitoring blood glucose during pregnancy for women with pre-existing diabetes,Cochrane Database Syst Rev. 2019 May 23;5(5):CD009613. doi: 10.1002/14651858.CD009613.pub4.,Jones LV,2019,6.8,0.9,15,6.7,0.9,15,-0.014797526,0.0789027783,0,0,,post,0.1,0.108,0,1
12074206,4,0,USA,Funding source: Takeda Pharmaceuticals,commercial,27640062,published data only,1,1,,2,,2,2,,1,,1,1,,,,,,,,,,,,,,2,,2,2,,,,,,,,566,"Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy","Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S; Pioglitazone 014 Study Group.",Int J Clin Pract. 2002 May;56(4):251-7.,Rosenstock J,2002,5,3,0.8737719285,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Rosenstock reports: Patients (n=566) receiving stable insulin regimens for aSO days yet who had HbAic s8.0% and C-peptide >0.7 pg/l were randomised to receive once-daily 15 mg pioglitazone, 30 mg pioglitazone, or placebo in a 16-week multicentre, double-blind, placebo-controlled trial.",27640062,,,Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control,Cochrane Database Syst Rev. 2016 Sep 18;9(9):CD006992. doi: 10.1002/14651858.CD006992.pub2.,Vos RC,2016,,,,,,,,,0,,,dif,-0.87,0.009570122,0,0
12196430,6,0,USA,"Funding: ""Supported in part by a co-operative agreement with the Centers for Disease Control and Prevention""",non-commercial,25188210,published data only,2,2,0,0,2,1,,,,,,,,,,,,,,,,,,,2,2,,,,,,,,,,,200,A randomized trial of an intervention to improve self-care behaviors of African-American women with type 2 diabetes: impact on physical activity,"Keyserling TC, Samuel-Hodge CD, Ammerman AS, Ainsworth BE, Henríquez-Roldán CF, Elasy TA, Skelly AH, Johnston LF, Bangdiwala SI.",Diabetes Care. 2002 Sep;25(9):1576-83. doi: 10.2337/diacare.25.9.1576.,Keyserling TC,2002,9,3,,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Keyserling reports: 200 African-American women,40 years of age with type 2 diabetes, were randomized to one of three treatment conditions: clinic and community (group A), clinic only (group B), or minimal intervention (group C).",25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,10.7,3.1,60,11.5,3.81,58,,,0,,,post,-0.8,0.4104442529,0,0
12196430,12,0,USA,"Funding: ""Supported in part by a co-operative agreement with the Centers for Disease Control and Prevention""",non-commercial,25188210,published data only,2,2,0,0,2,1,,,,,,,,,,,,,,,,,,,2,2,,,,,,,,,,,200,A randomized trial of an intervention to improve self-care behaviors of African-American women with type 2 diabetes: impact on physical activity,"Keyserling TC, Samuel-Hodge CD, Ammerman AS, Ainsworth BE, Henríquez-Roldán CF, Elasy TA, Skelly AH, Johnston LF, Bangdiwala SI.",Diabetes Care. 2002 Sep;25(9):1576-83. doi: 10.2337/diacare.25.9.1576.,Keyserling TC,2002,9,3,,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Keyserling reports: 200 African-American women,40 years of age with type 2 diabetes, were randomized to one of three treatment conditions: clinic and community (group A), clinic only (group B), or minimal intervention (group C).",25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,10.8,2.94,54,10.7,3.02,57,,,0,,,post,0.1,0.3200736842,0,0
12351463,4,0,USA,Funding source: Bristol Myers Squibb,commercial,27640062,published data only,2,2,,0,,0,0,,0,,0,0,,,,,,,,,,,,,,2,,2,2,,,,,,,,88,Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes,"Strowig SM, Avilés-Santa ML, Raskin P.",Diabetes Care. 2002 Oct;25(10):1691-8. doi: 10.2337/diacare.25.10.1691.,Strowig SM,2002,3,3,0.5459402639,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Strowig reports: A total of 88 type 2 diabetic subjects using insulin monotherapy (baseline HbAlc 8.7%) were randomly assigned to insulin alone (n  31), insulin plus metformin (n27), or insulin plus troglitazone (n30) for 4 months.",27640062,,,Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control,Cochrane Database Syst Rev. 2016 Sep 18;9(9):CD006992. doi: 10.1002/14651858.CD006992.pub2.,Vos RC,2016,7.1,1,27,7,1,31,-0.011658727,0.0385861669,0,0,,dif,0,0.1167953717,0,1
12401734,6,0,Multi-countr,Funding: Unrestricted grant from Bayer AG & Bayer Vital GmbH,commercial,22258959,published data only,1,1,0,0,1,,,,,,,,,,,,,,,,,,,,1,0,,,,,,,,,,,223,Meal-related structured self-monitoring of blood glucose: effect on diabetes control in non-insulin-treated type 2 diabetic patients,"Schwedes U, Siebolds M, Mertes G; SMBG Study Group.",Diabetes Care. 2002 Nov;25(11):1928-32. doi: 10.2337/diacare.25.11.1928.,Schwedes U,2002,3,2,0.739371603,1,"From Cochrane: Number of participants: 250 patients. From Schwedes reports: ""Of the 250 randomized patients, 223 were included in the PP analysis (SMGB group, n  113; control group, n  110). """,22258959,,,Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin,Cochrane Database Syst Rev. 2012 Jan 18;1:CD005060. doi: 10.1002/14651858.CD005060.pub3.,Malanda UL,2012,7.47,1.27,113,7.81,1.52,110,-0.135262064,0.0097336138,0,0,,dif,-0.46,0.0283957603,0,1
12401759,4,1,Netherlands,"COMMERCIAL FUNDING: Yes, but the study investigators stated that they were the sole originators of the study protocol. NON-COMMERCIAL FUNDING: No",commercial,20091571,published and unpublished data,2,2,0,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,79,A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing,"DeVries JH, Snoek FJ, Kostense PJ, Masurel N, Heine RJ; Dutch Insulin Pump Study Group.",Diabetes Care. 2002 Nov;25(11):2074-80. doi: 10.2337/diacare.25.11.2074.,DeVries JH,2002,5,2,0.0916966983,1,From Cochrane: WHO PARTICIPATED: 79 participants were included in this study,20091571,,,Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2010 Jan 20;(1):CD005103. doi: 10.1002/14651858.CD005103.pub2.,Misso ML,2010,8.36,1.46,32,9.18,1.21,40,,,0,,,dif,-0.82,0.103215,0,0
12453950,4,0,Netherlands,"Funding source: Byk, Lifescan, Merck Lipha, MSD, Novo Nordsik",commercial,27640062,published data only,2,1,,2,,2,2,,1,,1,1,,,,,,,,,,,,,,2,,2,2,,,,,,,,353,Combination of insulin and metformin in the treatment of type 2 diabetes,"Wulffelé MG, Kooy A, Lehert P, Bets D, Ogterop JC, Borger van der Burg B, Donker AJ, Stehouwer CD.",Diabetes Care. 2002 Dec;25(12):2133-40. doi: 10.2337/diacare.25.12.2133.,Wulffelé MG,2002,8,2,0.9558949173,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Wullfele reports: Of the 390 subjects, 37 dropped out (12 in the placebo and 25 in the metformin group). Of",27640062,,,Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control,Cochrane Database Syst Rev. 2016 Sep 18;9(9):CD006992. doi: 10.1002/14651858.CD006992.pub2.,Vos RC,2016,6.94,0.98,171,7.61,1.17,181,-0.084874668,0.0059989072,0,0,,dif,-0.64,0.0089562373,0,1
12649049,10,0,USA,"Funding: Supported in part by Grant RO1-DK-51581 from the National Institute of Diabetes, Digestive, and Kidney Diseases",non-commercial,23543567,published data only,1,1,1,,,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,320,"The D-Net diabetes self-management program: long-term implementation, outcomes, and generalization results","Glasgow RE, Boles SM, McKay HG, Feil EG, Barrera M Jr.",Prev Med. 2003 Apr;36(4):410-9. doi: 10.1016/s0091-7435(02)00056-7.,Glasgow RE,2003,5,4,0.0042723004,1,From Cochrane:Insufficient evidence to permit judgement. Unclear reporting of numbers included in the trial. From Glasgow 2003:Participants were 320 adult type 2 diabetes patients from participating primary care offices,23543567,,,Computer-based diabetes self-management interventions for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2013 Mar 28;2013(3):CD008776. doi: 10.1002/14651858.CD008776.pub2.,Pal K,2013,7.42,1.1,80,7.68,1.1,80,,,0,,,post,-0.26,0.03025,0,0
12663589,3,0,Spain,COMMERCIAL FUNDING: not reported NON-COMMERCIAL FUNDING: not reported,not reported,22258980,published data only,1,1,1,2,,,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,75,The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is no,"Chico A, Vidal-Ríos P, Subirà M, Novials A.",Diabetes Care. 2003 Apr;26(4):1153-7. doi: 10.2337/diacare.26.4.1153.,Chico A,2003,4,2,0.947017739,1,"From Cochrane: WHO PARTICIPATED: 105 patients, 75 with type 1 DM, randomised to CGM (n=40) or SMBG (n=30). All patients completed follow-up.",22258980,,,Continuous glucose monitoring systems for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008101. doi: 10.1002/14651858.CD008101.pub2.,Langendam M,2012,7.5,1.2,40,7.5,0.8,35,0.4034222783,0.0292529892,0,0,,dif,-0.3,0.0901428571,0,1
12663625,12,0,Italy,COMMERCIAL FUNDING: No - NON-COMMERCIAL FUNDING: Yes,non-commercial,20091571,published and unpublished data,2,1,0,,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,32,Both continuous subcutaneous insulin infusion and a multiple daily insulin injection regimen with glargine as basal insulin are equally better th,"Lepore G, Dodesini AR, Nosari I, Trevisan R.",Diabetes Care. 2003 Apr;26(4):1321-2. doi: 10.2337/diacare.26.4.1321.,Lepore G,2003,4,2,0.8920430705,1,From Cochrane: WHO PARTICIPATED: 32 participants were included in this study.,20091571,,,Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2010 Jan 20;(1):CD005103. doi: 10.1002/14651858.CD005103.pub2.,Misso ML,2010,8.2,1.2,16,7.9,1.2,16,-0.037219601,0.0738936123,0,0,,post,0.3,0.18,0,1
12728068,3,1,Sweden,COMMERCIAL FUNDING: Minimed Inc,commercial,22258980,published data only,1,1,2,2,,,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,27,Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes: a controlled crossover study,"Ludvigsson J, Hanas R.",Pediatrics. 2003 May;111(5 Pt 1):933-8. doi: 10.1542/peds.111.5.933.,Ludvigsson J,2003,2,2,,1,"From Cochrane: WHO PARTICIPATED: 32 patients with type 1 diabetes treated with intensive insulin therapy or insulin infusion pumps, randomised 1:1 to start with open CGM or blinded CGM (control group). 5 patients did not complete follow-up.",22258980,,,Continuous glucose monitoring systems for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008101. doi: 10.1002/14651858.CD008101.pub2.,Langendam M,2012,7.42,1.01,13,7.5,1.12,14,-0.089365444,0.0895794322,0,0,,dif,0.0502,0.12285,0,1
12734781,6,0,Multi-countr,Funding: commercial funding (Sanofi),commercial,33166419,published and unpublished data,2,2,1,2,1,2,0,0,,1,2,1,2,0,0,,,,,,,,,,2,2,2,2,0,2,,,,,,,570,"A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 dia","Massi Benedetti M, Humburg E, Dressler A, Ziemen M.",Horm Metab Res. 2003 Mar;35(3):189-96. doi: 10.1055/s-2003-39080.,Massi Benedetti,2003,4,2,0.5439190662,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Beneddetti reports: 570 patients with Type 2 diabetes, aged 34 - 80 years, were treated for 52 weeks with insulin glargine or NPH insulin given once daily at bedtime. Previous",33166419,,,(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Nov 9;11(11):CD005613. doi: 10.1002/14651858.CD005613.pub4.,Semlitsch T,2020,,,,,,,,,0,,,dif,-0.08,0.0087097556,0,0
12747810,2,0,Finland,Non) commercial funding: not reported,not reported,23235661,published data only,2,2,0,1,1,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,13,Quality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine: a single-blind randomised placebo co,"Paile-Hyvärinen M, Wahlbeck K, Eriksson JG.",BMC Fam Pract. 2003 May 14;4:7. doi: 10.1186/1471-2296-4-7. Epub 2003 May 14.,Paile-Hyvärinen,2003,3,2,0.7767400574,1,Characteristics of included studies in Cochrane review does not report on number randomized; Paile reports: We randomised 15 mildly depressed women with non-optimally controlled type 2 diabetes to a 10-week single-blind treatment with either paroxetine 20 mg per day or placebo.,23235661,,,Psychological and pharmacological interventions for depression in patients with diabetes mellitus and depression,Cochrane Database Syst Rev. 2012 Dec 12;12:CD008381. doi: 10.1002/14651858.CD008381.pub2.,Baumeister H,2012,,,,,,,,,1,,,dif,-0.37,0.0377071429,0,0
12757987,12,0,Spain,Funding: -;  checked Recasens publication and found no information on funding,not reported,27362975,published and unpublished data,1,1,0,0,1,1,,,,,,,,,,,,,,,,,,,0,0,,,,,,,,,,,45,Insulin lispro is as effective as regular insulin in optimising metabolic control and preserving beta-cell function at onset of type 1 diabetes m,"Recasens M, Aguilera E, Morínigo R, Casamitjana R, Nicoletti F, Gomis R, Conget I.",Diabetes Res Clin Pract. 2003 Jun;60(3):153-9. doi: 10.1016/s0168-8227(03)00036-6.,Recasens M,2003,7,2,0.7190387903,1,"Characteristics of included studies in Cochrane review does not report on number randomized; From Recasens - Patients were randomly assigned to intensive insulin therapy using insulin lispro (lispro) (lispro, n=22; 22.8 years) or intensiveinsulin therapy using regular insulin (regular) (regular, n=23; 24.4 years):",27362975,,,Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus,Cochrane Database Syst Rev. 2016 Jun 30;2016(6):CD012161. doi: 10.1002/14651858.CD012161.,Fullerton B,2016,6.25,1.46,22,6.36,1.01,23,0.3863233059,0.0522842058,0,0,,post,-0.11,0.141243083,0,1
12809451,6,0,Multi-countr,Funding: commercial funding (Sanofi),commercial,33166419,published and unpublished data,2,2,1,2,,2,,0,,1,2,,2,,0,,,,,,,,,,2,2,,2,,2,,,,,,,695,"Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type","Fritsche A, Schweitzer MA, Häring HU; 4001 Study Group.",Ann Intern Med. 2003 Jun 17;138(12):952-9. doi: 10.7326/0003-4819-138-12-200306170-00006.,Fritsche A,2003,3,3,0.2589774898,1,Characteristics of included studies in Cochrane review does not report on number randomized; Fritsche reports: 695 patients with type 2 diabetes who were previously treated with oral antidiabetic agents.,33166419,,,(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Nov 9;11(11):CD005613. doi: 10.1002/14651858.CD005613.pub4.,Semlitsch T,2020,8.13,1.26,216,8.21,1.3,220,-0.021416684,0.0048551079,0,0,,dif,-0.12,0.0154154261,0,1
12881874,2,0,China,Funding: Not stated,not reported,23543567,published data only,1,1,0,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,150,[Computer assisted nutrition therapy for patients with type 2 diabetes],"Zhou YD, Gu W.",Zhejiang Da Xue Xue Bao Yi Xue Ban. 2003 Jun;32(3):244-8. doi: 10.3785/j.issn.1008-9292.2003.03.019.,Zhou YD,2003,2,2,0.9962045384,1,"From Cochrane:""150 patients are randomly allocated to two groups"". No missing data.",23543567,,,Computer-based diabetes self-management interventions for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2013 Mar 28;2013(3):CD008776. doi: 10.1002/14651858.CD008776.pub2.,Pal K,2013,8.03,1.09,88,8.77,1.74,62,-0.381791973,0.0149887879,0,0,,post,-0.74,0.0623333944,0,1
14513883,6,0.68,Israel,COMMERCIAL FUNDING: Yes - Tayco Diagnostica NON-COMMERCIAL FUNDING: No,commercial,20091571,published data only,1,1,0,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,16,Continuous subcutaneous insulin infusion versus multiple daily injections in adolescents with type I diabetes mellitus: a randomized open crossov,"Cohen D, Weintrob N, Benzaquen H, Galatzer A, Fayman G, Phillip M.",J Pediatr Endocrinol Metab. 2003 Sep;16(7):1047-50. doi: 10.1515/jpem.2003.16.7.1047.,Cohen D,2003,6,2,,1,From Cochrane:WHO PARTICIPATED: 16 participants were included in this study.,20091571,,,Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2010 Jan 20;(1):CD005103. doi: 10.1002/14651858.CD005103.pub2.,Misso ML,2010,8.15,1.3,12,8.57,0.44,12,1.1326443221,0.0597027991,0,1,6+,post,-0.42,0.09214,0,1
14520226,6,0,Northern Ire,"Funding: Department of Health and Social Sevices, Northern lreland, the Northern Ireland Mother and Baby Appeal, the Metabolic Unit Research Fund, Royal Victoria Hospital, Belfast, the Royal Maternity Hospital, Royal Victoria Hospital, Belfast, and the Irish Perinatal Society.",non-commercial,31120549,published data only,1,2,2,2,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,61,Preprandial versus postprandial blood glucose monitoring in type 1 diabetic pregnancy: a randomized controlled clinical trial,"Manderson JG, Patterson CC, Hadden DR, Traub AI, Ennis C, McCance DR.",Am J Obstet Gynecol. 2003 Aug;189(2):507-12. doi: 10.1067/s0002-9378(03)00497-6.,Manderson JG,2003,6,2,0.7536343791,1,from cochrane: Number randomised: 61,24782359,28602020,31120549,Techniques of monitoring blood glucose during pregnancy for women with pre-existing diabetes,Cochrane Database Syst Rev. 2019 May 23;5(5):CD009613. doi: 10.1002/14651858.CD009613.pub4.,Jones LV,2019,6.3,0.7,31,6,0.8,30,-0.182799097,0.036049227,0,0,,post,0.3,0.0371397849,0,1
14578243,6,0,USA,Funding: commercial funding (Sanofi),commercial,33166419,published and unpublished data,2,2,1,2,,2,,0,,1,2,,2,,0,,,,,,,,,,2,2,,2,,2,,,,,,,756,The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients,"Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators.",Diabetes Care. 2003 Nov;26(11):3080-6. doi: 10.2337/diacare.26.11.3080.,Riddle MC,2003,3,2,0.8717285063,1,Characteristics of included studies in Cochrane review does not report on number randomized; Riddle reports: 756 overweight men and women with inadequate glycemic control (HbA1c 7.5%) on one or two oral agents continued,33166419,,,(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Nov 9;11(11):CD005613. doi: 10.1002/14651858.CD005613.pub4.,Semlitsch T,2020,6.96,,,6.97,,,,,0,,,dif,-0.03,0.0028597557,0,0
14584871,3,0,Brazil,"Funding source: Grants from CAPES - Coordenação de Aperfeiçoamento de Pessoal de Nivel Superior (Brazilian Ministry of Education organisation to fund graduate education), and FAPESP (Fundação de Amparo à Pesquisa do Estado de São Paulo (São Paulo Research Foundation) - grant 2000/14108-8).  ""Conflict of interests: Not reported""",non-commercial,26545069,published and unpublished data,2,1,0,2,,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,30,Effect of non-surgical periodontal therapy on glycemic control in patients with type 2 diabetes mellitus,"Rodrigues DC, Taba MJ, Novaes AB, Souza SL, Grisi MF.",J Periodontol. 2003 Sep;74(9):1361-7. doi: 10.1902/jop.2003.74.9.1361.,Rodrigues DC,2003,5,2,0.8985984597,1,"From Cochrane:Number randomised: 30; Number evaluated: Unclear, assumed 30. No information re: attrition",26545069,,,Treatment of periodontal disease for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2015 Nov 6;2015(11):CD004714. doi: 10.1002/14651858.CD004714.pub3.,Simpson TC,2015,9.2,1.6,15,7.6,1.4,15,-0.057400918,0.0808138216,0,0,,post,1.6,0.3013333333,1,1
14633807,38,0,Finland,"Funding: commercial funding (Novo Nordisk Foundation)/non-commercial funding (Finnish Academy,Ministry of Education, Yrjö Jahnsson Foundation, and the Finnish Diabetes Research",both,29205264,published data only,2,2,2,,,2,2,,,,2,,,2,,,2,2,,,,2,,,0,,,1,1,,,,1,,,,522,The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity,"Lindström J, Louheranta A, Mannelin M, Rastas M, Salminen V, Eriksson J, Uusitupa M, Tuomilehto J; Finnish Diabetes Prevention Study Group.",Diabetes Care. 2003 Dec;26(12):3230-6. doi: 10.2337/diacare.26.12.3230.,Lindström J,2003,8,2,0.4783668568,1,from cochrane - no info on # randomized found; NEJM We randomly assigned 522 middle-aged,29205264,,,"Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus",Cochrane Database Syst Rev. 2017 Dec 4;12(12):CD003054. doi: 10.1002/14651858.CD003054.pub4.,Hemmingsen B,2017,,,,,,,,,0,,,dif,-0.2,0.0033318406,0,0
14707887,6,0,France,"Funding: (blank in Cochrane) Guerci does not report funding source - A search for the Auto-Surveillance Intervention Active (ASIA) study shows the primary funder is the Korean Health 21 R&D Project, Ministry of Health & Welfare, Republic of Korea. Assisting organization: Medtronic Korea Co., Ltd.",commercial,22258959,published data only,1,0,0,0,1,,,,,,,,,,,,,,,,,,,,0,0,,,,,,,,,,,689,Self-monitoring of blood glucose significantly improves metabolic control in patients with type 2 diabetes mellitus: the Auto-Surveillance Interv,"Guerci B, Drouin P, Grangé V, Bougnères P, Fontaine P, Kerlan V, Passa P, Thivolet Ch, Vialettes B, Charbonnel B; ASIA Group.",Diabetes Metab. 2003 Dec;29(6):587-94. doi: 10.1016/s1262-3636(07)70073-3.,Guerci B,2003,10,2,0.9892308657,1,From Cochrane:Number of participants: 689,22258959,,,Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin,Cochrane Database Syst Rev. 2012 Jan 18;1:CD005060. doi: 10.1002/14651858.CD005060.pub3.,Malanda UL,2012,8.1,1.6,345,8.4,1.4,344,0.1698786254,0.0031135455,0,0,,dif,-0.28,0.0137683889,0,1
14709198,24,0,Italy,"COMMERCIAL FUNDING: Yes- NON-COMMERCIAL FUNDING: Yes - International Centre for Diabetes Research, Italy",both,20091571,published data only,2,1,0,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,19,A 2-year pilot trial of continuous subcutaneous insulin infusion versus intensive insulin therapy in patients with newly diagnosed type 1 diabete,"Pozzilli P, Crinò A, Schiaffini R, Manfrini S, Fioriti E, Coppolino G, Pitocco D, Visalli N, Corbi S, Spera S, Suraci C, Cervoni M, Matteoli MC, Patera IP, Ghirlanda G; IMDIAB Group.",Diabetes Technol Ther. 2003;5(6):965-74. doi: 10.1089/152091503322641006.,Pozzilli P,2003,15,2,0.4069676902,1,"From Cochrane: WHO PARTICIPATED: 23 participants were included in this study. Eleven participants were randomised to CSII and seven completed. Twelve participants were randomised to, and completed MI.From Pozzilli: ""Twenty-three patients (between 12 and 35 years old, mean 6 SD 18.4 6 9 years) were randomized.. Table 1 reports on 19 patients.",20091571,,,Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2010 Jan 20;(1):CD005103. doi: 10.1002/14651858.CD005103.pub2.,Misso ML,2010,6.3,0.5,7,6.2,0.3,12,0.5323517095,0.1479043631,0,0,,post,0.1,0.0432142857,0,1
14747225,3,0,Switzerland,Commercial funding: grant from manufacturer Non-commercial funding: nil,commercial,24000051,published data only,1,1,1,2,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,61,Efficacy of Ipomoea batatas (Caiapo) on diabetes control in type 2 diabetic subjects treated with diet,"Ludvik B, Neuffer B, Pacini G.",Diabetes Care. 2004 Feb;27(2):436-40. doi: 10.2337/diacare.27.2.436.,Ludvik B,2004,3,2,0.0842616165,1,Ludvik reports:This investigation was performed in a total of 61 clinically stable,22336861,24000051,,Sweet potato for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2013 Sep 3;2013(9):CD009128. doi: 10.1002/14651858.CD009128.pub3.,Ooi CP,2013,6.68,0.77,30,7.1,1.06,31,-0.25794411,0.0362203974,1,0,,post,-0.42,0.0560084946,0,1
15220227,4,0,USA,COMMERCIAL FUNDING: Yes - pharmaceutical and industry. NON-COMMERCIAL FUNDING: Yes - government and foundations.,both,20091571,published data only,2,1,0,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,32,"A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin g","Doyle EA, Weinzimer SA, Steffen AT, Ahern JA, Vincent M, Tamborlane WV.",Diabetes Care. 2004 Jul;27(7):1554-8. doi: 10.2337/diacare.27.7.1554.,Doyle EA,2004,6,2,0.582072564,1,From Cochrane: WHO PARTCIPATED: 32 participants were included in this study.,20091571,,,Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2010 Jan 20;(1):CD005103. doi: 10.1002/14651858.CD005103.pub2.,Misso ML,2010,7.2,1,16,8.1,1.2,16,-0.064455466,0.0736901536,0,0,,post,-0.9,0.1525,0,1
15223975,1,0,Italy,Sources of funding: not mentioned. Trial authors' declarations of interest: not mentioned,not reported,31476798,published data only,2,1,0,2,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,229,Flexible treatment of gestational diabetes modulated on ultrasound evaluation of intrauterine growth: a controlled randomized clinical trial,"Bonomo M, Cetin I, Pisoni MP, Faden D, Mion E, Taricco E, Nobile de Santis M, Radaelli T, Motta G, Costa M, Solerte L, Morabito A.",Diabetes Metab. 2004 Jun;30(3):237-44. doi: 10.1016/s1262-3636(07)70114-3.,Bonomo M,2004,12,2,0.4510253964,1,from Cochrane:160 women randomised to intervention group and 80 women randomised to control group.,31476798,,,Fetal biometry for guiding the medical management of women with gestational diabetes mellitus for improving maternal and perinatal health,Cochrane Database Syst Rev. 2019 Sep 3;9(9):CD012544. doi: 10.1002/14651858.CD012544.pub2.,Rao U,2019,5.2,0.5,151,5.1,0.4,78,0.2005741104,0.0100734923,0,0,,post,0.1,0.0037069112,0,1
15237068,4,0.50884,Israel,COMMERCIAL FUNDING: Yes - NON-COMMERCIAL FUNDING: No,commercial,20091571,published and unpublished data,1,1,0,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,23,Glycemic patterns detected by continuous subcutaneous glucose sensing in children and adolescents with type 1 diabetes mellitus treated by multip,"Weintrob N, Schechter A, Benzaquen H, Shalitin S, Lilos P, Galatzer A, Phillip M.",Arch Pediatr Adolesc Med. 2004 Jul;158(7):677-84. doi: 10.1001/archpedi.158.7.677.,Weintrob N,2004,7,2,,1,From Cochrane: WHO PARTICIPATED: 23 participants were included in this study. Eleven participants were randomised to start with CSII-MI and ten completed CSII-MI. Twelve participants were randomised to start with MICSII and ten completed MI-CSII.,20091571,,,Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2010 Jan 20;(1):CD005103. doi: 10.1002/14651858.CD005103.pub2.,Misso ML,2010,8,0.8,22,8.2,0.8,22,0.0246816613,0.0308312281,0,0,,post,-0.2,0.0285765818,0,1
15334791,12,0,Italy,Funding: not reported,not reported,32501595,published data only,1,1,2,2,2,2,2,2,2,2,2,,,,,,,,,,,,,,0,0,0,0,0,0,0,0,0,,,,148,Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin,"Derosa G, Franzetti I, Gadaleta G, Ciccarelli L, Fogari R.",Diabetes Nutr Metab. 2004 Jun;17(3):143-50.,Derosa G,2004,5,2,0.9999999999,1,Characteristics of included studies in Cochrane review does not report on number randomized; Derosa report: We evaluated 164 patients,32501595,,,Metformin monotherapy for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Jun 5;6(6):CD012906. doi: 10.1002/14651858.CD012906.pub2.,Gnesin F,2020,7,0.9,75,6.9,0.7,73,0.2366982919,0.0142503874,0,0,,post,0.1,0.0175123288,0,1
15536785,3,0,Slovenia,Funding source: Not reported. Conflict of interests: Not reported,not reported,26545069,published and unpublished data,1,1,0,1,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,20,Periodontal treatment by Arestin and its effects on glycemic control in type 1 diabetes patients,"Skaleric U, Schara R, Medvescek M, Hanlon A, Doherty F, Lessem J.",J Int Acad Periodontol. 2004 Oct;6(4 Suppl):160-5.,Skaleric U,2004,6,2,0.7224171983,1,"From Cochrane:Number randomised: 20; Number evaluated: 20 at 3 months, 20 at 6 months",26545069,,,Treatment of periodontal disease for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2015 Nov 6;2015(11):CD004714. doi: 10.1002/14651858.CD004714.pub3.,Simpson TC,2015,8.48,1.41,10,8.91,1.24,10,0.1775281783,0.1281639922,0,0,,post,-0.43,0.35257,0,1
15536785,6,0,Slovenia,Funding source: Not reported. Conflict of interests: Not reported,not reported,26545069,published and unpublished data,1,1,0,1,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,20,Periodontal treatment by Arestin and its effects on glycemic control in type 1 diabetes patients,"Skaleric U, Schara R, Medvescek M, Hanlon A, Doherty F, Lessem J.",J Int Acad Periodontol. 2004 Oct;6(4 Suppl):160-5.,Skaleric U,2004,6,2,0.7224171983,1,"From Cochrane:Number randomised: 20; Number evaluated: 20 at 3 months, 20 at 6 months",26545069,,,Treatment of periodontal disease for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2015 Nov 6;2015(11):CD004714. doi: 10.1002/14651858.CD004714.pub3.,Simpson TC,2015,8.5,0.6,10,8.53,0.75,10,-0.219482948,0.124728563,0,0,,post,-0.03,0.09225,0,1
15569141,12,0,UK,Funding: Pfizer; Aventis UK; Eli Lilly; NovoNordisk; Boehringer Ingleheim; Servier Laboratories UK; Takeda UK,commercial,25188210,published data only,1,1,0,1,1,1,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,361,Evaluation of delivery of enhanced diabetes care to patients of South Asian ethnicity: the United Kingdom Asian Diabetes Study (UKADS),"O'Hare JP, Raymond NT, Mughal S, Dodd L, Hanif W, Ahmad Y, Mishra K, Jones A, Kumar S, Szczepura A, Hillhouse EW, Barnett AH; UKADS Study Group.",Diabet Med. 2004 Dec;21(12):1357-65. doi: 10.1111/j.1464-5491.2004.01373.x.,O'Hare JP,2004,12,2,0.9974545561,1,"Characteristics of included studies in Cochrane review does not report on number randomized; O'Hare reports: Of 401 patients recruited to the study, 361 (90%), comprising 178 from Coventry and 183 from Birmingham were eligible and included in the analyses.",25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,,,,,,,,,0,,,dif,-0.03,0.0270431061,0,0
15579760,12,0,Austria,Funding: not reported,not reported,32501595,published data only,2,2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1194,"Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial","Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P; Quartet [corrected] Study Group.",J Clin Endocrinol Metab. 2004 Dec;89(12):6068-76. doi: 10.1210/jc.2003-030861.,Schernthaner G,2004,5,2,0.8030879058,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Schernthaner reports: Eleven hundred and ninety-nine patients with poorly controlled type 2 diabetes mellitus [glycosylated hemoglobin (HbA1c), 7.5–11%; normal, 4.3–6.1%] were randomized",32501595,,,Metformin monotherapy for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Jun 5;6(6):CD012906. doi: 10.1002/14651858.CD012906.pub2.,Gnesin F,2020,,,,,,,,,0,,,dif,-0.09,0.0031996803,0,0
15595336,3,0,USA,COMMERCIAL FUNDING: Medtronic Inc,commercial,22258980,published data only,2,2,1,2,,,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,109,Use of the Continuous Glucose Monitoring System to guide therapy in patients with insulin-treated diabetes: a randomized controlled trial,"Tanenberg R, Bode B, Lane W, Levetan C, Mestman J, Harmel AP, Tobian J, Gross T, Mastrototaro J.",Mayo Clin Proc. 2004 Dec;79(12):1521-6. doi: 10.4065/79.12.1521.,Tanenberg R,2004,9,2,0.041124718,1,"From Cochrane: WHO PARTICIPATED: 128 patients with insulin treated diabetes, randomised to CGM (n=62) or SMBG (n=66). 19 patients dropped out; 4 had missing HbA1c values.",22258980,,,Continuous glucose monitoring systems for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008101. doi: 10.1002/14651858.CD008101.pub2.,Langendam M,2012,8.3,0.9,51,8.3,0.9,54,0.0005596337,0.0202602968,0,0,,dif,-0.01,0.0430460784,0,1
15616230,12,0,USA,"Funding: Agency for Health, Research and Quality, grant HS-10123",non-commercial,23543567,published data only,1,2,0,,,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,886,Randomized effectiveness trial of a computer-assisted intervention to improve diabetes care,"Glasgow RE, Nutting PA, King DK, Nelson CC, Cutter G, Gaglio B, Rahm AK, Whitesides H.",Diabetes Care. 2005 Jan;28(1):33-9. doi: 10.2337/diacare.28.1.33.,Glasgow RE,2005,8,2,0.8215947094,1,From Cochrane:Follow-up rates: Intervention:379/469 = 81%. Control: 354/417 = 85%.,23543567,,,Computer-based diabetes self-management interventions for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2013 Mar 28;2013(3):CD008776. doi: 10.1002/14651858.CD008776.pub2.,Pal K,2013,7.14,1.38,290,7.13,1.06,270,0.2622609395,0.0038124215,0,0,,post,0.01,0.010728378,0,1
15642076,6,0,Multi-countr,Funding: unclear - Haak study has as its 3rd author an employee from Novo Nordisk - products evaluated were from Novo Nordisk,commercial,33166419,published and unpublished data,2,2,1,2,1,2,0,0,,1,2,1,2,0,0,,,,,,,,,,2,2,2,2,2,2,,,,,,,505,Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with t,"Haak T, Tiengo A, Draeger E, Suntum M, Waldhäusl W.",Diabetes Obes Metab. 2005 Jan;7(1):56-64. doi: 10.1111/j.1463-1326.2004.00373.x.,Haak T,2005,5,2,0.8929887949,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Haak reports: This was a 26-week, multinational, open-label, parallel group trial with 505 patients with type 2 diabetes",33166419,,,(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Nov 9;11(11):CD005613. doi: 10.1002/14651858.CD005613.pub4.,Semlitsch T,2020,7.63,1.22,315,7.48,1.01,155,0.16740931,0.0050640647,0,0,,dif,0.2,0.01569064,0,1
15766369,3,0,Turkey,Funding source: not reported,not reported,35420698,published and unpublished data,2,2,0,0,2,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,44,The effect of improved periodontal health on metabolic control in type 2 diabetes mellitus,"Kiran M, Arpak N, Unsal E, Erdoan MF.",J Clin Periodontol. 2005 Mar;32(3):266-72. doi: 10.1111/j.1600-051X.2005.00658.x.,Kiran M,2005,4,2,0.3093341803,1,From Cochrane:Number randomised: 44; Number evaluated: 44,20464734,26545069,35420698,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,6.51,0.8,22,7.31,2.08,22,-0.838110751,0.0542602388,0,1,4,post,-0.8,0.2257454545,0,1
15808142,6,0,USA,"Funding: (blank in Cochrane)- Davidson reports: ""This study was supported by grants from Eli Lilly and Company and the NIH (DK 54047).",both,22258959,published data only,1,1,0,2,1,,,,,,,,,,,,,,,,,,,,2,2,,,,,,,,,,,88,"The effect of self monitoring of blood glucose concentrations on glycated hemoglobin levels in diabetic patients not taking insulin: a blinded, r","Davidson MB, Castellanos M, Kain D, Duran P.",Am J Med. 2005 Apr;118(4):422-5. doi: 10.1016/j.amjmed.2004.12.006.,Davidson MB,2005,4,2,0.2721648828,1,From Cochrane:Number of participants: 89,22258959,,,Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin,Cochrane Database Syst Rev. 2012 Jan 18;1:CD005060. doi: 10.1002/14651858.CD005060.pub3.,Malanda UL,2012,7.5,1.55,43,7.9,1.5,45,0.0851946233,0.025605359,0,0,,dif,-0.2,0.1575348837,0,1
15946117,3,0,USA,"Funding: American Diabetes Association Innovation Award, which in part is supported by NovoNordisk Pharmaceuticals",both,25188210,published data only,1,1,0,0,2,0,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,25,Diabetes self-management among low-income Spanish-speaking patients: a pilot study,"Rosal MC, Olendzki B, Reed GW, Gumieniak O, Scavron J, Ockene I.",Ann Behav Med. 2005 Jun;29(3):225-35. doi: 10.1207/s15324796abm2903_9.,Rosal MC,2005,6,2,0.8828976904,1,Characteristics of included studies in Cochrane review does not report on number randomized; Rosal reports:Participants were randomly assigned to an intervention (n = 15) or a control (n = 10) condition.,25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,,,,,,,,,0,,,dif,-0.56,0.0803366667,0,0
15946117,6,0,USA,"Funding: American Diabetes Association Innovation Award, which in part is supported by NovoNordisk Pharmaceuticals",both,25188210,published data only,1,1,0,0,2,0,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,25,Diabetes self-management among low-income Spanish-speaking patients: a pilot study,"Rosal MC, Olendzki B, Reed GW, Gumieniak O, Scavron J, Ockene I.",Ann Behav Med. 2005 Jun;29(3):225-35. doi: 10.1207/s15324796abm2903_9.,Rosal MC,2005,6,2,0.8828976904,1,Characteristics of included studies in Cochrane review does not report on number randomized; Rosal reports:Participants were randomly assigned to an intervention (n = 15) or a control (n = 10) condition.,25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,,,,,,,,,0,,,dif,-0.73,0.1037166667,0,0
15978304,6,0,USA,"Funding source: Eli Lilly, Takeda Europe",commercial,27640062,published data only,2,2,,2,,2,2,,1,,1,1,,,,,,,,,,,,,,2,,2,2,,,,,,,,289,Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlle,"Mattoo V, Eckland D, Widel M, Duran S, Fajardo C, Strand J, Knight D, Grossman L, Oakley D, Tan M; H6E-MC-GLAT study group.",Clin Ther. 2005 May;27(5):554-67. doi: 10.1016/j.clinthera.2005.05.005.,Mattoo V,2005,10,2,0.0571231724,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Mattoo reports: Of the 289 patients randomized to treatment (mean [SD] age, 58.9 [7.1] years; 164 women, 125 men), 142 received PIO + INS and 147 received PLB + INS. A total of 263 patients completed the study.",27640062,,,Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control,Cochrane Database Syst Rev. 2016 Sep 18;9(9):CD006992. doi: 10.1002/14651858.CD006992.pub2.,Vos RC,2016,8.11,1.07,142,8.66,0.97,147,,,0,,,dif,-0.56,0.0162939686,0,0
15998278,3,0,Spain,Funding source: Not reported. Conflict of interests: Not reported,not reported,26545069,published and unpublished data,1,1,0,1,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,60,Effect of non-surgical periodontal treatment with or without doxycycline on the periodontium of type 1 diabetic patients,"Llambés F, Silvestre FJ, Hernández-Mijares A, Guiha R, Caffesse R.",J Clin Periodontol. 2005 Aug;32(8):915-20. doi: 10.1111/j.1600-051X.2005.00736.x.,Llambés F,2005,5,2,0.4105033518,1,From Cochrane:Number randomised: 72; Number evaluated: 60,26545069,,,Treatment of periodontal disease for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2015 Nov 6;2015(11):CD004714. doi: 10.1002/14651858.CD004714.pub3.,Simpson TC,2015,7.71,1.74,30,7.45,1.29,30,0.2645895822,0.0383709037,0,0,,post,0.26,0.15639,0,1
16026361,12.01,0,Japan,Funding: not reported,not reported,32501595,published data only,2,1,,,,,,,,,,2,2,2,2,2,2,2,2,2,,,,,,,,,,,,,,,,,114,"Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes","Yamanouchi T, Sakai T, Igarashi K, Ichiyanagi K, Watanabe H, Kawasaki T.",Diabet Med. 2005 Aug;22(8):980-5. doi: 10.1111/j.1464-5491.2005.01656.x.,Yamanouchi T,2005,6,3,0.04470424,1,Characteristics of included studies in Cochrane review does not report on number randomized; Yamanouchi reports: total of 114 patients with Type 2 diabetes who had never used oral hypoglycaemic drugs were studied for 12 months,32501595,,,Metformin monotherapy for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Jun 5;6(6):CD012906. doi: 10.1002/14651858.CD012906.pub2.,Gnesin F,2020,7.8,1,38,7.7,0.9,34,0.0908037455,0.0303239244,0,0,,post,0.1,0.0501393189,0,1
16026361,12.02,0,Japan,Funding: not reported,not reported,32501595,published data only,2,1,,,,,,,,,,2,2,2,2,2,2,2,2,2,,,,,,,,,,,,,,,,,114,"Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes","Yamanouchi T, Sakai T, Igarashi K, Ichiyanagi K, Watanabe H, Kawasaki T.",Diabet Med. 2005 Aug;22(8):980-5. doi: 10.1111/j.1464-5491.2005.01656.x.,Yamanouchi T,2005,6,3,0.04470424,1,Characteristics of included studies in Cochrane review does not report on number randomized; Yamanouchi reports: total of 114 patients with Type 2 diabetes who had never used oral hypoglycaemic drugs were studied for 12 months,32501595,,,Metformin monotherapy for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Jun 5;6(6):CD012906. doi: 10.1002/14651858.CD012906.pub2.,Gnesin F,2020,7.8,1,38,7.9,1,35,0.0115592875,0.0299076933,0,0,,post,-0.1,0.054887218,0,1
16241873,5,0,USA,"Funding: American Diabetes Association (Medical Scholars Award), by the Warren G. Magnuson Institute for Biomedical Research and Health Professional Training (Magnuson Scholarship), and by an Alpha Omega Alpha Student Research Fellowship",non-commercial,23543567,published data only,2,2,0,,,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,50,"A randomized, controlled trial of an automated wireless messaging system for diabetes","Leu MG, Norris TE, Hummel J, Isaac M, Brogan MW.",Diabetes Technol Ther. 2005 Oct;7(5):710-8; discussion 719-20. doi: 10.1089/dia.2005.7.710.,Leu MG,2005,5,2,,1,"From Cochrane:18% dropout rate in control and intervention arms. From Leu:""The remaining 50 patients(37 with type 2 diabetes and 13 with type1 diabetes) enrolled in the study: 25 in eachgroup.",23543567,,,Computer-based diabetes self-management interventions for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2013 Mar 28;2013(3):CD008776. doi: 10.1002/14651858.CD008776.pub2.,Pal K,2013,8.2,,,7.9,,,,,0,,,dif,0.17,0.1140710526,0,0
16259492,1,0,USA,Funding: National Institutes of Health grants and the core of the Michigan Diabetes Research and Training Center,non-commercial,25188210,published data only,1,1,0,0,1,0,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,225,Evaluating a problem-based empowerment program for African Americans with diabetes: results of a randomized controlled trial,"Anderson RM, Funnell MM, Nwankwo R, Gillard ML, Oh M, Fitzgerald JT.",Ethn Dis. 2005 Autumn;15(4):671-8.,Anderson RM,2005,6,2,0.6123341862,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Anderson reports: The study enrolled 239 participants; 125 were randomized to a six-session program, and 114 were randomized to the wait-listed control group.",25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,8.34,1.91,117,8.13,2.08,108,-0.111050602,0.0101187043,0,0,,post,0.21,0.0712396011,0,1
16298697,3,0,USA,Funding: National Institute of Nursing Research Grant,non-commercial,25188210,published data only,2,1,0,1,2,1,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,41,Symptom-focused management for African American women with Type 2 diabetes: a pilot study,"Skelly AH, Carlson JR, Leeman J, Holditch-Davis D, Soward AC.",Appl Nurs Res. 2005 Nov;18(4):213-20. doi: 10.1016/j.apnr.2004.08.008.,Skelly AH,2005,5,2,0.9018558232,1,Characteristics of included studies in Cochrane review does not report on number randomized; Skelly reports: Forty-one participants were randomly assigned to either the intervention or the comparison group.,25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,7.92,1.3,22,8.46,2.6,17,,,0,,,post,-0.54,0.4744652406,0,0
16433711,6,0.68,multi-countr,COMMERCIAL FUNDING: Yes - NON-COMMERCIAL FUNDING: No,commercial,20091571,published and unpublished data,2,2,0,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,256,Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic c,"Hoogma RP, Hammond PJ, Gomis R, Kerr D, Bruttomesso D, Bouter KP, Wiefels KJ, de la Calle H, Schweitzer DH, Pfohl M, Torlone E, Krinelke LG, Bolli GB; 5-Nations Study Group.",Diabet Med. 2006 Feb;23(2):141-7. doi: 10.1111/j.1464-5491.2005.01738.x.,Hoogma RP,2006,13,2,0.6426963015,1,From Cochrane: WHO PARTICIPATED: 256 participants were included in this study.,20091571,,,Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2010 Jan 20;(1):CD005103. doi: 10.1002/14651858.CD005103.pub2.,Misso ML,2010,7.45,1,229,7.67,1.18,229,-0.136399516,0.0028808396,0,0,,post,-0.22,0.0034393013,0,1
16456680,9,0,Multi-countr,Funding: commercial and non-commercial funding (Academy of Finland; Sanofi),both,33166419,published and unpublished data,2,2,1,2,1,1,,0,,1,2,1,1,,0,,,,,,,,,,2,2,2,2,,2,,,,,,,110,Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study,"Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M, Vähätalo M, Virtamo H, Nikkilä K, Tulokas T, Hulme S, Hardy K, McNulty S, Hänninen J, Levänen H, Lahdenperä S, Lehtonen R, Ryysy L.",Diabetologia. 2006 Mar;49(3):442-51. doi: 10.1007/s00125-005-0132-0. Epub 2006 Feb 3.,Yki-Järvinen H,2006,15,2,0.1072460575,1,Characteristics of included studies in Cochrane review does not report on number randomized; Y reports: 110 insulin-naive type 2 diabetic patients with poor glycaemic control (HbA1c ?8.0%) on oral hypoglycaemic agents (90% using sulfonylurea plus metformin) were randomised,33166419,,,(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Nov 9;11(11):CD005613. doi: 10.1002/14651858.CD005613.pub4.,Semlitsch T,2020,7.14,0.94,61,7.16,0.98,49,-0.040909733,0.019772477,0,0,,dif,0.17,0.0492739378,0,1
16513202,6,0,Japan,Funding: unclear - Yokoyama does not appear to report on funding or support,not reported,33166419,published data only,1,1,,,,1,,0,,,,,1,,0,,,,,,,,,,,,,1,,1,,,,,,,62,Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy,"Yokoyama H, Tada J, Kamikawa F, Kanno S, Yokota Y, Kuramitsu M.",Diabetes Res Clin Pract. 2006 Jul;73(1):35-40. doi: 10.1016/j.diabres.2005.12.009. Epub 2006 Mar 2.,Yokoyama H,2006,6,2,0.2216434773,1,Characteristics of included studies in Cochrane review does not report on number randomized; Yokoyama reports: A total of 62 patients with type 2 diabetes on mealtime rapidacting insulin analogue and bedtime NPH were randomized to either continuation of bedtime NPH (n = 31) or morning glargine (n = 31) for 6 months while continuing,33166419,,,(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Nov 9;11(11):CD005613. doi: 10.1002/14651858.CD005613.pub4.,Semlitsch T,2020,6.6,,,7,,,,,0,,,dif,-0.7,0.0323387097,0,0
16570235,3,1,Germany,COMMERCIAL FUNDING: Medtronic Minimed,commercial,22258980,published data only,1,1,1,2,,,,,,,,,,,,,,,,,,,,,2,1,,,,,,,,,,,30,Results of a randomised controlled cross-over trial on the effect of continuous subcutaneous glucose monitoring (CGMS) on glycaemic control in ch,"Deiss D, Hartmann R, Schmidt J, Kordonouri O.",Exp Clin Endocrinol Diabetes. 2006 Feb;114(2):63-7. doi: 10.1055/s-2006-923887.,Deiss D,2006,4,2,0.8516211534,1,From Cochrane: WHO PARTICIPATED: 30 children with type 1 diabetes. 15 were randomised to start with open CGM and 15 patients with blinded CGM (control group). No dropouts.,22258980,,,Continuous glucose monitoring systems for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008101. doi: 10.1002/14651858.CD008101.pub2.,Langendam M,2012,7.8,1.1,15,8.3,1.1,15,0.0620543145,0.0790290077,0,0,,dif,0.1,0.1613333333,0,1
16634838,3,0,Germany,Commercial funding,commercial,22972104,published data only,1,1,2,,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,65,"Effects of a cinnamon extract on plasma glucose, HbA, and serum lipids in diabetes mellitus type 2","Mang B, Wolters M, Schmitt B, Kelb K, Lichtinghagen R, Stichtenoth DO, Hahn A.",Eur J Clin Invest. 2006 May;36(5):340-4. doi: 10.1111/j.1365-2362.2006.01629.x.,Mang B,2006,7,2,0.3600108702,1,"From Cochrane: Participants: 79 participants recruited, 65 analysed (cinnamon = 33, placebo = 32).",22972104,,,Cinnamon for diabetes mellitus,Cochrane Database Syst Rev. 2012 Sep 12;2012(9):CD007170. doi: 10.1002/14651858.CD007170.pub2.,Leach MJ,2012,6.83,0.83,33,6.68,0.7,32,0.1475824721,0.0335534292,1,0,,post,0.15,0.0361882576,0,1
16715577,6,0,Multi-countr,Funding: commercial funding (Sanofi),commercial,33166419,published and unpublished data,2,2,1,2,,2,,0,,1,2,,2,,0,,,,,,,,,,2,2,,2,,2,,,,,,,481,Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride,"Eliaschewitz FG, Calvo C, Valbuena H, Ruiz M, Aschner P, Villena J, Ramirez LA, Jimenez J; HOE 901/4013 LA Study Group.",Arch Med Res. 2006 May;37(4):495-501. doi: 10.1016/j.arcmed.2005.10.015.,Eliaschewitz FG,2006,8,2,0.7023426708,1,Characteristics of included studies in Cochrane review does not report on number randomized; Eliaschewitz reports: received glimepiride plus insulin glargine (n = 231) or NPH insulin (n = 250) using a forced titration algorithm.  Sample size here is from Table 2 in publication.,33166419,,,(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Nov 9;11(11):CD005613. doi: 10.1002/14651858.CD005613.pub4.,Semlitsch T,2020,7.65,1.3,218,7.78,1.29,244,0.0248093752,0.0046260041,0,0,,dif,0.06,0.0152422507,0,1
16732007,6,0,Multi-countr,Funding: commercial funding (Novo Nordisk),commercial,33166419,published and unpublished data,2,2,1,2,,2,,0,,1,2,,2,,0,,,,,,,,,,1,1,,1,,1,,,,,,,475,"A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drug","Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P.",Diabetes Care. 2006 Jun;29(6):1269-74. doi: 10.2337/dc05-1365.,Hermansen K,2006,6,2,0.29343833,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Hermansen reports: Individuals (n  476) with HbA1c (A1C) 7.5–10.0% were randomized to addition of twice-daily insulin detemir or NPH insulin in a parallel-group, multicenter trial.",33166419,,,(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Nov 9;11(11):CD005613. doi: 10.1002/14651858.CD005613.pub4.,Semlitsch T,2020,6.58,0.97,230,6.46,0.96,232,,,0,,,dif,0.06,0.0037243449,0,0
16761010,3,0,USA,"Cochrane provide no info: Manuscript reports:""We gratefully acknowledge the donation of the laboratory analyses by Quest Diagnostics and of the glucose meters, software and technical support by Roche Diagnostics. We are greatly indebted to Barbara Cleave, RN, BScN, CDE and Doris Roberts, RN, BSN, CDE, PHN for their tireless assistance with this project.""",commercial,27142841,published data only,2,1,0,1,,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,22,Managing type I diabetes in pregnancy: how near normal is necessary?,"Sacks DA, Feig DS, Liu IL, Wolde-Tsadik G.",J Perinatol. 2006 Aug;26(8):458-62. doi: 10.1038/sj.jp.7211546. Epub 2006 Jun 8.,Sacks DA,2006,4,2,0.7729134782,1,From Cochrane: 26 pregnant women with type 1 diabetes who presented for antenatal care before 13 weeks' GA.,20824880,22895976,27142841,Different intensities of glycaemic control for pregnant women with pre-existing diabetes,Cochrane Database Syst Rev. 2016 May 4;2016(5):CD008540. doi: 10.1002/14651858.CD008540.pub4.,Middleton P,2016,6.3,0.7,13,7.5,1.5,9,-0.60687261,0.1208558284,0,0,,post,-1.2,0.2876923077,0,1
16761010,6,0,USA,"Cochrane provide no info: Manuscript reports:""We gratefully acknowledge the donation of the laboratory analyses by Quest Diagnostics and of the glucose meters, software and technical support by Roche Diagnostics. We are greatly indebted to Barbara Cleave, RN, BScN, CDE and Doris Roberts, RN, BSN, CDE, PHN for their tireless assistance with this project.""",commercial,27142841,published data only,2,1,0,1,,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,22,Managing type I diabetes in pregnancy: how near normal is necessary?,"Sacks DA, Feig DS, Liu IL, Wolde-Tsadik G.",J Perinatol. 2006 Aug;26(8):458-62. doi: 10.1038/sj.jp.7211546. Epub 2006 Jun 8.,Sacks DA,2006,4,2,0.7729134782,1,From Cochrane: 26 pregnant women with type 1 diabetes who presented for antenatal care before 13 weeks' GA.,20824880,22895976,27142841,Different intensities of glycaemic control for pregnant women with pre-existing diabetes,Cochrane Database Syst Rev. 2016 May 4;2016(5):CD008540. doi: 10.1002/14651858.CD008540.pub4.,Middleton P,2016,5.6,0.8,13,6.1,0.6,9,0.3521234731,0.1180980375,0,0,,post,-0.5,0.0892307692,0,1
16761010,9,0,USA,"Cochrane provide no info: Manuscript reports:""We gratefully acknowledge the donation of the laboratory analyses by Quest Diagnostics and of the glucose meters, software and technical support by Roche Diagnostics. We are greatly indebted to Barbara Cleave, RN, BScN, CDE and Doris Roberts, RN, BSN, CDE, PHN for their tireless assistance with this project.""",commercial,27142841,published data only,2,1,0,1,,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,22,Managing type I diabetes in pregnancy: how near normal is necessary?,"Sacks DA, Feig DS, Liu IL, Wolde-Tsadik G.",J Perinatol. 2006 Aug;26(8):458-62. doi: 10.1038/sj.jp.7211546. Epub 2006 Jun 8.,Sacks DA,2006,4,2,0.7729134782,1,From Cochrane: 26 pregnant women with type 1 diabetes who presented for antenatal care before 13 weeks' GA.,20824880,22895976,27142841,Different intensities of glycaemic control for pregnant women with pre-existing diabetes,Cochrane Database Syst Rev. 2016 May 4;2016(5):CD008540. doi: 10.1002/14651858.CD008540.pub4.,Middleton P,2016,5.9,0.6,13,6.2,0.8,9,-0.258391266,0.1180988686,0,0,,post,-0.3,0.0988034188,0,1
16787523,4,0,USA,NON-COMMERCIAL FUNDING: Agency for Health Care Research and Quality,non-commercial,22258980,published data only,2,2,1,2,,,,,,,,,,,,,,,,,,,,,1,2,,,,,,,,,,,27,"Continuous subcutaneous glucose monitoring in children with type 1 diabetes mellitus: a single-blind, randomized, controlled trial","Lagarde WH, Barrows FP, Davenport ML, Kang M, Guess HA, Calikoglu AS.",Pediatr Diabetes. 2006 Jun;7(3):159-64. doi: 10.1111/j.1399-543X.2006.00162.x.,Lagarde WH,2006,6,2,0.933779024,1,"From Cochrane:WHO PARTICIPATED: 27 children with type 1 diabetes, randomised to CGM (n=18) or SMBG (n=9). No dropouts.",22258980,,,Continuous glucose monitoring systems for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008101. doi: 10.1002/14651858.CD008101.pub2.,Langendam M,2012,7.8,0.88,18,8.6,0.95,9,-0.011665492,0.1035185128,0,0,,dif,-0.33,0.0932888889,0,1
16801571,3,0,Australia,COMMERCIAL FUNDING: Medtronic Inc,commercial,22258980,published data only,2,2,1,2,,,,,,,,,,,,,,,,,,,,,2,2,,,,,,,,,,,36,Continuous glucose monitoring-guided insulin adjustment in children and adolescents on near-physiological insulin regimens: a randomized controll,"Yates K, Hasnat Milton A, Dear K, Ambler G.",Diabetes Care. 2006 Jul;29(7):1512-7. doi: 10.2337/dc05-2315.,Yates K,2006,4,2,0.5665239072,1,"From Cochrane: WHO PARTICIPATED: 36 patients with type 1 diabetes, 19 in the CGM group and 17 in the control group. No dropouts.",22258980,,,Continuous glucose monitoring systems for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008101. doi: 10.1002/14651858.CD008101.pub2.,Langendam M,2012,7.9,0.9372,19,7.6,0.5863,17,0.4266830445,0.06361525,0,0,,dif,0,0.0767063141,0,1
16801571,6,0,Australia,COMMERCIAL FUNDING: Medtronic Inc,commercial,22258980,published data only,2,2,1,2,,,,,,,,,,,,,,,,,,,,,2,2,,,,,,,,,,,36,Continuous glucose monitoring-guided insulin adjustment in children and adolescents on near-physiological insulin regimens: a randomized controll,"Yates K, Hasnat Milton A, Dear K, Ambler G.",Diabetes Care. 2006 Jul;29(7):1512-7. doi: 10.2337/dc05-2315.,Yates K,2006,4,2,0.5665239072,1,"From Cochrane: WHO PARTICIPATED: 36 patients with type 1 diabetes, 19 in the CGM group and 17 in the control group. No dropouts.",22258980,,,Continuous glucose monitoring systems for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008101. doi: 10.1002/14651858.CD008101.pub2.,Langendam M,2012,8.2,1.4578,19,7.8,0.8794,17,0.4515033515,0.064936957,0,0,,dif,0,0.1250213699,0,1
17011662,6,0,China,Funding: commercial funding (Sanofi-Aventis),commercial,33166419,published and unpublished data,2,2,1,2,1,1,,0,,1,2,1,1,,0,,,,,,,,,,2,2,2,2,,2,,,,,,,443,Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients,"Pan CY, Sinnassamy P, Chung KD, Kim KW; LEAD Study Investigators Group.",Diabetes Res Clin Pract. 2007 Apr;76(1):111-8. doi: 10.1016/j.diabres.2006.08.012. Epub 2006 Oct 2.,Pan CY,2007,4,2,0.5941357155,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Pan reports: 443 patients received either once-daily insulin glargine (n = 220) or NPH insulin (n = 223) at bedtime,",33166419,,,(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Nov 9;11(11):CD005613. doi: 10.1002/14651858.CD005613.pub4.,Semlitsch T,2020,7.9,1.09,220,8.13,1.09,223,0.0287260539,0.0047230725,0,0,,dif,-0.22,0.0105323115,0,1
17130215,3.01,0,Multi-countr,COMMERCIAL FUNDING: Medtronic,commercial,22258980,published data only,2,2,1,2,,,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,156,Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring,"Deiss D, Bolinder J, Riveline JP, Battelino T, Bosi E, Tubiana-Rufi N, Kerr D, Phillip M.",Diabetes Care. 2006 Dec;29(12):2730-2. doi: 10.2337/dc06-1134.,Deiss D,2006,8,3,0.3013498635,1,"From Cochrane: WHO PARTICIPATED: 81 children and 81 adults with type 1 diabetes, randomised 1:1:1 to two CGM (both n=54) and 1 control group (n=54). 156 patients completed the study.",22258980,,,Continuous glucose monitoring systems for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008101. doi: 10.1002/14651858.CD008101.pub2.,Langendam M,2012,8.55,1.18,54,9.28,1.54,54,-0.184259088,0.0200868201,0,0,,dif,-0.6,0.0409259259,0,1
17130215,3.02,0,Multi-countr,COMMERCIAL FUNDING: Medtronic,commercial,22258980,published data only,2,2,1,2,,,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,156,Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring,"Deiss D, Bolinder J, Riveline JP, Battelino T, Bosi E, Tubiana-Rufi N, Kerr D, Phillip M.",Diabetes Care. 2006 Dec;29(12):2730-2. doi: 10.2337/dc06-1134.,Deiss D,2006,8,3,0.3013498635,1,"From Cochrane: WHO PARTICIPATED: 81 children and 81 adults with type 1 diabetes, randomised 1:1:1 to two CGM (both n=54) and 1 control group (n=54). 156 patients completed the study.",22258980,,,Continuous glucose monitoring systems for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008101. doi: 10.1002/14651858.CD008101.pub2.,Langendam M,2012,8.89,1.25,54,9.28,1.54,54,-0.165632438,0.0201002179,0,0,,dif,-0.3,0.0498148148,0,1
17137468,3,0,USA,Funding source: grants from Veterans Affairs Health Services Research and Development Service and Boston University (VA HSR&D QUERI DII-99.206 and NIH K24 DE00419). Dentsply International provided ultrasonic scalers  and Colgate Oral Pharmaceuticals provided the gluconate rinse (PerioGards),both,35420698,published and unpublished data,2,2,0,0,2,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,165,Does periodontal care improve glycemic control? The Department of Veterans Affairs Dental Diabetes Study,"Jones JA, Miller DR, Wehler CJ, Rich SE, Krall-Kaye EA, McCoy LC, Christiansen CL, Rothendler JA, Garcia RI.",J Clin Periodontol. 2007 Jan;34(1):46-52. doi: 10.1111/j.1600-051X.2006.01002.x. Epub 2006 Nov 24.,Jones JA,2007,9,2,0.7895376388,1,"From Cochrane:Number randomised: 193; Number evaluated: 165 (Gp A 82, Gp B 83)/132 depending on outcome",20464734,26545069,35420698,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,9.28,1.42,82,9.59,1.56,83,-0.061077693,0.0130254119,0,0,,post,-0.31,0.0539107258,0,1
17145742,48.01,0,USA,Funding: commercial funding (GSK),commercial,32501595,published data only,2,2,2,2,2,2,2,2,2,2,2,,,,,,,,,,,,,,0,0,0,0,0,0,0,0,0,,,,4351,"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G; ADOPT Study Group.",N Engl J Med. 2006 Dec 7;355(23):2427-43. doi: 10.1056/NEJMoa066224. Epub 2006 Dec 4.,Kahn SE,2006,11,3,0.7524406759,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Khan reports: We evaluated rosiglitazone, metformin, and glyburide as initial treatment for recently diagnosed type 2 diabetes in a double-blind, randomized, controlled clinical trial involving 4360 patients.",32501595,,,Metformin monotherapy for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Jun 5;6(6):CD012906. doi: 10.1002/14651858.CD012906.pub2.,Gnesin F,2020,,,,,,,,,0,,,dif,-0.24,0.003108871,0,0
17145742,48.02,0,USA,Funding: commercial funding (GSK),commercial,32501595,published data only,2,2,2,2,2,2,2,2,2,2,2,,,,,,,,,,,,,,0,0,0,0,0,0,0,0,0,,,,4351,"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G; ADOPT Study Group.",N Engl J Med. 2006 Dec 7;355(23):2427-43. doi: 10.1056/NEJMoa066224. Epub 2006 Dec 4.,Kahn SE,2006,11,3,0.7524406759,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Khan reports: We evaluated rosiglitazone, metformin, and glyburide as initial treatment for recently diagnosed type 2 diabetes in a double-blind, randomized, controlled clinical trial involving 4360 patients.",32501595,,,Metformin monotherapy for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Jun 5;6(6):CD012906. doi: 10.1002/14651858.CD012906.pub2.,Gnesin F,2020,,,,,,,,,0,,,dif,0.26,0.003092785,0,0
17175680,2,0,USA,"Funding: National Institute of Diabetes & Digestive & Kidney Diseases, Grant #DK35524. Copic Insurance Company introduced the project to private physician offices",non-commercial,23543567,published data only,1,1,1,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,335,"Effects of a brief computer-assisted diabetes self-management intervention on dietary, biological and quality-of-life outcomes","Glasgow RE, Nutting PA, Toobert DJ, King DK, Strycker LA, Jex M, O'Neill C, Whitesides H, Merenich J.",Chronic Illn. 2006 Mar;2(1):27-38. doi: 10.1177/17423953060020011001.,Glasgow RE,2006,9,2,0.151981381,1,"From Cochrane: Attrition was modest (10%) by the 2-month assessment, and not different across conditions. From Glasgow 2006:""Type 2 diabetes primary care patients (n=335) from fee-for-service and health maintenance organizationsettings were randomized",23543567,,,Computer-based diabetes self-management interventions for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2013 Mar 28;2013(3):CD008776. doi: 10.1002/14651858.CD008776.pub2.,Pal K,2013,7.3,1.5,147,7.5,1.8,152,-0.155133623,0.0074475848,0,0,,post,-0.2,0.0366219119,0,1
17379048,3,0,USA,"COMMERCIAL FUNDING: Daiichi Sankyo, Inc",commercial,23235674,published data only,1,1,2,,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,65,"Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect","Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL.",Clin Ther. 2007 Jan;29(1):74-83. doi: 10.1016/j.clinthera.2007.01.003.,Zieve FJ,2007,5,2,0.1041717608,1,From Cochrane: WHO PARTCIPATED: 65 patients with T2DM,23235674,,,Colesevelam for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2012 Dec 12;12(12):CD009361. doi: 10.1002/14651858.CD009361.pub2.,Ooi CP,2012,7.7,0.6,27,8.3,1.2,32,-0.614796092,0.0374980751,1,1,3,dif,-0.5,0.0334606481,0,1
17392542,3,0,USA,Non-commercial finding,non-commercial,22972104,published data only,1,1,2,,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,57,The effect of cinnamon on A1C among adolescents with type 1 diabetes,"Altschuler JA, Casella SJ, MacKenzie TA, Curtis KM.",Diabetes Care. 2007 Apr;30(4):813-6. doi: 10.2337/dc06-1871.,Altschuler JA,2007,4,2,0.197078443,1,"From Cochrane:Participants: 72 adolescents randomised, 57 analysed (cinnamon = 28, placebo = 29). Mean age (cinnamon = 14.7 ± 1.4 years, placebo = 15.2 ± 1.7 years).",22972104,,,Cinnamon for diabetes mellitus,Cochrane Database Syst Rev. 2012 Sep 12;2012(9):CD007170. doi: 10.1002/14651858.CD007170.pub2.,Leach MJ,2012,8.8,1.6,28,8.7,1.4,29,0.1226202209,0.0397739551,1,0,,post,0.1,0.1590147783,0,1
17479164,9,0,USA,"Funding: commercial funding by Genentech Center for Clinical Research in Endocrinology, Pfizer Pharmaceuticals; non-commercial funding by an F-32 National Research Service Award from the National Institutes of Health, Research",both,33210751,published data only,2,2,2,,,,2,2,,2,2,,2,2,,,,2,2,,2,2,,2,0,,,,0,0,,0,0,,0,,81,Effects of growth hormone and pioglitazone in viscerally obese adults with impaired glucose tolerance: a factorial clinical trial,"Attallah H, Friedlander AL, Nino-Murcia M, Hoffman AR.",PLoS Clin Trials. 2007 May 4;2(5):e21. doi: 10.1371/journal.pctr.0020021.,Attallah H,2007,4,4,0.2558413795,1,Characteristics of included studies in Cochrane review does not report on number randomized; Atallah reports: 81 patients randomized shown in Table 2 -62 abdominally obese adults aged 40–75 with impaired glucose tolerance.,33210751,,,Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Nov 19;11(11):CD013516. doi: 10.1002/14651858.CD013516.pub2.,Ipsen EØ,2020,5.7,0.39,15,5.8,0.4,16,-0.005552528,0.0744303158,1,0,,post,-0.1,0.02014,0,1
17493509,3,0,Philippines,COMMERCIAL FUNDING: yes NON-COMMERCIAL FUNDING: no,commercial,22895968,published data only,2,2,2,,,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,40,The effect of Momordica charantia capsule preparation on glycemic control in type 2 diabetes mellitus needs further studies,"Dans AM, Villarruz MV, Jimeno CA, Javelosa MA, Chua J, Bautista R, Velez GG.",J Clin Epidemiol. 2007 Jun;60(6):554-9. doi: 10.1016/j.jclinepi.2006.07.009. Epub 2006 Nov 13.,Dans AM,2007,7,2,0.1586684755,1,"Dans reports: ""The trial included 40 patients""",20166099,22895968,,Momordica charantia for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2012 Aug 15;(8):CD007845. doi: 10.1002/14651858.CD007845.pub3.,Ooi CP,2012,8.2,1.25,20,8.57,0.3,20,1.4706996278,0.0566254921,1,1,6+,dif,-0.22,0.087725,0,1
17509069,12,0,USA,Funding: commercial funding (Novartis),commercial,32501595,published data only,2,2,2,2,2,2,2,2,2,2,2,,,,,,,,,,,,,,0,0,0,0,0,0,0,0,0,,,,780,Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes,"Schweizer A, Couturier A, Foley JE, Dejager S.",Diabet Med. 2007 Sep;24(9):955-61. doi: 10.1111/j.1464-5491.2007.02191.x. Epub 2007 May 17.,Schweizer A,2007,4,2,0.0127532702,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Schweizer reports: Double-blind, randomized, multicentre, active-controlled, parallel-group study of 52-week treatment with vildagliptin (100 mg daily, n= 526) or metformin (titrated to 2000 mg daily,n=254) in",32501595,,,Metformin monotherapy for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Jun 5;6(6):CD012906. doi: 10.1002/14651858.CD012906.pub2.,Gnesin F,2020,,,,,,,,,0,,,dif,-0.4,0.0198945001,0,0
17561800,3,0,USA,"Funding: ""This study was supported by grant R21-DK-071694 from the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health"". Declarations of interest: ""C.J.H., L.D., K.R., W.M., D.M., and J.G. have nothing to disclose. W.P.S. has stock ownership in Insight Telehealth Systems. A.A.B. is a consultant for Insight Telehealth Systems"".",non-commercial,29081069,published data only,1,1,0,1,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,63,Use of an internet-based telemedicine system to manage underserved women with gestational diabetes mellitus,"Homko CJ, Santamore WP, Whiteman V, Bower M, Berger P, Geifman-Holtzman O, Bove AA.",Diabetes Technol Ther. 2007 Jun;9(3):297-306. doi: 10.1089/dia.2006.0034.,Homko CJ,2007,7,2,0.6247313592,1,from Cochrane:61 women randomised,29081069,,,Different methods and settings for glucose monitoring for gestational diabetes during pregnancy,Cochrane Database Syst Rev. 2017 Oct 29;10(10):CD011069. doi: 10.1002/14651858.CD011069.pub2.,Raman P,2017,6.1,0.8,32,6.2,2.2,25,-0.997795227,0.04393745,0,1,5,post,-0.1,0.2136,0,1
17563345,2,0,USA,Non-commercial funding,non-commercial,22972104,published data only,1,1,1,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,57,Effect of cinnamon on glucose and lipid levels in non insulin-dependent type 2 diabetes,"Blevins SM, Leyva MJ, Brown J, Wright J, Scofield RH, Aston CE.",Diabetes Care. 2007 Sep;30(9):2236-7. doi: 10.2337/dc07-0098. Epub 2007 Jun 11.,Blevins SM,2007,6,2,0.2183346357,1,"From Cochrane: Participants: 60 participants randomised, 57 analysed (cinnamon = 29, placebo = 28).",22972104,,,Cinnamon for diabetes mellitus,Cochrane Database Syst Rev. 2012 Sep 12;2012(9):CD007170. doi: 10.1002/14651858.CD007170.pub2.,Leach MJ,2012,7.3,1.7,29,7.3,1.4,27,0.1925284701,0.0417002603,1,0,,post,0,0.172247765,0,1
17570858,6,0,Finland,Commercial funding: GlaxoSmithKline,commercial,23235661,published data only,2,2,2,2,2,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,43,Quality of life and metabolic status in mildly depressed patients with type 2 diabetes treated with paroxetine: a double-blind randomised placebo,"Paile-Hyvärinen M, Wahlbeck K, Eriksson JG.",BMC Fam Pract. 2007 Jun 15;8:34. doi: 10.1186/1471-2296-8-34.,Paile-Hyvärinen,2007,3,2,0.1770808536,1,Characteristics of included studies in Cochrane review does not report on number randomized; Pail reports: We randomised 49 mildly depressed primary care outpatients with non-optimally controlled diabetes to a 6-month double-blind treatment,23235661,,,Psychological and pharmacological interventions for depression in patients with diabetes mellitus and depression,Cochrane Database Syst Rev. 2012 Dec 12;12:CD008381. doi: 10.1002/14651858.CD008381.pub2.,Baumeister H,2012,8.3,0.98,23,8.4,0.95,14,,,1,,,post,-0.1,0.1062208075,0,0
17591623,6,0,UK,Funding: National Health Service and the National Institute for Health Research health technology assessment programme.,non-commercial,22258959,published data only,2,2,0,0,2,,,,,,,,,,,,,,,,,,,,2,2,,,,,,,,,,,453,Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial,"Farmer A, Wade A, Goyder E, Yudkin P, French D, Craven A, Holman R, Kinmonth AL, Neil A.",BMJ. 2007 Jul 21;335(7611):132. doi: 10.1136/bmj.39247.447431.BE. Epub 2007 Jun 25.,Farmer A,2007,9,3,0.7870349278,1,From Cochrane:Number of participants: 453,22258959,,,Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin,Cochrane Database Syst Rev. 2012 Jan 18;1:CD005060. doi: 10.1002/14651858.CD005060.pub3.,Malanda UL,2012,7.3,1.0083,301,7.4,1,152,0.0202551845,0.0051889423,0,0,,dif,-0.07,0.0056856553,0,1
17591623,12,0,UK,Funding: National Health Service and the National Institute for Health Research health technology assessment programme.,non-commercial,22258959,published data only,2,2,0,0,2,,,,,,,,,,,,,,,,,,,,2,2,,,,,,,,,,,453,Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial,"Farmer A, Wade A, Goyder E, Yudkin P, French D, Craven A, Holman R, Kinmonth AL, Neil A.",BMJ. 2007 Jul 21;335(7611):132. doi: 10.1136/bmj.39247.447431.BE. Epub 2007 Jun 25.,Farmer A,2007,9,3,0.7870349278,1,From Cochrane:Number of participants: 453,22258959,,,Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin,Cochrane Database Syst Rev. 2012 Jan 18;1:CD005060. doi: 10.1002/14651858.CD005060.pub3.,Malanda UL,2012,7.3502,0.9687,301,7.5,1.2,152,-0.195535606,0.0052315513,0,0,,dif,-0.15,0.0088659993,0,1
17645559,5,0,Multi-countr,Commercial other funding: grant from manufacturer Non-commercial funding: nil,commercial,24000051,published data only,1,1,1,2,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,61,Improved metabolic control by Ipomoea batatas (Caiapo) is associated with increased adiponectin and decreased fibrinogen levels in type 2 diabeti,"Ludvik B, Hanefeld M, Pacini G.",Diabetes Obes Metab. 2008 Jul;10(7):586-92. doi: 10.1111/j.1463-1326.2007.00752.x. Epub 2007 Jul 21.,Ludvik B,2008,3,2,0.8778586119,1,"Ludvik reports:The recruitment involved 88 patients, but only 61 completed the study; ""for 5 months""",22336861,24000051,,Sweet potato for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2013 Sep 3;2013(9):CD009128. doi: 10.1002/14651858.CD009128.pub3.,Ooi CP,2013,6.25,0.57,27,6.5,0.7,34,-0.16212748,0.036230332,1,0,,post,-0.25,0.026445098,0,1
17684167,3,0,USA,Funding: supported by a grant from the Paso del Norte Health Foundation through the Center for Border Health Research,non-commercial,25188210,published data only,1,1,0,0,2,0,,,,,,,,,,,,,,,,,,,2,2,,,,,,,,,,,150,Promotora diabetes intervention for Mexican Americans,"Lujan J, Ostwald SK, Ortiz M.",Diabetes Educ. 2007 Jul-Aug;33(4):660-70. doi: 10.1177/0145721707304080.,Lujan J,2007,3,2,0.7108173424,1,Characteristics of included studies in Cochrane review does not report on number randomized; Lujan reports:One hundred fifty Mexican American participants were recruited at a Catholic faith-based clinic and randomized into 2 groups.,25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,7.75,2,73,7.84,1.7,70,0.1736426863,0.0159769134,0,0,,post,-0.09,0.0960802348,0,1
17684167,6,0,USA,Funding: supported by a grant from the Paso del Norte Health Foundation through the Center for Border Health Research,non-commercial,25188210,published data only,1,1,0,0,2,0,,,,,,,,,,,,,,,,,,,2,2,,,,,,,,,,,150,Promotora diabetes intervention for Mexican Americans,"Lujan J, Ostwald SK, Ortiz M.",Diabetes Educ. 2007 Jul-Aug;33(4):660-70. doi: 10.1177/0145721707304080.,Lujan J,2007,3,2,0.7108173424,1,Characteristics of included studies in Cochrane review does not report on number randomized; Lujan reports:One hundred fifty Mexican American participants were recruited at a Catholic faith-based clinic and randomized into 2 groups.,25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,7.76,1.87,71,8.01,1.8,70,0.0697084269,0.0161362013,0,0,,post,-0.25,0.095537827,0,1
17718288,3,0,Thailand,(Non-)/commercial funding: not stated; publication does not reportfunding source. Cochrane statements is interpreted as publication not informing on funding sources.,not reported,22972104,published data only,1,1,0,,,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,60,The effect of cinnamon cassia powder in type 2 diabetes mellitus,"Suppapitiporn S, Kanpaksi N, Suppapitiporn S.",J Med Assoc Thai. 2006 Sep;89 Suppl 3:S200-5.,Suppapitiporn S,2006,3,2,0.532928222,1,"From Cochrane:Participants: 60 participants recruited, 60 analysed (cinnamon = 20, placebo = 40).",22972104,,,Cinnamon for diabetes mellitus,Cochrane Database Syst Rev. 2012 Sep 12;2012(9):CD007170. doi: 10.1002/14651858.CD007170.pub2.,Leach MJ,2012,7.76,0.95,20,7.87,0.96,40,0.016911018,0.041971782,1,0,,post,-0.11,0.068165,0,1
17726570,6.01,0,Turkey,Funding source: not stated,not reported,27640062,published data only,2,1,,1,,1,1,,1,,1,1,,,,,,,,,,,,,,2,,2,2,,,,,,,,66,Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type,"Yilmaz H, Gursoy A, Sahin M, Guvener Demirag N.",Acta Diabetol. 2007 Dec;44(4):187-92. doi: 10.1007/s00592-007-0004-9. Epub 2007 Aug 29.,Yilmaz H,2007,4,4,0.9906681642,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Yilmaz reports: Sixty-six poorly controlled type 2 diabetic patients on insulin monotherapy were involved. They were randomized to insulin alone,",27640062,,,Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control,Cochrane Database Syst Rev. 2016 Sep 18;9(9):CD006992. doi: 10.1002/14651858.CD006992.pub2.,Vos RC,2016,6.9,1.2,17,7.6,1.2,19,0.0998655494,0.0656178624,0,0,,dif,-0.9,0.1938427245,0,1
17726570,6.02,0,Turkey,Funding source: not stated,not reported,27640062,published data only,2,1,,1,,1,1,,1,,1,1,,,,,,,,,,,,,,2,,2,2,,,,,,,,66,Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type,"Yilmaz H, Gursoy A, Sahin M, Guvener Demirag N.",Acta Diabetol. 2007 Dec;44(4):187-92. doi: 10.1007/s00592-007-0004-9. Epub 2007 Aug 29.,Yilmaz H,2007,4,4,0.9906681642,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Yilmaz reports: Sixty-six poorly controlled type 2 diabetic patients on insulin monotherapy were involved. They were randomized to insulin alone,",27640062,,,Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control,Cochrane Database Syst Rev. 2016 Sep 18;9(9):CD006992. doi: 10.1002/14651858.CD006992.pub2.,Vos RC,2016,7.7,1.8,15,7.6,1.2,19,0.3991640517,0.0725490455,0,0,,dif,0.5,0.3523435088,0,1
17909165,2,0,USA,Funding: grant from University of Arizona,non-commercial,25188210,published data only,2,1,0,0,2,0,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,17,A feasibility study of a culturally tailored diabetes intervention for Mexican Americans,"Vincent D, Pasvogel A, Barrera L.",Biol Res Nurs. 2007 Oct;9(2):130-41. doi: 10.1177/1099800407304980.,Vincent D,2007,3,2,0.4049459366,1,Characteristics of included studies in Cochrane review does not report on number randomized; Vincent reports: The study used a pretest/posttest control group design with 10 participants in each group (N = 17).,25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,6.14,0.5,9,6.84,1.3,8,-0.854587797,0.1572077155,0,1,4,post,-0.7,0.2390277778,0,1
18018467,4,0,China,Funding source: not reported,not reported,35420698,published and unpublished data,1,1,0,0,1,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,46,Effect of non-surgical periodontal therapy on patients with type 2 diabetes mellitus,"Yun F, Firkova EI, Jun-Qi L, Xun H.",Folia Med (Plovdiv). 2007;49(1-2):32-6.,Yun F,2007,4,2,0.0102094003,1,From Cochrane:Number randomised: 46; Number evaluated: 46,20464734,26545069,35420698,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,7.49,1.34,23,7.64,1.73,23,-0.235204121,0.0511450732,0,0,,post,-0.15,0.2081956522,0,1
18058596,4,0,Germany,Funding source: Sanofi-Aventis,commercial,27640062,published data only,2,2,,0,0,0,0,,0,0,0,0,,,,,,,,,,,,,,2,2,2,2,,,,,,,,52,Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insu,"Schiel R, Müller UA.",Exp Clin Endocrinol Diabetes. 2007 Nov;115(10):627-33. doi: 10.1055/s-2007-984445.,Schiel R,2007,2,3,0.9826407972,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Schiel reports: In an open, controlled, randomized, parallel-group, single-centre, 16-week pilot study, 52 patients",27640062,,,Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control,Cochrane Database Syst Rev. 2016 Sep 18;9(9):CD006992. doi: 10.1002/14651858.CD006992.pub2.,Vos RC,2016,7.87,0.66,17,7.83,1.13,17,-0.542422913,0.0680459262,0,1,3,dif,-0.1,0.0771058824,0,1
18096810,6,0,USA,Funding: National Institutues of Health/National Institutes of Nursing Research grant and Michigan Diabetes Research and Training Center,non-commercial,25188210,published data only,1,1,0,0,2,0,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,417,Spanish diabetes self-management with and without automated telephone reinforcement: two randomized trials,"Lorig K, Ritter PL, Villa F, Piette JD.",Diabetes Care. 2008 Mar;31(3):408-14. doi: 10.2337/dc07-1313. Epub 2007 Dec 20.,Lorig K,2008,4,2,0.364451313,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Lorig reports:A total of 567 Spanish-speaking adults with type 2 diabetes were randomized to a usual-care control group or 6-week community-based, peer-led SDSMP.",25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,,,,,,,,,0,,,dif,-0.358,0.0255127813,0,0
18204830,12,0,multi-countr,"COMMERCIAL FUNDING: Yes: ""The study was funded and monitored by Novo Nordisk"".NON-COMMERCIAL FUNDING: No.",commercial,21735405,published and unpublished data,2,2,0,,,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,582,"A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drug","Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G.",Diabetologia. 2008 Mar;51(3):408-16. doi: 10.1007/s00125-007-0911-x. Epub 2008 Jan 16.,Rosenstock J,2008,6,2,0.0736983791,1,"From Cochrane: WHO PARTCIPATED: SEX (female% / male%): 245 (42.1%) / 337 (57.9%).Rosenstock reports: ""Insulin-naive adults (n=582, HbA1c 7.5–10.0%, BMI?40.0 kg/m2) were randomised 1:1",21735405,,,Insulin detemir versus insulin glargine for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Jul 6;2011(7):CD006383. doi: 10.1002/14651858.CD006383.pub2.,Swinnen SG,2011,7.16,1.31,268,7.12,1.33,275,,,0,,,post,0.04,0.0128357218,0,0
18227359,12,0,USA,Funding: Supported by grant 5R44DK060272-3 from the US National Institute of Diabetes and Digestive and Kidney Diseases to PHCC LP Pueblo Colorado,non-commercial,23543567,published data only,2,2,0,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,310,Clinic-based support to help overweight patients with type 2 diabetes increase physical activity and lose weight,"Christian JG, Bessesen DH, Byers TE, Christian KK, Goldstein MG, Bock BC.",Arch Intern Med. 2008 Jan 28;168(2):141-6. doi: 10.1001/archinternmed.2007.13.,Christian JG,2008,6,2,0.7137026345,1,From Cochrane:Follow-up rates: Intervention: 141/155 = 91%. Control: 132/155 = 85%.,23543567,,,Computer-based diabetes self-management interventions for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2013 Mar 28;2013(3):CD008776. doi: 10.1002/14651858.CD008776.pub2.,Pal K,2013,,,,,,,,,0,,,dif,0.319,0.0420968246,0,0
18307459,4,0.68,Italy,COMMERCIAL FUNDING: Yes - Disetronic Medical System AG (one of the study investigators was a full time employee and another was funded to attend conferences)NON-COMMERCIAL FUNDING: No,commercial,20091571,published data only,2,2,0,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,39,"In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than","Bruttomesso D, Crazzolara D, Maran A, Costa S, Dal Pos M, Girelli A, Lepore G, Aragona M, Iori E, Valentini U, Del Prato S, Tiengo A, Buhr A, Trevisan R, Baritussio A.",Diabet Med. 2008 Mar;25(3):326-32. doi: 10.1111/j.1464-5491.2007.02365.x.,Bruttomesso D,2008,15,2,0.6142214738,1,"From Cochrane: WHO PARTICIPATED: 42 participants were included in this study Bruttomesso: ""Finally, 42 patients were enrolled and data from 39 patients were analysed.""",20091571,,,Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2010 Jan 20;(1):CD005103. doi: 10.1002/14651858.CD005103.pub2.,Misso ML,2010,7.1,0.7,39,7.2,0.8,39,-0.119511492,0.0170708343,0,0,,post,-0.1,0.0094461538,0,1
18420662,6,0,Northern Ire,Funding: Northern Ireland research and development office,non-commercial,22258959,published data only,2,2,0,0,2,,,,,,,,,,,,,,,,,,,,2,2,,,,,,,,,,,184,Efficacy of self monitoring of blood glucose in patients with newly diagnosed type 2 diabetes (ESMON study): randomised controlled trial,"O'Kane MJ, Bunting B, Copeland M, Coates VE; ESMON study group.",BMJ. 2008 May 24;336(7654):1174-7. doi: 10.1136/bmj.39534.571644.BE. Epub 2008 Apr 17.,O'Kane MJ,2008,4,2,0.9705821386,1,From Cochrane:Number of participants: 195,22258959,,,Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin,Cochrane Database Syst Rev. 2012 Jan 18;1:CD005060. doi: 10.1002/14651858.CD005060.pub3.,Malanda UL,2012,7,0.9,96,7,1.1,88,-0.201100455,0.0115846052,0,0,,dif,-0.2,0.0960511364,0,1
18420662,12,0,Northern Ire,Funding: Northern Ireland research and development office,non-commercial,22258959,published data only,2,2,0,0,2,,,,,,,,,,,,,,,,,,,,2,2,,,,,,,,,,,184,Efficacy of self monitoring of blood glucose in patients with newly diagnosed type 2 diabetes (ESMON study): randomised controlled trial,"O'Kane MJ, Bunting B, Copeland M, Coates VE; ESMON study group.",BMJ. 2008 May 24;336(7654):1174-7. doi: 10.1136/bmj.39534.571644.BE. Epub 2008 Apr 17.,O'Kane MJ,2008,4,2,0.9705821386,1,From Cochrane:Number of participants: 195,22258959,,,Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin,Cochrane Database Syst Rev. 2012 Jan 18;1:CD005060. doi: 10.1002/14651858.CD005060.pub3.,Malanda UL,2012,6.9,0.8,96,6.9,1.2,88,-0.405847239,0.0116155421,0,0,,dif,-0.2,0.0947962121,0,1
18454655,3,0,Brazil,"Funding source: Grant from Sao Paulo Research foundation (04/09844-8), National Council for Scientific and Technological Development (470638/2006) and a scholarship from Coordination for the Improvement of Graduated Personnel. Doxycycline was donated by Pfizer, BrazilConflict of interests: Authors declare no conflict of interests exist article: ""The authors thank Pfizer, Brazilian Division,Sao Paulo, SP, Brazil, for the donation of medicine. Conflict of interests: Authors declare no conflict of interests exist",non-commercial,26545069,published data only,1,1,1,1,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,30,Effects of periodontal therapy on glycemic control and inflammatory markers,"O'Connell PA, Taba M, Nomizo A, Foss Freitas MC, Suaid FA, Uyemura SA, Trevisan GL, Novaes AB, Souza SL, Palioto DB, Grisi MF.",J Periodontol. 2008 May;79(5):774-83. doi: 10.1902/jop.2008.070250.,O'Connell PA,2008,11,2,0.6819366611,1,From Cochrane:Number randomised: 35; Number evaluated: 30,26545069,,,Treatment of periodontal disease for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2015 Nov 6;2015(11):CD004714. doi: 10.1002/14651858.CD004714.pub3.,Simpson TC,2015,10.3,2.3,15,9.8,2,15,0.0897266325,0.0826408347,0,0,,post,0.5,0.6193333333,0,1
18458145,6,0,multi-countr,"COMMERCIAL FUNDING: Daiichi Sankyo, Inc",commercial,23235674,published data only,1,1,2,,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,461,Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-ba,"Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR.",Diabetes Care. 2008 Aug;31(8):1479-84. doi: 10.2337/dc08-0283. Epub 2008 May 5.,Fonseca VA,2008,5,2,0.8481787335,1,From Cochrane: WHO PARTCIPATED: 461 patients with T2DM,23235674,,,Colesevelam for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2012 Dec 12;12(12):CD009361. doi: 10.1002/14651858.CD009361.pub2.,Ooi CP,2012,7.8,1.06,218,8.5,1.25,218,-0.07892497,0.0048134591,1,0,,dif,-0.6,0.0081651376,0,1
18466210,14,0,Netherlands,"COMMERCIAL FUNDING: No - NON-COMMERCIAL FUNDING: Yes - Ministry of Health and the trust Funds of National Health Insurance CIEs and of University Hospitals (VAZ/VWS). Additional funding was obtained from the Child Health and Wellbeing Fund, the Volkskracht Fund and the van Leeuwen Lignac Fund, all in Rotterdam, the Netherlands.",non-commercial,20091571,published data only,1,2,1,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,38,Effects of insulin pump vs. injection treatment on quality of life and impact of disease in children with type 1 diabetes mellitus in a randomize,"Nuboer R, Borsboom GJ, Zoethout JA, Koot HM, Bruining J.",Pediatr Diabetes. 2008 Jul 28;9(4 Pt 1):291-6. doi: 10.1111/j.1399-5448.2008.00396.x. Epub 2008 May 7.,Nuboer R,2008,5,2,0.1094985706,1,"From Cochrane: WHO PARTICIPATED: 39 participants were included in this study. 20 participants (13 female, 7 male) were randomised to CSII and 19 completed (12 female, 7 male), and the other 19 participants (9 female, 10 male) were randomised to and completed MI.From Nuboer: ""Thirty-nine patients were enrolled in 11 months time, 20 from our own clinic and 19 referred for the duration of the investigation."" Table 1 reports on 38 patients",20091571,,,Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2010 Jan 20;(1):CD005103. doi: 10.1002/14651858.CD005103.pub2.,Misso ML,2010,7.49,0.5,19,7.97,0.78,19,-0.382435346,0.0593807757,0,0,,post,-0.48,0.0451789474,0,1
18494813,6,0,Multi-countr,Funding: Unristricted grant from Servier,commercial,22258959,published data only,2,2,0,0,1,,,,,,,,,,,,,,,,,,,,2,0,,,,,,,,,,,610,The efficacy of self-monitoring of blood glucose in the management of patients with type 2 diabetes treated with a gliclazide modified release-ba,"Barnett AH, Krentz AJ, Strojek K, Sieradzki J, Azizi F, Embong M, Imamoglu S, Perusicová J, Uliciansky V, Winkler G.",Diabetes Obes Metab. 2008 Dec;10(12):1239-47. doi: 10.1111/j.1463-1326.2008.00894.x. Epub 2008 May 20.,Barnett AH,2008,10,2,0.1922765764,1,From Cochrane:Number of participants: 610,22258959,,,Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin,Cochrane Database Syst Rev. 2012 Jan 18;1:CD005060. doi: 10.1002/14651858.CD005060.pub3.,Malanda UL,2012,6.95,0.97,311,7.2,1.22,299,-0.194018954,0.0034602547,0,0,,dif,-0.24,0.00974433,0,1
18502301,24,0,UK,Funding: grants from UKAD study from numerous organisations,non-commercial,25188210,published data only,1,1,0,1,1,1,,,,,,,,,,,,,,,,,,,2,1,,,,,,,,,,,1486,Enhanced diabetes care to patients of south Asian ethnic origin (the United Kingdom Asian Diabetes Study): a cluster randomised controlled trial,"Bellary S, O'Hare JP, Raymond NT, Gumber A, Mughal S, Szczepura A, Kumar S, Barnett AH; UKADS Study Group.",Lancet. 2008 May 24;371(9626):1769-76. doi: 10.1016/S0140-6736(08)60764-3.,Bellary S,2008,8,2,0.7664458724,1,Characteristics of included studies in Cochrane review does not report on number randomized; Bellary reports: assigned by simplerandomisation to intervention (enhanced care including additional time with practice nurse and support from a link worker and diabetes-specialist nurse [nine practices; n=868]) or control (standard care [12 practices; n=618]) groups.,25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,,,,,,,,,0,,,dif,-0.1,0.0071462846,0,0
18663165,4,0,multi-countr,"COMMERCIAL FUNDING: Daiichi Sankyo, Inc",commercial,23235674,published data only,1,1,2,,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,287,Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy,"Goldberg RB, Fonseca VA, Truitt KE, Jones MR.",Arch Intern Med. 2008 Jul 28;168(14):1531-40. doi: 10.1001/archinte.168.14.1531.,Goldberg RB,2008,4,2,0.3295454567,1,From Cochrane: WHO PARTCIPATED: 287 patients with T2DM,23235674,,,Colesevelam for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2012 Dec 12;12(12):CD009361. doi: 10.1002/14651858.CD009361.pub2.,Ooi CP,2012,7.8,0.84,144,8.3,1.01,136,-0.122364967,0.0074415213,1,0,,dif,-0.5,0.0087765523,0,1
18715214,3,0,USA,COMMERCIAL FUNDING: Medtronic Inc,commercial,22258980,published data only,1,1,2,2,,,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,138,Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study,"Hirsch IB, Abelseth J, Bode BW, Fischer JS, Kaufman FR, Mastrototaro J, Parkin CG, Wolpert HA, Buckingham BA.",Diabetes Technol Ther. 2008 Oct;10(5):377-83. doi: 10.1089/dia.2008.0068.,Hirsch IB,2008,9,2,0.7610448362,1,"From Cochrane: WHO PARTICIPATED: 146 patients with type 1 diabetes, treated with insulin by pump, randomised to insulin pump with integrated CGM (n=72) or insulin pump + SMBG (n=74). 8 patients did not complete follow-up",22258980,,,Continuous glucose monitoring systems for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008101. doi: 10.1002/14651858.CD008101.pub2.,Langendam M,2012,7.67,0.92,65,7.76,0.6,72,0.4398108233,0.0153804166,0,0,,dif,-0.19,0.0132417094,0,1
18715214,3.01,0,USA,COMMERCIAL FUNDING: Medtronic Inc,commercial,22258980,published data only,1,1,2,2,,,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,138,Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study,"Hirsch IB, Abelseth J, Bode BW, Fischer JS, Kaufman FR, Mastrototaro J, Parkin CG, Wolpert HA, Buckingham BA.",Diabetes Technol Ther. 2008 Oct;10(5):377-83. doi: 10.1089/dia.2008.0068.,Hirsch IB,2008,9,2,0.7610448362,1,"From Cochrane: WHO PARTICIPATED: 146 patients with type 1 diabetes, treated with insulin by pump, randomised to insulin pump with integrated CGM (n=72) or insulin pump + SMBG (n=74). 8 patients did not complete follow-up",22258980,,,Continuous glucose monitoring systems for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008101. doi: 10.1002/14651858.CD008101.pub2.,Langendam M,2012,7.61,0.9,49,7.66,0.58,49,0.4458312523,0.0216698563,0,0,,dif,-0.12,0.0156816327,0,1
18715214,3.02,0,USA,COMMERCIAL FUNDING: Medtronic Inc,commercial,22258980,published data only,1,1,2,2,,,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,138,Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study,"Hirsch IB, Abelseth J, Bode BW, Fischer JS, Kaufman FR, Mastrototaro J, Parkin CG, Wolpert HA, Buckingham BA.",Diabetes Technol Ther. 2008 Oct;10(5):377-83. doi: 10.1089/dia.2008.0068.,Hirsch IB,2008,9,2,0.7610448362,1,"From Cochrane: WHO PARTICIPATED: 146 patients with type 1 diabetes, treated with insulin by pump, randomised to insulin pump with integrated CGM (n=72) or insulin pump + SMBG (n=74). 8 patients did not complete follow-up",22258980,,,Continuous glucose monitoring systems for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008101. doi: 10.1002/14651858.CD008101.pub2.,Langendam M,2012,7.86,0.97,16,7.97,0.59,23,0.521320678,0.0605065038,0,1,3,dif,-0.34,0.0500565217,0,1
18715214,6,0,USA,COMMERCIAL FUNDING: Medtronic Inc,commercial,22258980,published data only,1,1,2,2,,,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,138,Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study,"Hirsch IB, Abelseth J, Bode BW, Fischer JS, Kaufman FR, Mastrototaro J, Parkin CG, Wolpert HA, Buckingham BA.",Diabetes Technol Ther. 2008 Oct;10(5):377-83. doi: 10.1089/dia.2008.0068.,Hirsch IB,2008,9,2,0.7610448362,1,"From Cochrane: WHO PARTICIPATED: 146 patients with type 1 diabetes, treated with insulin by pump, randomised to insulin pump with integrated CGM (n=72) or insulin pump + SMBG (n=74). 8 patients did not complete follow-up",22258980,,,Continuous glucose monitoring systems for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008101. doi: 10.1002/14651858.CD008101.pub2.,Langendam M,2012,7.77,0.92,66,7.84,0.81,72,0.1369260648,0.0153127955,0,0,,dif,-0.15,0.0148378788,0,1
18715214,6.01,0,USA,COMMERCIAL FUNDING: Medtronic Inc,commercial,22258980,published data only,1,1,2,2,,,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,138,Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study,"Hirsch IB, Abelseth J, Bode BW, Fischer JS, Kaufman FR, Mastrototaro J, Parkin CG, Wolpert HA, Buckingham BA.",Diabetes Technol Ther. 2008 Oct;10(5):377-83. doi: 10.1089/dia.2008.0068.,Hirsch IB,2008,9,2,0.7610448362,1,"From Cochrane: WHO PARTICIPATED: 146 patients with type 1 diabetes, treated with insulin by pump, randomised to insulin pump with integrated CGM (n=72) or insulin pump + SMBG (n=74). 8 patients did not complete follow-up",22258980,,,Continuous glucose monitoring systems for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008101. doi: 10.1002/14651858.CD008101.pub2.,Langendam M,2012,7.68,0.84,49,7.66,0.67,49,0.2234726125,0.0216676772,0,0,,dif,-0.05,0.0175061224,0,1
18715214,6.02,0,USA,COMMERCIAL FUNDING: Medtronic Inc,commercial,22258980,published data only,1,1,2,2,,,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,138,Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study,"Hirsch IB, Abelseth J, Bode BW, Fischer JS, Kaufman FR, Mastrototaro J, Parkin CG, Wolpert HA, Buckingham BA.",Diabetes Technol Ther. 2008 Oct;10(5):377-83. doi: 10.1089/dia.2008.0068.,Hirsch IB,2008,9,2,0.7610448362,1,"From Cochrane: WHO PARTICIPATED: 146 patients with type 1 diabetes, treated with insulin by pump, randomised to insulin pump with integrated CGM (n=72) or insulin pump + SMBG (n=74). 8 patients did not complete follow-up",22258980,,,Continuous glucose monitoring systems for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008101. doi: 10.1002/14651858.CD008101.pub2.,Langendam M,2012,8.02,1.11,17,8.21,0.97,23,0.1664965083,0.0586979954,0,0,,dif,-0.42,0.0640920716,0,1
18721168,6,0,Sweden,"COMMERCIAL FUNDING: No- NON-COMMERCIAL FUNDING: No - This research was partly supported by Research and Development Center, county of Gavleborg’, Sweden, The Swedish Children’s Diabetes Foundation’, Novo Nordisk Scandinavia, and Roche Diagnostics, Sweden.  Hujoel - made the decision to classify the study as partly commercially funded.",both,20091571,published data only,1,1,1,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,72,Improved treatment satisfaction but no difference in metabolic control when using continuous subcutaneous insulin infusion vs. multiple daily inj,"Skogsberg L, Fors H, Hanas R, Chaplin JE, Lindman E, Skogsberg J.",Pediatr Diabetes. 2008 Oct;9(5):472-9. doi: 10.1111/j.1399-5448.2008.00390.x. Epub 2008 Aug 20.,Skogsberg L,2008,6,2,0.6794451011,1,From Cochrane: WHO PARTICIPATED: 72 participants were randomised and 67 participants completed the study,20091571,,,Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2010 Jan 20;(1):CD005103. doi: 10.1002/14651858.CD005103.pub2.,Misso ML,2010,5.5,1.166,34,5.7,1.849,38,-0.422986165,0.0335850976,0,0,,post,-0.2,0.1299553885,0,1
18779236,3.01,0,USA,NON-COMMERCIAL FUNDING: Juvenile Diabetes Research Foundation,non-commercial,22258980,published data only,1,1,1,2,,,,,,,,,,,,,,,,,,,,,2,2,,,,,,,,,,,322,Continuous glucose monitoring and intensive treatment of type 1 diabetes,"Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group; Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R, Fiallo-Scharer R, Fox LA, Gilliam LK, Hirsch IB, Huang ES, Kollman C, Kowalski AJ, Laffel L, Lawrence JM, Lee J, Mauras N, O'Grady",N Engl J Med. 2008 Oct 2;359(14):1464-76. doi: 10.1056/NEJMoa0805017. Epub 2008 Sep 8.,Juvenile Diabete,2008,18,2,0.7952546846,1,"From Cochrane:WHO PARTICIPATED: 322 patients with type 1 diabetes, in three age groups (n=CGM/ n=SMBG): 8-14 years (56/58), 15-25 years (57/53) and >25 years (52/46). 98% completed follow-up.",22258980,,,Continuous glucose monitoring systems for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008101. doi: 10.1002/14651858.CD008101.pub2.,Langendam M,2012,,,,,,,,,0,,,dif,-0.29,0.0092098662,0,0
18779236,3.02,0,USA,NON-COMMERCIAL FUNDING: Juvenile Diabetes Research Foundation,non-commercial,22258980,published data only,1,1,1,2,,,,,,,,,,,,,,,,,,,,,2,2,,,,,,,,,,,322,Continuous glucose monitoring and intensive treatment of type 1 diabetes,"Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group; Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R, Fiallo-Scharer R, Fox LA, Gilliam LK, Hirsch IB, Huang ES, Kollman C, Kowalski AJ, Laffel L, Lawrence JM, Lee J, Mauras N, O'Grady",N Engl J Med. 2008 Oct 2;359(14):1464-76. doi: 10.1056/NEJMoa0805017. Epub 2008 Sep 8.,Juvenile Diabete,2008,18,2,0.7952546846,1,"From Cochrane:WHO PARTICIPATED: 322 patients with type 1 diabetes, in three age groups (n=CGM/ n=SMBG): 8-14 years (56/58), 15-25 years (57/53) and >25 years (52/46). 98% completed follow-up.",22258980,,,Continuous glucose monitoring systems for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008101. doi: 10.1002/14651858.CD008101.pub2.,Langendam M,2012,,,,,,,,,0,,,dif,-0.22,0.0122942072,0,0
18779236,3.03,0,USA,NON-COMMERCIAL FUNDING: Juvenile Diabetes Research Foundation,non-commercial,22258980,published data only,1,1,1,2,,,,,,,,,,,,,,,,,,,,,2,2,,,,,,,,,,,322,Continuous glucose monitoring and intensive treatment of type 1 diabetes,"Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group; Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R, Fiallo-Scharer R, Fox LA, Gilliam LK, Hirsch IB, Huang ES, Kollman C, Kowalski AJ, Laffel L, Lawrence JM, Lee J, Mauras N, O'Grady",N Engl J Med. 2008 Oct 2;359(14):1464-76. doi: 10.1056/NEJMoa0805017. Epub 2008 Sep 8.,Juvenile Diabete,2008,18,2,0.7952546846,1,"From Cochrane:WHO PARTICIPATED: 322 patients with type 1 diabetes, in three age groups (n=CGM/ n=SMBG): 8-14 years (56/58), 15-25 years (57/53) and >25 years (52/46). 98% completed follow-up.",22258980,,,Continuous glucose monitoring systems for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008101. doi: 10.1002/14651858.CD008101.pub2.,Langendam M,2012,,,,,,,,,0,,,dif,-0.24,0.0135360222,0,0
18779236,6.01,0,USA,NON-COMMERCIAL FUNDING: Juvenile Diabetes Research Foundation,non-commercial,22258980,published data only,1,1,1,2,,,,,,,,,,,,,,,,,,,,,2,2,,,,,,,,,,,322,Continuous glucose monitoring and intensive treatment of type 1 diabetes,"Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group; Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R, Fiallo-Scharer R, Fox LA, Gilliam LK, Hirsch IB, Huang ES, Kollman C, Kowalski AJ, Laffel L, Lawrence JM, Lee J, Mauras N, O'Grady",N Engl J Med. 2008 Oct 2;359(14):1464-76. doi: 10.1056/NEJMoa0805017. Epub 2008 Sep 8.,Juvenile Diabete,2008,18,2,0.7952546846,1,"From Cochrane:WHO PARTICIPATED: 322 patients with type 1 diabetes, in three age groups (n=CGM/ n=SMBG): 8-14 years (56/58), 15-25 years (57/53) and >25 years (52/46). 98% completed follow-up.",22258980,,,Continuous glucose monitoring systems for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008101. doi: 10.1002/14651858.CD008101.pub2.,Langendam M,2012,,,,,,,,,0,,,dif,-0.52,0.0104329431,0,0
18779236,6.02,0,USA,NON-COMMERCIAL FUNDING: Juvenile Diabetes Research Foundation,non-commercial,22258980,published data only,1,1,1,2,,,,,,,,,,,,,,,,,,,,,2,2,,,,,,,,,,,322,Continuous glucose monitoring and intensive treatment of type 1 diabetes,"Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group; Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R, Fiallo-Scharer R, Fox LA, Gilliam LK, Hirsch IB, Huang ES, Kollman C, Kowalski AJ, Laffel L, Lawrence JM, Lee J, Mauras N, O'Grady",N Engl J Med. 2008 Oct 2;359(14):1464-76. doi: 10.1056/NEJMoa0805017. Epub 2008 Sep 8.,Juvenile Diabete,2008,18,2,0.7952546846,1,"From Cochrane:WHO PARTICIPATED: 322 patients with type 1 diabetes, in three age groups (n=CGM/ n=SMBG): 8-14 years (56/58), 15-25 years (57/53) and >25 years (52/46). 98% completed follow-up.",22258980,,,Continuous glucose monitoring systems for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008101. doi: 10.1002/14651858.CD008101.pub2.,Langendam M,2012,,,,,,,,,0,,,dif,0.03,0.0144330354,0,0
18779236,6.03,0,USA,NON-COMMERCIAL FUNDING: Juvenile Diabetes Research Foundation,non-commercial,22258980,published data only,1,1,1,2,,,,,,,,,,,,,,,,,,,,,2,2,,,,,,,,,,,322,Continuous glucose monitoring and intensive treatment of type 1 diabetes,"Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group; Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R, Fiallo-Scharer R, Fox LA, Gilliam LK, Hirsch IB, Huang ES, Kollman C, Kowalski AJ, Laffel L, Lawrence JM, Lee J, Mauras N, O'Grady",N Engl J Med. 2008 Oct 2;359(14):1464-76. doi: 10.1056/NEJMoa0805017. Epub 2008 Sep 8.,Juvenile Diabete,2008,18,2,0.7952546846,1,"From Cochrane:WHO PARTICIPATED: 322 patients with type 1 diabetes, in three age groups (n=CGM/ n=SMBG): 8-14 years (56/58), 15-25 years (57/53) and >25 years (52/46). 98% completed follow-up.",22258980,,,Continuous glucose monitoring systems for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008101. doi: 10.1002/14651858.CD008101.pub2.,Langendam M,2012,,,,,,,,,0,,,dif,-0.15,0.0194918719,0,0
18782641,7,0,Multi-countr,"SOURCE OF FUNDING: Amylin Pharmaceuticals and Eli Lilly and Company.OTHER: Conflict of interest: One author has been a consultant for and received lecture honoraria from Amylin, Eli Lilly and Novo Nordisk.",commercial,21975753,published data only,1,1,0,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,295,"Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study","Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L; DURATION-1 Study Group.",Lancet. 2008 Oct 4;372(9645):1240-50. doi: 10.1016/S0140-6736(08)61206-4. Epub 2008 Sep 7.,Drucker DJ,2008,7,2,0.1821774921,1,"From Cochrane:NUMBERS: Randomised: 303, Analysed as ITT: 295""",21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,0,,,dif,0.4,0.0195256481,0,0
18818254,6,0,UK,Funding: this was an investigator initiated study funded by the Ipswich Diabetes Centre Charity Research Fund. HRM also received salary support from Diabetes UK. The study equipment (6 x CGMS Gold monitors and 300 sensors) was donated free of charge by Medtronic UK. The research was sponsored by Ipswich Hospital NHS Trust and was independent of all the study funders.,both,31120549,published data only,2,2,2,2,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,71,Effectiveness of continuous glucose monitoring in pregnant women with diabetes: randomised clinical trial,"Murphy HR, Rayman G, Lewis K, Kelly S, Johal B, Duffield K, Fowler D, Campbell PJ, Temple RC.",BMJ. 2008 Sep 25;337:a1680. doi: 10.1136/bmj.a1680.,Murphy HR,2008,9,2,0.8438152013,1,from cochrane: Number randomised: 71.,24782359,28602020,31120549,Techniques of monitoring blood glucose during pregnancy for women with pre-existing diabetes,Cochrane Database Syst Rev. 2019 May 23;5(5):CD009613. doi: 10.1002/14651858.CD009613.pub4.,Jones LV,2019,5.8,0.6,38,6.4,0.7,33,-0.057781647,0.0306362617,0,0,,post,-0.6,0.0243221691,0,1
18852398,6,0,multi-countr,"COMMERCIAL FUNDING: Daiichi Sankyo, Inc",commercial,23235674,published data only,1,1,2,,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,316,Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects,"Bays HE, Goldberg RB, Truitt KE, Jones MR.",Arch Intern Med. 2008 Oct 13;168(18):1975-83. doi: 10.1001/archinte.168.18.1975.,Bays HE,2008,4,2,0.8173257207,1,From Cochrane: WHO PARTCIPATED: 316 patients with type 2 diabetes mellituT2DM,23235674,,,Colesevelam for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2012 Dec 12;12(12):CD009361. doi: 10.1002/14651858.CD009361.pub2.,Ooi CP,2012,7.7,1.07,148,8.3,1.09,152,0.0565977347,0.007001638,1,0,,dif,-0.6,0.0122949324,0,1
18931095,6.01,0,Multi-countr,"SOURCE OF FUNDING: Novo Nordisk (presumably). OTHER: Conflict of interest: Some authors are members of advisory board and have received honoraria from Novo Nordisk, and work for Novo Nordisk. OTHER: Conflict of interest: First author has received research support from different pharmaceutical companies and has acted as a consultant for some of the companies.Another author has served on advisory boards and received honorarium or consulting fees from different pharmaceutical companies. He has also received research grants from Merck, Pfizer, sanofi-aventis, Novo Nordisk, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Forest, Takeda, Novartis, AstraZeneca, Amylin, Johnson & Johnson, Daiichi Sankyo, Boehringer Ingelheim and MannKind. One author is an employee",commercial,21975753,published data only,2,2,2,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,1087,"Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglu","Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M, Matthews DR; LEAD-2 Study Group.",Diabetes Care. 2009 Jan;32(1):84-90. doi: 10.2337/dc08-1355. Epub 2008 Oct 17.,Nauck M,2009,9,5,0.6785880511,1,"From Cochrane:NUMBERS: Randomised: 1091 (4 withdrew consent before treatment), Analysed as ITT: 1087""",21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,1,,,dif,-1.1,0.0200104167,0,0
18931095,6.02,0,Multi-countr,"SOURCE OF FUNDING: Novo Nordisk (presumably). OTHER: Conflict of interest: Some authors are members of advisory board and have received honoraria from Novo Nordisk, and work for Novo Nordisk. OTHER: Conflict of interest: First author has received research support from different pharmaceutical companies and has acted as a consultant for some of the companies.Another author has served on advisory boards and received honorarium or consulting fees from different pharmaceutical companies. He has also received research grants from Merck, Pfizer, sanofi-aventis, Novo Nordisk, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Forest, Takeda, Novartis, AstraZeneca, Amylin, Johnson & Johnson, Daiichi Sankyo, Boehringer Ingelheim and MannKind. One author is an employee",commercial,21975753,published data only,2,2,2,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,1087,"Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglu","Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M, Matthews DR; LEAD-2 Study Group.",Diabetes Care. 2009 Jan;32(1):84-90. doi: 10.2337/dc08-1355. Epub 2008 Oct 17.,Nauck M,2009,9,5,0.6785880511,1,"From Cochrane:NUMBERS: Randomised: 1091 (4 withdrew consent before treatment), Analysed as ITT: 1087""",21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,1,,,dif,-1.1,0.0200561983,0,0
18931095,6.03,0,Multi-countr,"SOURCE OF FUNDING: Novo Nordisk (presumably). OTHER: Conflict of interest: Some authors are members of advisory board and have received honoraria from Novo Nordisk, and work for Novo Nordisk. OTHER: Conflict of interest: First author has received research support from different pharmaceutical companies and has acted as a consultant for some of the companies.Another author has served on advisory boards and received honorarium or consulting fees from different pharmaceutical companies. He has also received research grants from Merck, Pfizer, sanofi-aventis, Novo Nordisk, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Forest, Takeda, Novartis, AstraZeneca, Amylin, Johnson & Johnson, Daiichi Sankyo, Boehringer Ingelheim and MannKind. One author is an employee",commercial,21975753,published data only,2,2,2,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,1087,"Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglu","Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M, Matthews DR; LEAD-2 Study Group.",Diabetes Care. 2009 Jan;32(1):84-90. doi: 10.2337/dc08-1355. Epub 2008 Oct 17.,Nauck M,2009,9,5,0.6785880511,1,"From Cochrane:NUMBERS: Randomised: 1091 (4 withdrew consent before treatment), Analysed as ITT: 1087""",21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,0,,,dif,0,0.020066615,0,0
18931095,6.04,0,Multi-countr,"SOURCE OF FUNDING: Novo Nordisk (presumably). OTHER: Conflict of interest: Some authors are members of advisory board and have received honoraria from Novo Nordisk, and work for Novo Nordisk. OTHER: Conflict of interest: First author has received research support from different pharmaceutical companies and has acted as a consultant for some of the companies.Another author has served on advisory boards and received honorarium or consulting fees from different pharmaceutical companies. He has also received research grants from Merck, Pfizer, sanofi-aventis, Novo Nordisk, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Forest, Takeda, Novartis, AstraZeneca, Amylin, Johnson & Johnson, Daiichi Sankyo, Boehringer Ingelheim and MannKind. One author is an employee",commercial,21975753,published data only,2,2,2,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,1087,"Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglu","Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M, Matthews DR; LEAD-2 Study Group.",Diabetes Care. 2009 Jan;32(1):84-90. doi: 10.2337/dc08-1355. Epub 2008 Oct 17.,Nauck M,2009,9,5,0.6785880511,1,"From Cochrane:NUMBERS: Randomised: 1091 (4 withdrew consent before treatment), Analysed as ITT: 1087""",21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,0,,,dif,0,0.0199426502,0,0
18931095,6.05,0,Multi-countr,"SOURCE OF FUNDING: Novo Nordisk (presumably). OTHER: Conflict of interest: Some authors are members of advisory board and have received honoraria from Novo Nordisk, and work for Novo Nordisk. OTHER: Conflict of interest: First author has received research support from different pharmaceutical companies and has acted as a consultant for some of the companies.Another author has served on advisory boards and received honorarium or consulting fees from different pharmaceutical companies. He has also received research grants from Merck, Pfizer, sanofi-aventis, Novo Nordisk, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Forest, Takeda, Novartis, AstraZeneca, Amylin, Johnson & Johnson, Daiichi Sankyo, Boehringer Ingelheim and MannKind. One author is an employee",commercial,21975753,published data only,2,2,2,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,1087,"Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglu","Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M, Matthews DR; LEAD-2 Study Group.",Diabetes Care. 2009 Jan;32(1):84-90. doi: 10.2337/dc08-1355. Epub 2008 Oct 17.,Nauck M,2009,9,5,0.6785880511,1,"From Cochrane:NUMBERS: Randomised: 1091 (4 withdrew consent before treatment), Analysed as ITT: 1087""",21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,0,,,dif,0,0.0200299688,0,0
18959604,6,0,Spain,Funding: commercial funding (Novo Nordisk),commercial,33166419,published and unpublished data,2,2,1,2,1,2,0,0,,1,2,1,2,0,0,,,,,,,,,,2,2,2,2,2,2,,,,,,,271,Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 di,"Fajardo Montañana C, Hernández Herrero C, Rivas Fernández M.",Diabet Med. 2008 Aug;25(8):916-23. doi: 10.1111/j.1464-5491.2008.02483.x.,Fajardo Montañan,2008,3,2,0.6835484969,1,Characteristics of included studies in Cochrane review does not report on number randomized; Fajardo reports: Subjects received either detemir ( n = 125) or NPH (n=146) once daily,33166419,,,(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Nov 9;11(11):CD005613. doi: 10.1002/14651858.CD005613.pub4.,Semlitsch T,2020,7.83,1.1,124,7.81,1.02,146,0.0735456038,0.0078461562,0,0,,dif,-0.02,0.0146314415,0,1
19108786,12,0,multi-countr,"COMMERCIAL FUNDING: Yes: ""This study was supported by Novo Nordisk A/S, Bagsvaerd, Denmark"".NON-COMMERCIAL FUNDING: No",commercial,21735405,published and unpublished data,2,2,0,,,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,319,"A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a","Hollander P, Cooper J, Bregnhøj J, Pedersen CB.",Clin Ther. 2008 Nov;30(11):1976-87. doi: 10.1016/j.clinthera.2008.11.001.,Hollander P,2008,4,2,0.534221938,1,"From Cochrane: WHO PARTCIPATED: SEX (female% / male%): 34 (42.0%) / 185 (58.0%). - Cochrane lists sample size for detemir arm only - not glargine arm. Hollander reports: ""The intention-to-treat population included 319 patients""",21735405,,,Insulin detemir versus insulin glargine for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Jul 6;2011(7):CD006383. doi: 10.1002/14651858.CD006383.pub2.,Swinnen SG,2011,7.19,1,214,7.03,1,105,,,0,,,post,0.16,0.0141967067,0,0
19132857,4,0,USA,COMMERCIAL FUNDING: Medtronic Inc,commercial,22258980,published data only,1,1,2,2,,,,,,,,,,,,,,,,,,,,,2,1,,,,,,,,,,,28,Patient-reported outcomes for an integrated real-time continuous glucose monitoring/insulin pump system,"Peyrot M, Rubin RR.",Diabetes Technol Ther. 2009 Jan;11(1):57-62. doi: 10.1089/dia.2008.0002.,Peyrot M,2009,2,2,0.4305637459,1,"From Cochrane:WHO PARTICIPATED: 28 patients with type 1 diabetes, CSII-naive, randomised 1:1 to insulin pump with integrated CGM or insulin pump + SMBG. 27 patients completed follow-up",22258980,,,Continuous glucose monitoring systems for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008101. doi: 10.1002/14651858.CD008101.pub2.,Langendam M,2012,7.16,0.75,14,7.3,0.92,13,-0.18792221,0.0885655562,0,0,,dif,-0.69,0.1226373626,0,1
19168253,3,0,Japan,Funding source: supported by Grants-in Aid from the Ministry of Health and Welfare of Japan (H16-Iryo-020) and the Mitsui Sumitomo insurance foundation,non-commercial,35420698,published and unpublished data,1,0,0,0,1,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,49,"Multi-center intervention study on glycohemoglobin (HbA1c) and serum, high-sensitivity CRP (hs-CRP) after local anti-infectious periodontal treat","Katagiri S, Nitta H, Nagasawa T, Uchimura I, Izumiyama H, Inagaki K, Kikuchi T, Noguchi T, Kanazawa M, Matsuo A, Chiba H, Nakamura N, Kanamura N, Inoue S, Ishikawa I, Izumi Y.",Diabetes Res Clin Pract. 2009 Mar;83(3):308-15. doi: 10.1016/j.diabres.2008.10.016. Epub 2009 Jan 24.,Katagiri S,2009,16,2,0.8979109948,1,"From Cochrane:Number randomised: 49 (Gp A 32, Gp B 17) Number evaluated: 49",26545069,35420698,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,7.04,0.91,32,6.89,1.13,17,-0.252656321,0.051958207,0,0,,post,0.15,0.1009898897,0,1
19168253,6,0,Japan,Funding source: supported by Grants-in Aid from the Ministry of Health and Welfare of Japan (H16-Iryo-020) and the Mitsui Sumitomo insurance foundation,non-commercial,35420698,published and unpublished data,1,0,0,0,1,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,49,"Multi-center intervention study on glycohemoglobin (HbA1c) and serum, high-sensitivity CRP (hs-CRP) after local anti-infectious periodontal treat","Katagiri S, Nitta H, Nagasawa T, Uchimura I, Izumiyama H, Inagaki K, Kikuchi T, Noguchi T, Kanazawa M, Matsuo A, Chiba H, Nakamura N, Kanamura N, Inoue S, Ishikawa I, Izumi Y.",Diabetes Res Clin Pract. 2009 Mar;83(3):308-15. doi: 10.1016/j.diabres.2008.10.016. Epub 2009 Jan 24.,Katagiri S,2009,16,2,0.8979109948,1,"From Cochrane:Number randomised: 49 (Gp A 32, Gp B 17) Number evaluated: 49",26545069,35420698,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,7,1,32,6.85,0.82,17,0.1617710676,0.0513337043,0,0,,post,0.15,0.0708029412,0,1
19271419,3,0,Mexico,"Non-commercial funding: Consejo Nacional de Ciencia y Tecnología de México, Mexican Social Security Institute Foundation Civil Association",non-commercial,23235661,published data only,2,2,2,2,2,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,21,"Efficacy and safety of oral magnesium supplementation in the treatment of depression in the elderly with type 2 diabetes: a randomized, equivalen","Barragán-Rodríguez L, Rodríguez-Morán M, Guerrero-Romero F.",Magnes Res. 2008 Dec;21(4):218-23.,Barragán-Rodrígu,2008,3,2,0.5694578363,1,Characteristics of included studies in Cochrane review does not report on number randomized; Barragan reports: 23 elderly patients,23235661,,,Psychological and pharmacological interventions for depression in patients with diabetes mellitus and depression,Cochrane Database Syst Rev. 2012 Dec 12;12:CD008381. doi: 10.1002/14651858.CD008381.pub2.,Baumeister H,2012,8.8,1.2,12,8.9,1.4,9,-0.159296686,0.124203216,0,0,,post,-0.1,0.3377777778,0,1
19277602,36,0,India,Funding: non-commercial funding: India Diabetes Research Foundation,non-commercial,33210751,published data only,2,2,2,,,2,2,2,2,2,2,,2,2,,,2,2,2,2,1,2,,2,1,,,1,1,1,1,1,1,,1,,407,Pioglitazone does not enhance the effectiveness of lifestyle modification in preventing conversion of impaired glucose tolerance to diabetes in A,"Ramachandran A, Snehalatha C, Mary S, Selvam S, Kumar CK, Seeli AC, Shetty AS.",Diabetologia. 2009 Jun;52(6):1019-26. doi: 10.1007/s00125-009-1315-x. Epub 2009 Mar 10.,Ramachandran A,2009,7,2,0.6588048147,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Rachamadran reports: In a community-based, placebo-controlled 3 year prospective study, 407 participants with impaired glucose tolerance (mean age 45.3±6.2 years, mean BMI 25.9± 3.3 kg/m2) were sequentially grouped to receive either",33210751,,,Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Nov 19;11(11):CD013516. doi: 10.1002/14651858.CD013516.pub2.,Ipsen EØ,2020,6.2,0.7,181,6.3,0.8,186,-0.117447843,0.0056676476,1,0,,dif,-0.1,0.0069767718,0,1
19289857,6.01,0,Multi-countr,"SOURCE OF FUNDING: Novo Nordisk (presumably)OTHER: Conflict of interest Novo Nordisk, Denmark",commercial,21975753,published data only,2,2,2,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,533,Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with,"Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, Hale PM, Zdravkovic M, Blonde L; LEAD-4 Study Investigators.",Diabetes Care. 2009 Jul;32(7):1224-30. doi: 10.2337/dc08-2124. Epub 2009 Mar 16.,Zinman B,2009,9,3,0.4658446806,1,From Cochrane: NUMBERS: 533 randomised; LIR 1.2 mg:178; LIR 1.8 mg:178; Placebo:177,21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,1,,,dif,-1,0.0199314258,0,0
19289857,6.02,0,Multi-countr,"SOURCE OF FUNDING: Novo Nordisk (presumably)OTHER: Conflict of interest Novo Nordisk, Denmark",commercial,21975753,published data only,2,2,2,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,533,Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with,"Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, Hale PM, Zdravkovic M, Blonde L; LEAD-4 Study Investigators.",Diabetes Care. 2009 Jul;32(7):1224-30. doi: 10.2337/dc08-2124. Epub 2009 Mar 16.,Zinman B,2009,9,3,0.4658446806,1,From Cochrane: NUMBERS: 533 randomised; LIR 1.2 mg:178; LIR 1.8 mg:178; Placebo:177,21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,1,,,dif,-1,0.0199314258,0,0
19289857,6.03,0,Multi-countr,"SOURCE OF FUNDING: Novo Nordisk (presumably)OTHER: Conflict of interest Novo Nordisk, Denmark",commercial,21975753,published data only,2,2,2,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,533,Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with,"Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, Hale PM, Zdravkovic M, Blonde L; LEAD-4 Study Investigators.",Diabetes Care. 2009 Jul;32(7):1224-30. doi: 10.2337/dc08-2124. Epub 2009 Mar 16.,Zinman B,2009,9,3,0.4658446806,1,From Cochrane: NUMBERS: 533 randomised; LIR 1.2 mg:178; LIR 1.8 mg:178; Placebo:177,21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,0,,,dif,0,0.0198752809,0,0
19317822,6.01,0,Multi-countr,"SOURCE OF FUNDING: Novo Nordisk. OTHER: Conflict of interest: One author had received lecture fees from Novo Nordisk, Servier, MSD. The second author had received honoraria, grants and lecture fees from Novo Nordisk. The remaining authors had no conflict of interest",commercial,21975753,published data only,1,1,2,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,1041,"Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight cont","Marre M, Shaw J, Brändle M, Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD, Colagiuri S; LEAD-1 SU study group.",Diabet Med. 2009 Mar;26(3):268-78. doi: 10.1111/j.1464-5491.2009.02666.x.,Marre M,2009,9,5,0.7683416341,1,"From Cochrane:NUMBERS: 1712 screened; Randomised: 1041""",21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,1,,,dif,-1.33,0.013425,0,0
19317822,6.02,0,Multi-countr,"SOURCE OF FUNDING: Novo Nordisk. OTHER: Conflict of interest: One author had received lecture fees from Novo Nordisk, Servier, MSD. The second author had received honoraria, grants and lecture fees from Novo Nordisk. The remaining authors had no conflict of interest",commercial,21975753,published data only,1,1,2,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,1041,"Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight cont","Marre M, Shaw J, Brändle M, Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD, Colagiuri S; LEAD-1 SU study group.",Diabet Med. 2009 Mar;26(3):268-78. doi: 10.1111/j.1464-5491.2009.02666.x.,Marre M,2009,9,5,0.7683416341,1,"From Cochrane:NUMBERS: 1712 screened; Randomised: 1041""",21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,1,,,dif,-1.33,0.013748538,0,0
19317822,6.03,0,Multi-countr,"SOURCE OF FUNDING: Novo Nordisk. OTHER: Conflict of interest: One author had received lecture fees from Novo Nordisk, Servier, MSD. The second author had received honoraria, grants and lecture fees from Novo Nordisk. The remaining authors had no conflict of interest",commercial,21975753,published data only,1,1,2,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,1041,"Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight cont","Marre M, Shaw J, Brändle M, Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD, Colagiuri S; LEAD-1 SU study group.",Diabet Med. 2009 Mar;26(3):268-78. doi: 10.1111/j.1464-5491.2009.02666.x.,Marre M,2009,9,5,0.7683416341,1,"From Cochrane:NUMBERS: 1712 screened; Randomised: 1041""",21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,0,,,dif,0,0.0089209064,0,0
19317822,6.04,0,Multi-countr,"SOURCE OF FUNDING: Novo Nordisk. OTHER: Conflict of interest: One author had received lecture fees from Novo Nordisk, Servier, MSD. The second author had received honoraria, grants and lecture fees from Novo Nordisk. The remaining authors had no conflict of interest",commercial,21975753,published data only,1,1,2,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,1041,"Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight cont","Marre M, Shaw J, Brändle M, Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD, Colagiuri S; LEAD-1 SU study group.",Diabet Med. 2009 Mar;26(3):268-78. doi: 10.1111/j.1464-5491.2009.02666.x.,Marre M,2009,9,5,0.7683416341,1,"From Cochrane:NUMBERS: 1712 screened; Randomised: 1041""",21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,0,,,dif,-0.66,0.0104025635,0,0
19317822,6.05,0,Multi-countr,"SOURCE OF FUNDING: Novo Nordisk. OTHER: Conflict of interest: One author had received lecture fees from Novo Nordisk, Servier, MSD. The second author had received honoraria, grants and lecture fees from Novo Nordisk. The remaining authors had no conflict of interest",commercial,21975753,published data only,1,1,2,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,1041,"Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight cont","Marre M, Shaw J, Brändle M, Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD, Colagiuri S; LEAD-1 SU study group.",Diabet Med. 2009 Mar;26(3):268-78. doi: 10.1111/j.1464-5491.2009.02666.x.,Marre M,2009,9,5,0.7683416341,1,"From Cochrane:NUMBERS: 1712 screened; Randomised: 1041""",21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,0,,,dif,-0.66,0.0107261015,0,0
19366970,2.01,0,Multi-countr,"SOURCE OF FUNDING: Hoffmann-La Roche, Switzerland.OTHER: Association of some of the authors with Roche",commercial,21975753,published data only,2,2,2,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,297,Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowe,"Nauck MA, Ratner RE, Kapitza C, Berria R, Boldrin M, Balena R.",Diabetes Care. 2009 Jul;32(7):1237-43. doi: 10.2337/dc08-1961. Epub 2009 Apr 14.,Nauck MA,2009,6,6,0.7566576014,1,From Cochrane:NUMBERS: 306 randomised (safety database 297);(assessed 1 week after 8 consecutive weeks of treatment),21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,1,,,dif,-1,0.0102040816,0,0
19366970,2.02,0,Multi-countr,"SOURCE OF FUNDING: Hoffmann-La Roche, Switzerland.OTHER: Association of some of the authors with Roche",commercial,21975753,published data only,2,2,2,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,297,Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowe,"Nauck MA, Ratner RE, Kapitza C, Berria R, Boldrin M, Balena R.",Diabetes Care. 2009 Jul;32(7):1237-43. doi: 10.2337/dc08-1961. Epub 2009 Apr 14.,Nauck MA,2009,6,6,0.7566576014,1,From Cochrane:NUMBERS: 306 randomised (safety database 297);(assessed 1 week after 8 consecutive weeks of treatment),21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,1,,,dif,-1,0.0101020408,0,0
19366970,2.03,0,Multi-countr,"SOURCE OF FUNDING: Hoffmann-La Roche, Switzerland.OTHER: Association of some of the authors with Roche",commercial,21975753,published data only,2,2,2,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,297,Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowe,"Nauck MA, Ratner RE, Kapitza C, Berria R, Boldrin M, Balena R.",Diabetes Care. 2009 Jul;32(7):1237-43. doi: 10.2337/dc08-1961. Epub 2009 Apr 14.,Nauck MA,2009,6,6,0.7566576014,1,From Cochrane:NUMBERS: 306 randomised (safety database 297);(assessed 1 week after 8 consecutive weeks of treatment),21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,1,,,dif,-0.8,0.0102040816,0,0
19383882,8,0,USA,Funding: Centers for Disease Control and Prevention,non-commercial,25188210,published data only,2,2,0,0,2,0,,,,,,,,,,,,,,,,,,,2,2,,,,,,,,,,,201,A randomized trial of a church-based diabetes self-management program for African Americans with type 2 diabetes,"Samuel-Hodge CD, Keyserling TC, Park S, Johnston LF, Gizlice Z, Bangdiwala SI.",Diabetes Educ. 2009 May-Jun;35(3):439-54. doi: 10.1177/0145721709333270. Epub 2009 Apr 21.,Samuel-Hodge CD,2009,6,2,0.6180558613,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Samuel-Hodge reports: Churchesmwere randomized to receive the special intervention (SI;13 churches, 117 participants) or the minimal intervention(MI; 11 churches, 84 participants).",25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,7.4,1.01,102,7.8,0.85,72,,,0,,,post,-0.4,0.0200357026,0,0
19383882,12,0,USA,Funding: Centers for Disease Control and Prevention,non-commercial,25188210,published data only,2,2,0,0,2,0,,,,,,,,,,,,,,,,,,,2,2,,,,,,,,,,,201,A randomized trial of a church-based diabetes self-management program for African Americans with type 2 diabetes,"Samuel-Hodge CD, Keyserling TC, Park S, Johnston LF, Gizlice Z, Bangdiwala SI.",Diabetes Educ. 2009 May-Jun;35(3):439-54. doi: 10.1177/0145721709333270. Epub 2009 Apr 21.,Samuel-Hodge CD,2009,6,2,0.6180558613,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Samuel-Hodge reports: Churchesmwere randomized to receive the special intervention (SI;13 churches, 117 participants) or the minimal intervention(MI; 11 churches, 84 participants).",25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,7.5,1,101,7.6,0.83,69,,,0,,,post,-0.1,0.0198850481,0,0
19396424,3,0,Australia,COMMERCIAL FUNDING: Medtronic inc,commercial,22258980,published data only,2,2,1,2,,,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,62,Glycaemic impact of patient-led use of sensor-guided pump therapy in type 1 diabetes: a randomised controlled trial,"O'Connell MA, Donath S, O'Neal DN, Colman PG, Ambler GR, Jones TW, Davis EA, Cameron FJ.",Diabetologia. 2009 Jul;52(7):1250-7. doi: 10.1007/s00125-009-1365-0. Epub 2009 Apr 25.,O'Connell MA,2009,8,2,0.3304816944,1,"From Cochrane:WHO PARTICIPATED: 62 patients with type 1 diabetes on CSII, randomised 1:1. 54 patients completed follow-up",22258980,,,Continuous glucose monitoring systems for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008101. doi: 10.1002/14651858.CD008101.pub2.,Langendam M,2012,7.1,0.8,26,7.8,0.9,29,-0.021625836,0.0402425161,0,0,,dif,-0.5,0.0409151194,0,1
19429875,6,0,USA,NON-COMMERCIAL FUNDING: Juvenile Diabetes Research Fund,non-commercial,22258980,published data only,1,1,2,2,,,,,,,,,,,,,,,,,,,,,1,2,,,,,,,,,,,129,The effect of continuous glucose monitoring in well-controlled type 1 diabetes,"Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group; Beck RW, Hirsch IB, Laffel L, Tamborlane WV, Bode BW, Buckingham B, Chase P, Clemons R, Fiallo-Scharer R, Fox LA, Gilliam LK, Huang ES, Kollman C, Kowalski AJ, Lawrence JM, Lee J, Mauras N, O'Grady",Diabetes Care. 2009 Aug;32(8):1378-83. doi: 10.2337/dc09-0108. Epub 2009 May 8.,Juvenile Diabete,2009,18,2,0.75078212,1,"From Cochrane: WHO PARTICIPATED: 129 patients with type 1 diabetes, randomised to CGM (n=67) or control group (n=62). 127 patients completed follow-up",22258980,,,Continuous glucose monitoring systems for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008101. doi: 10.1002/14651858.CD008101.pub2.,Langendam M,2012,6.4,0.5,67,6.8,0.5,62,0.0600017109,0.0161999436,0,0,,dif,-0.31,0.0060046461,0,1
19515413,6,0,Multi-countr,"SOURCE OF FUNDING: Novo Nordisk. OTHER: Conflict of interest: main author is a member of advisory board and have received honoraria from Novo Nordisk and various other pharmaceutical companies, and work as consultant for various other pharmaceutical companies.",commercial,21975753,published data only,1,2,0,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,464,"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (L","Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L; LEAD-6 Study Group.",Lancet. 2009 Jul 4;374(9683):39-47. doi: 10.1016/S0140-6736(09)60659-0. Epub 2009 Jun 8.,Buse JB,2009,8,2,0.5094229317,1,"From Cochrane:NUMBERS: 464 randomised; LIR: 233; EX: 231; (exposed LIR: 235; EX: 232)""",21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,0,,,dif,0.33,0.0128312729,0,0
19526210,60,0,Multi-countr,Funding: commercial funding (Sanofi-Aventis),commercial,33166419,published and unpublished data,2,2,1,2,1,2,,0,,1,2,2,2,,0,,,,,,,,,,2,2,2,2,,2,,,,,,,1017,Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes:,"Rosenstock J, Fonseca V, McGill JB, Riddle M, Hallé JP, Hramiak I, Johnston P, Davis M.",Diabetologia. 2009 Sep;52(9):1778-88. doi: 10.1007/s00125-009-1415-7. Epub 2009 Jun 13.,Rosenstock J,2009,8,2,0.6702265373,1,Characteristics of included studies in Cochrane review does not report on number randomized; Rosenstock reports: Patients were randomised by the investigator according to the centralised interactive voice response system to receive twice-daily NPH insulin (n=509) or once-daily basal insulin glargine (n=515).,33166419,,,(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Nov 9;11(11):CD005613. doi: 10.1002/14651858.CD005613.pub4.,Semlitsch T,2020,,,,,,,,,0,,,dif,0.21,0.0071907007,0,0
19538239,3,0,South Korea,"Funding: Seoul R & BD Project. The development of the HSA business model and technology was sponsored by the Ministry of Commerce, Industry and Energy",non-commercial,23543567,published data only,1,1,0,,,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,111,A Ubiquitous Chronic Disease Care system using cellular phones and the internet,"Yoo HJ, Park MS, Kim TN, Yang SJ, Cho GJ, Hwang TG, Baik SH, Choi DS, Park GH, Choi KM.",Diabet Med. 2009 Jun;26(6):628-35. doi: 10.1111/j.1464-5491.2009.02732.x.,Yoo HJ,2009,10,2,0.8349699061,1,From Cochrane:Five patients (8.1%) dropped out of the intervention group and seven (10%) out of the control group. From Yoo:included 123 patients at a university hospital and a community public health centre.,23543567,,,Computer-based diabetes self-management interventions for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2013 Mar 28;2013(3):CD008776. doi: 10.1002/14651858.CD008776.pub2.,Pal K,2013,7.1,0.8,57,7.6,1,54,-0.155546541,0.0192433944,0,0,,post,-0.5,0.0297465887,0,1
19560388,3.02,0,France,COMMERCIAL FUNDING: Menarini Diagnostics,commercial,22258980,published data only,2,1,1,2,,,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,9,"Multicentre, randomised, controlled study of the impact of continuous sub-cutaneous glucose monitoring (GlucoDay) on glycaemic control in type 1","Cosson E, Hamo-Tchatchouang E, Dufaitre-Patouraux L, Attali JR, Pariès J, Schaepelynck-Bélicar P.",Diabetes Metab. 2009 Sep;35(4):312-8. doi: 10.1016/j.diabet.2009.02.006. Epub 2009 Jun 26.,Cosson E,2009,6,2,0.3125716858,1,"From Cochrane:WHO PARTICIPATED: 48 patients with type 1 or 2 diabetes with poor glycaemic control, randomised to CGM (n=25) or control group (blinded CGM, n=23), 34 patients completed the study, of which 9 with type 1 diabetes (3 in CGM group and 6 in control group).",22258980,,,Continuous glucose monitoring systems for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008101. doi: 10.1002/14651858.CD008101.pub2.,Langendam M,2012,8.47,0.83,3,8.72,0.89,6,0.1085606241,0.4999436847,0,0,,dif,-0.31,0.1259,0,1
19565569,6,0,multi-countr,"COMMERCIAL FUNDING: Yes: ""This trial was funded and monitored by Novo Nordisk"".NON-COMMERCIAL FUNDING: No.",commercial,21735405,published and unpublished data,1,1,0,,,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,385,"Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2","Raskin P, Gylvin T, Weng W, Chaykin L.",Diabetes Metab Res Rev. 2009 Sep;25(6):542-8. doi: 10.1002/dmrr.989.,Raskin P,2009,4,2,0.2655597659,1,"From Cochrane: WHO PARTCIPATED:SEX (female% / male%): 175 (45.5%) / 210 (54.5%). Raskin reports: ""385 patients were randomized 2 : 1"".",21735405,,,Insulin detemir versus insulin glargine for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Jul 6;2011(7):CD006383. doi: 10.1002/14651858.CD006383.pub2.,Swinnen SG,2011,7.33,1.2,251,7.02,1.09,128,,,0,,,post,0.31,0.015019083,0,0
19590029,3,0,Italy,Funding: not mentioned.,not reported,31120549,published data only,0,0,2,2,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,203,The effect of telemedicine on outcome and quality of life in pregnant women with diabetes,"Dalfrà MG, Nicolucci A, Lapolla A; TISG.",J Telemed Telecare. 2009;15(5):238-42. doi: 10.1258/jtt.2009.081213.,Dalfrà MG,2009,3,2,0.3296542811,1,from cochrane - 88 women with gestational diabetes in the telemedicine group and 115 in the control group;17 women with type 1 diabetes in the telemedicine group and 15 in the control group.,28602020,29081069,31120549,Techniques of monitoring blood glucose during pregnancy for women with pre-existing diabetes,Cochrane Database Syst Rev. 2019 May 23;5(5):CD009613. doi: 10.1002/14651858.CD009613.pub4.,Jones LV,2019,6.7,0.7,17,6.5,0.8,15,-0.168117143,0.0731211015,0,0,,post,0.2,0.0714901961,0,1
19592625,4.01,0,Multi-countr,"SOURCE OF FUNDING: GlaxoSmithKline, Middlesex, UK",commercial,21975753,published data only,1,1,2,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,345,"Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and","Rosenstock J, Reusch J, Bush M, Yang F, Stewart M; Albiglutide Study Group.",Diabetes Care. 2009 Oct;32(10):1880-6. doi: 10.2337/dc09-0366. Epub 2009 Jul 10.,Rosenstock J,2009,5,10,0.8622473986,1,"From Cochrane: Randomised: 361, received treatment (and included in the safety analysis): 356, efficacy analysis: 345;",21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,0,,,dif,-0.08,0.0445814655,0,0
19592625,4.02,0,Multi-countr,"SOURCE OF FUNDING: GlaxoSmithKline, Middlesex, UK",commercial,21975753,published data only,1,1,2,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,345,"Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and","Rosenstock J, Reusch J, Bush M, Yang F, Stewart M; Albiglutide Study Group.",Diabetes Care. 2009 Oct;32(10):1880-6. doi: 10.2337/dc09-0366. Epub 2009 Jul 10.,Rosenstock J,2009,5,10,0.8622473986,1,"From Cochrane: Randomised: 361, received treatment (and included in the safety analysis): 356, efficacy analysis: 345;",21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,1,,,dif,-0.7,0.0349709655,0,0
19592625,4.03,0,Multi-countr,"SOURCE OF FUNDING: GlaxoSmithKline, Middlesex, UK",commercial,21975753,published data only,1,1,2,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,345,"Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and","Rosenstock J, Reusch J, Bush M, Yang F, Stewart M; Albiglutide Study Group.",Diabetes Care. 2009 Oct;32(10):1880-6. doi: 10.2337/dc09-0366. Epub 2009 Jul 10.,Rosenstock J,2009,5,10,0.8622473986,1,"From Cochrane: Randomised: 361, received treatment (and included in the safety analysis): 356, efficacy analysis: 345;",21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,1,,,dif,-0.62,0.0504145,0,0
19656023,3,0,Brazil,"Funding source: Not reported. ""Conflict of interests: Authors declare no conflict of interests exists""",not reported,26545069,published and unpublished data,2,1,0,0,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,36,Effectiveness of full-mouth and partial-mouth scaling and root planing in treating chronic periodontitis in subjects with type 2 diabetes,"Santos VR, Lima JA, De Mendonça AC, Braz Maximo MB, Faveri M, Duarte PM.",J Periodontol. 2009 Aug;80(8):1237-45. doi: 10.1902/jop.2009.090030.,Santos VR,2009,6,2,0.2879535428,1,From Cochrane:Number randomised: 36; Number evaluated: 36,26545069,,,Treatment of periodontal disease for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2015 Nov 6;2015(11):CD004714. doi: 10.1002/14651858.CD004714.pub3.,Simpson TC,2015,9.8,2.3,18,9.6,2,18,0.1188182541,0.0677626591,0,0,,post,0.2,0.5161111111,0,1
19656023,6,0,Brazil,"Funding source: Not reported. ""Conflict of interests: Authors declare no conflict of interests exists""",not reported,26545069,published and unpublished data,2,1,0,0,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,36,Effectiveness of full-mouth and partial-mouth scaling and root planing in treating chronic periodontitis in subjects with type 2 diabetes,"Santos VR, Lima JA, De Mendonça AC, Braz Maximo MB, Faveri M, Duarte PM.",J Periodontol. 2009 Aug;80(8):1237-45. doi: 10.1902/jop.2009.090030.,Santos VR,2009,6,2,0.2879535428,1,From Cochrane:Number randomised: 36; Number evaluated: 36,26545069,,,Treatment of periodontal disease for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2015 Nov 6;2015(11):CD004714. doi: 10.1002/14651858.CD004714.pub3.,Simpson TC,2015,9.5,1.9,18,10.3,2.6,18,-0.232146588,0.0680546654,0,0,,post,-0.8,0.5761111111,0,1
19674806,12.01,0,Turkey,Funding: not reported,not reported,32501595,published data only,1,1,,,,,,,,,,,,,,,,,,,,,,,2,2,2,2,2,2,2,2,2,,,,50,"Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabe","Kiyici S, Ersoy C, Kaderli A, Fazlioglu M, Budak F, Duran C, Gul OO, Sigirli D, Baran I, Tuncel E, Erturk E, Imamoglu S.",Diabetes Res Clin Pract. 2009 Oct;86(1):44-50. doi: 10.1016/j.diabres.2009.07.004. Epub 2009 Aug 12.,Kiyici S,2009,12,3,0.9790922106,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Kiyici reports: Fifty type 2 diabetic patients were randomized to receive rosiglitazone 4 mg/day (n = 19) or metformin 850 mg/day (n = 16) with MNT or MNT alone (n = 15), for 52 weeks",32501595,,,Metformin monotherapy for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Jun 5;6(6):CD012906. doi: 10.1002/14651858.CD012906.pub2.,Gnesin F,2020,6.4,0.6,16,6.5,0.71,15,-0.155089027,0.0751660694,0,0,,post,-0.1,0.0561066667,0,1
19674806,12.02,0,Turkey,Funding: not reported,not reported,32501595,published data only,1,1,,,,,,,,,,,,,,,,,,,,,,,2,2,2,2,2,2,2,2,2,,,,50,"Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabe","Kiyici S, Ersoy C, Kaderli A, Fazlioglu M, Budak F, Duran C, Gul OO, Sigirli D, Baran I, Tuncel E, Erturk E, Imamoglu S.",Diabetes Res Clin Pract. 2009 Oct;86(1):44-50. doi: 10.1016/j.diabres.2009.07.004. Epub 2009 Aug 12.,Kiyici S,2009,12,3,0.9790922106,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Kiyici reports: Fifty type 2 diabetic patients were randomized to receive rosiglitazone 4 mg/day (n = 19) or metformin 850 mg/day (n = 16) with MNT or MNT alone (n = 15), for 52 weeks",32501595,,,Metformin monotherapy for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Jun 5;6(6):CD012906. doi: 10.1002/14651858.CD012906.pub2.,Gnesin F,2020,6.4,0.6,19,6.4,0.6,16,-0.005512188,0.0658886997,0,0,,post,0,0.0414473684,0,1
19688338,6,0,Multi-countr,"SOURCE OF FUNDING: Novo Nordisk (presumably). OTHER: Conflict of interest: Novo Nordisk, Amylin Pharmaceuticals",commercial,21975753,published data only,2,2,1,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,576,Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a,"Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Simó R; Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group.",Diabetologia. 2009 Oct;52(10):2046-55. doi: 10.1007/s00125-009-1472-y. Epub 2009 Aug 14.,Russell-Jones D,2009,9,3,0.2436050669,1,"From Cochrane: ""NUMBERS: 581 randomised, ITT population 576; LIR: 230, Placebo: 114, GLAR: 232""",21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,1,,,dif,-1.09,0.0200496339,0,0
19699832,6,0,USA,"Funding: not stated but does mention ""Missouri Breaks Industries, a local native American owned company assisted with recruitment and transportation of participants to study visits""",not reported,25188210,published data only,2,1,0,0,1,0,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,104,The medicine wheel nutrition intervention: a diabetes education study with the Cheyenne River Sioux Tribe,"Kattelmann KK, Conti K, Ren C.",J Am Diet Assoc. 2009 Sep;109(9):1532-9. doi: 10.1016/j.jada.2009.06.362.,Kattelmann KK,2009,3,2,0.0432864935,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Kattelman reports: One hundred fourteen Northern Plains Indians from Cheyenne River Sioux Tribe aged 18 to 65 years,mwith type 2 diabetes.",25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,8.4,2.14,51,8.5,2.18,53,-0.006315746,0.0225155745,0,0,,dif,-0.1,0.1300149464,0,1
19729522,6,0,USA,"Non-commercial funding: UCLA/DREW Project EXPORT, the National Center on Minority Health and Health disparities, the National Institutes of Health",non-commercial,23235661,published data only,2,2,2,2,2,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,89,Effect of pharmacological treatment of depression on A1C and quality of life in low-income Hispanics and African Americans with diabetes: a rando,"Echeverry D, Duran P, Bonds C, Lee M, Davidson MB.",Diabetes Care. 2009 Dec;32(12):2156-60. doi: 10.2337/dc09-0785. Epub 2009 Sep 3.,Echeverry D,2009,5,2,0.1656178898,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Echeverry reports: Therefore, 89 subjects whose baseline characteristics are summarized in Table 1 were randomly assigned;of these, 75 completed the study.",23235661,,,Psychological and pharmacological interventions for depression in patients with diabetes mellitus and depression,Cochrane Database Syst Rev. 2012 Dec 12;12:CD008381. doi: 10.1002/14651858.CD008381.pub2.,Baumeister H,2012,8,1.4,45,8.8,1.9,44,-0.210146283,0.0252610439,1,0,,post,-0.8,0.1256010101,0,1
19734396,3,0,USA,"(Non-)/commercial finding: not stated - Crawford states: ""Funding: Funding for this study was provided by the United States Air Force Surgeon General’s Office for Population Health Research.",non-commercial,22972104,published and unpublished data,2,2,0,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,109,"Effectiveness of cinnamon for lowering hemoglobin A1C in patients with type 2 diabetes: a randomized, controlled trial","Crawford P,C162",J Am Board Fam Med. 2009 Sep-Oct;22(5):507-12. doi: 10.3122/jabfm.2009.05.080093.,Crawford P,2009,2,2,0.4504884684,1,"From Cochrane: Participants: 109 participants analysed (cinnamon = 55, placebo = 54).",22972104,,,Cinnamon for diabetes mellitus,Cochrane Database Syst Rev. 2012 Sep 12;2012(9):CD007170. doi: 10.1002/14651858.CD007170.pub2.,Leach MJ,2012,7.64,1.7,55,7.91,1.5,54,0.1596014793,0.0206094761,1,0,,post,-0.27,0.0942121212,0,1
19758428,37,0,UK,Funding: non-commercial funding (Wellcome Trust),non-commercial,29205264,published data only,2,2,2,2,2,2,2,2,,2,2,,,2,2,2,,,,,,2,2,2,2,1,2,,2,1,,,,,,,102,"Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK","Penn L, White M, Oldroyd J, Walker M, Alberti KG, Mathers JC.",BMC Public Health. 2009 Sep 16;9:342. doi: 10.1186/1471-2458-9-342.,Penn L,2009,6,2,0.0432672352,1,from cochrane - no info on # randomized found; From BMC We recruited 102 participants,29205264,,,"Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus",Cochrane Database Syst Rev. 2017 Dec 4;12(12):CD003054. doi: 10.1002/14651858.CD003054.pub4.,Hemmingsen B,2017,5.8,0.4,26,5.7,0.5,28,-0.239007874,0.0404621863,0,0,,post,0.1,0.0150824176,0,1
19767384,6,0,France,COMMERCIAL FUNDING: Medtronic Inc,commercial,22258980,published data only,1,1,1,1,,,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,115,Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend s,"Raccah D, Sulmont V, Reznik Y, Guerci B, Renard E, Hanaire H, Jeandidier N, Nicolino M.",Diabetes Care. 2009 Dec;32(12):2245-50. doi: 10.2337/dc09-0750. Epub 2009 Sep 18.,Raccah D,2009,8,2,0.2175976844,1,"From Cochrane: WHO PARTICIPATED: 132 patients with type 1 diabetes, treated with MDI, randomised to insulin use by pump with integrated CGM (n=55) or pump + SMBG (n=60). 15 patients did not complete follow-up",22258980,,,Continuous glucose monitoring systems for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008101. doi: 10.1002/14651858.CD008101.pub2.,Langendam M,2012,8.3,1.33,55,8.71,1.11,60,0.2297217979,0.0187866248,0,0,,dif,-0.24,0.0363284848,0,1
19792844,3.01,0,Saudi-Arabia,"Funding source: Supported by a grant from King Abdulaziz University. Conflict of interests: Quote: ""The authors report no conflicts of interest related to this study""",non-commercial,26545069,published and unpublished data,2,1,0,0,,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,43,Short-term effects of photodynamic therapy on periodontal status and glycemic control of patients with diabetes,"Al-Zahrani MS, Bamshmous SO, Alhassani AA, Al-Sherbini MM.",J Periodontol. 2009 Oct;80(10):1568-73. doi: 10.1902/jop.2009.090206.,Al-Zahrani MS,2009,4,3,0.5759763287,1,From Cochrane: Number randomised: 45;Number evaluated: 43,26545069,,,Treatment of periodontal disease for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2015 Nov 6;2015(11):CD004714. doi: 10.1002/14651858.CD004714.pub3.,Simpson TC,2015,7.71,1.77,14,8.79,2.85,14,-0.343370668,0.0941490681,0,0,,post,-1.08,0.8039571429,0,1
19792844,3.02,0,Saudi-Arabia,"Funding source: Supported by a grant from King Abdulaziz University. Conflict of interests: Quote: ""The authors report no conflicts of interest related to this study""",non-commercial,26545069,published and unpublished data,2,1,0,0,,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,43,Short-term effects of photodynamic therapy on periodontal status and glycemic control of patients with diabetes,"Al-Zahrani MS, Bamshmous SO, Alhassani AA, Al-Sherbini MM.",J Periodontol. 2009 Oct;80(10):1568-73. doi: 10.1902/jop.2009.090206.,Al-Zahrani MS,2009,4,3,0.5759763287,1,From Cochrane: Number randomised: 45;Number evaluated: 43,26545069,,,Treatment of periodontal disease for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2015 Nov 6;2015(11):CD004714. doi: 10.1002/14651858.CD004714.pub3.,Simpson TC,2015,8.25,2.392,28,8.22,0.95,15,0.9015284418,0.0613673709,0,1,5,post,0.03,0.2645118095,0,1
19858437,24,0,USA,"Funding: grants from National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung and Blood Institute",non-commercial,25188210,published data only,2,2,0,0,2,1,,,,,,,,,,,,,,,,,,,2,1,,,,,,,,,,,488,"The effects of a nurse case manager and a community health worker team on diabetic control, emergency department visits, and hospitalizations amo","Gary TL, Batts-Turner M, Yeh HC, Hill-Briggs F, Bone LR, Wang NY, Levine DM, Powe NR, Saudek CD, Hill MN, McGuire M, Brancati FL.",Arch Intern Med. 2009 Oct 26;169(19):1788-94. doi: 10.1001/archinternmed.2009.338.,Gary TL,2009,12,2,0.756746435,1,Characteristics of included studies in Cochrane review does not report on number randomized; Gary reports: We randomly assigned 542 African Americans with type 2 DM enrolled in an urban managed care organization to either an intensive or minimal interventionmgroup.,25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,,,,,,,,,0,,,dif,-0.12,0.0243878168,0,0
19889003,3,0,USA,"Funding source: Takeda pharmaceuticals, Veterans Medical Research Foundation, Department of Veterans Affairs and the VA San Diego Healthcare System, University of California San Diego Clin Res. Centre NIH Grant",both,27640062,published data only,1,1,,2,,2,2,,1,,1,1,,,,,,,,,,,,,,2,,2,2,,,,,,,,25,Effects of intensive insulin therapy alone and with added pioglitazone on renal salt/water balance and fluid compartment shifts in type 2 diabete,"Mudaliar S, Chang AR, Aroda VR, Chao E, Burke P, Baxi S, Griver KA, O'Connor DT, Henry RR.",Diabetes Obes Metab. 2010 Feb;12(2):133-8. doi: 10.1111/j.1463-1326.2009.01126.x. Epub 2009 Nov 2.,Mudaliar S,2010,9,2,0.7099550004,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Muddallair reports: A total of 25 insulin-treated, obese patients with type 2 diabetes were randomized",27640062,,,Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control,Cochrane Database Syst Rev. 2016 Sep 18;9(9):CD006992. doi: 10.1002/14651858.CD006992.pub2.,Vos RC,2016,7.1,1.39,12,7.2,1.08,13,0.2693852234,0.0996570096,0,0,,dif,0.1,0.221600641,0,1
19902046,3.01,0,India,"Funding source: ""Source of support: Nil""",not reported,35420698,published data only,1,1,0,0,1,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,45,The effect of periodontal therapy on the improvement of glycemic control in patients with type 2 diabetes mellitus: A randomized controlled clini,"Singh S, Kumar V, Kumar S, Subbappa A.",Int J Diabetes Dev Ctries. 2008 Apr;28(2):38-44. doi: 10.4103/0973-3930.43097.,Singh S,2008,4,3,0.9999993827,1,From Cochrane:Number randomised: 45; Number evaluated: 45,26545069,35420698,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,7.3333,0.67788,15,8.1467,0.74053,15,0.0167820465,0.0776514324,0,0,,post,-0.8134,0.0671937317,0,1
19902046,3.02,0,India,"Funding source: ""Source of support: Nil""",not reported,35420698,published data only,1,1,0,0,1,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,45,The effect of periodontal therapy on the improvement of glycemic control in patients with type 2 diabetes mellitus: A randomized controlled clini,"Singh S, Kumar V, Kumar S, Subbappa A.",Int J Diabetes Dev Ctries. 2008 Apr;28(2):38-44. doi: 10.4103/0973-3930.43097.,Singh S,2008,4,3,0.9999993827,1,From Cochrane:Number randomised: 45; Number evaluated: 45,26545069,35420698,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,7.5467,0.65777,15,8.1467,0.74053,15,-0.04198607,0.0775881959,0,0,,post,-0.6,0.0654030703,0,1
19934458,4,0,USA,"Funding: National Institutes of Health, Lifescan, Johns Hopkins University School of Medicine General Clinical Research Center, National Center for Research Resources/National Institutes of Health",non-commercial,25188210,published data only,2,1,0,0,1,0,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,79,"A community-based, culturally tailored behavioral intervention for Korean Americans with type 2 diabetes","Kim MT, Han HR, Song HJ, Lee JE, Kim J, Ryu JP, Kim KB.",Diabetes Educ. 2009 Nov-Dec;35(6):986-94. doi: 10.1177/0145721709345774.,Kim MT,2009,7,2,0.9938572522,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Kim reports: A total of 79 KAIs, recruited from the Baltimore-Washington area, completed baseline, 18-week, and 30-week follow-ups (intervention, n = 40; control, n = 39). All participants had uncontrolled type 2 diabetes (hemoglobin A1C ?7.5%) at baseline.",25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,,,,,,,,,0,,,dif,-1.3,0.1163525641,0,0
19934458,7,0,USA,"Funding: National Institutes of Health, Lifescan, Johns Hopkins University School of Medicine General Clinical Research Center, National Center for Research Resources/National Institutes of Health",non-commercial,25188210,published data only,2,1,0,0,1,0,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,79,"A community-based, culturally tailored behavioral intervention for Korean Americans with type 2 diabetes","Kim MT, Han HR, Song HJ, Lee JE, Kim J, Ryu JP, Kim KB.",Diabetes Educ. 2009 Nov-Dec;35(6):986-94. doi: 10.1177/0145721709345774.,Kim MT,2009,7,2,0.9938572522,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Kim reports: A total of 79 KAIs, recruited from the Baltimore-Washington area, completed baseline, 18-week, and 30-week follow-ups (intervention, n = 40; control, n = 39). All participants had uncontrolled type 2 diabetes (hemoglobin A1C ?7.5%) at baseline.",25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,,,,,,,,,0,,,dif,-0.9,0.0925064103,0,0
20059361,2,0,USA,"COMMERCIAL FUNDING: Daiichi Sankyo, Inc",commercial,23235674,published data only,1,1,2,,,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,35,The effect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 diabetes: a pilot study,"Schwartz SL, Lai YL, Xu J, Abby SL, Misir S, Jones MR, Nagendran S.",Metab Syndr Relat Disord. 2010 Apr;8(2):179-88. doi: 10.1089/met.2009.0049.,Schwartz SL,2010,7,2,0.9629477493,1,From Cochrane: WHO PARTCIPATED: 35 patients with T2DM,23235674,,,Colesevelam for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2012 Dec 12;12(12):CD009361. doi: 10.1002/14651858.CD009361.pub2.,Ooi CP,2012,8.45,,16,9.26,,17,,,1,,,dif,-0.31,0.1386086262,0,0
20200301,6,0,multi-countr,"COMMERCIAL FUNDING: Yes: ""This study was sponsored by sanofi-aventis, Paris, France"".NON-COMMERCIAL FUNDING: No.",commercial,21735405,published and unpublished data,2,2,0,,,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,964,"A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients wit","Swinnen SG, Dain MP, Aronson R, Davies M, Gerstein HC, Pfeiffer AF, Snoek FJ, Devries JH, Hoekstra JB, Holleman F.",Diabetes Care. 2010 Jun;33(6):1176-8. doi: 10.2337/dc09-2294. Epub 2010 Mar 3.,Swinnen SG,2010,10,2,0.977936102,1,"From Cochrane: WHO PARTCIPATED: SEX (female% / male%): 437 (45.3%) / 527 (54.7%).Swinner reports: ""973 insulin-naive type 2 diabetic patients on stable oral glucose-lowering drugs with A1C 7.0–10.5% were randomized"".  Table A in Appendix reports on 964 patients",21735405,,,Insulin detemir versus insulin glargine for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Jul 6;2011(7):CD006383. doi: 10.1002/14651858.CD006383.pub2.,Swinnen SG,2011,7.1,0.9,486,7.2,0.9,478,0.0139687648,0.0021492206,0,0,,post,-0.1,0.0033612273,0,1
20299481,6,0,USA,Funding: The study was supported by National Institutes of Health Grant 1R18DK065729 and Robert Wood Johnson Foundation Grant 096223.,non-commercial,23543567,published data only,2,1,0,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,761,Online diabetes self-management program: a randomized study,"Lorig K, Ritter PL, Laurent DD, Plant K, Green M, Jernigan VB, Case S.",Diabetes Care. 2010 Jun;33(6):1275-81. doi: 10.2337/dc09-2153. Epub 2010 Mar 18.,Lorig K,2010,7,3,0.9910097398,1,From Cochrane: Follow-up rates: Intervention: 395/491 = 80%. Control: 238/270 = 88%.,23543567,,,Computer-based diabetes self-management interventions for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2013 Mar 28;2013(3):CD008776. doi: 10.1002/14651858.CD008776.pub2.,Pal K,2013,,,,,,,,,0,,,dif,-0.135,0.0043874837,0,0
20380655,6.01,0,Japan,SOURCE OF FUNDING: Novo Nordisk. OTHER: Conflict of interest: NR,commercial,21975753,published data only,1,1,2,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,264,Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide,"Kaku K, Rasmussen MF, Clauson P, Seino Y.",Diabetes Obes Metab. 2010 Apr;12(4):341-7. doi: 10.1111/j.1463-1326.2009.01194.x.,Kaku K,2010,4,3,0.9925430858,1,"From Cochrane:NUMBERS: Screened: 308; Randomised: 264""",21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,7.14,0.89,88,8.06,1.13,88,-0.117527271,0.0120263341,1,0,,dif,-1.06,0.0200840909,0,1
20380655,6.02,0,Japan,SOURCE OF FUNDING: Novo Nordisk. OTHER: Conflict of interest: NR,commercial,21975753,published data only,1,1,2,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,264,Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide,"Kaku K, Rasmussen MF, Clauson P, Seino Y.",Diabetes Obes Metab. 2010 Apr;12(4):341-7. doi: 10.1111/j.1463-1326.2009.01194.x.,Kaku K,2010,4,3,0.9925430858,1,"From Cochrane:NUMBERS: Screened: 308; Randomised: 264""",21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,6.67,0.83,88,8.06,1.13,88,-0.119229816,0.0120257337,1,0,,dif,-1.16,0.0178465909,0,1
20415693,24,0,Multi-countr,"Funding: commercial funding Merck & Co., Inc., Whitehouse Station, NJ",commercial,32501595,published data only,2,1,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,,,,,0,0,0,0,0,0,0,0,0,,,,454,Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes,"Williams-Herman D, Johnson J, Teng R, Golm G, Kaufman KD, Goldstein BJ, Amatruda JM.",Diabetes Obes Metab. 2010 May;12(5):442-51. doi: 10.1111/j.1463-1326.2010.01204.x.,Williams-Herman,2010,7,6,0.8566147834,1,"Characteristics of included studies in Cochrane review does not report on number randomized;Williams-Hermann reports: Of the 1091 patients who were randomized at baseline, 685 (47%) continued into the 50-week extension study. Big discrepancy in sample size is due to data abstraction from Table  2 in publication entitled:baseline characteristics of the efficacy analysis population.",32501595,,,Metformin monotherapy for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Jun 5;6(6):CD012906. doi: 10.1002/14651858.CD012906.pub2.,Gnesin F,2020,7.33,0.83,151,7.4,0.7,50,0.1730261269,0.0140317786,0,0,,post,-0.07,0.0143622517,0,1
20417856,6.01,0,Multi-countr,SOURCE OF FUNDING: Novo Nordisk. OTHER: Conflict of interest: Authors have received grants and consultancy fees from different pharmaceutical companies.,commercial,21975753,published data only,2,2,0,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,665,"Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomise","Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Thomsen AB, Søndergaard RE, Davies M; 1860-LIRA-DPP-4 Study Group.",Lancet. 2010 Apr 24;375(9724):1447-56. doi: 10.1016/S0140-6736(10)60307-8.,Pratley RE,2010,9,3,0.4831581182,1,From Cochrane:NUMBERS: Assessed: 1302; randomised: 665,21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,0,,,dif,0.26,0.0088403462,0,0
20417856,6.02,0,Multi-countr,SOURCE OF FUNDING: Novo Nordisk. OTHER: Conflict of interest: Authors have received grants and consultancy fees from different pharmaceutical companies.,commercial,21975753,published data only,2,2,0,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,665,"Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomise","Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Thomsen AB, Søndergaard RE, Davies M; 1860-LIRA-DPP-4 Study Group.",Lancet. 2010 Apr 24;375(9724):1447-56. doi: 10.1016/S0140-6736(10)60307-8.,Pratley RE,2010,9,3,0.4831581182,1,From Cochrane:NUMBERS: Assessed: 1302; randomised: 665,21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,0,,,dif,-0.34,0.0088202298,0,0
20417856,6.03,0,Multi-countr,SOURCE OF FUNDING: Novo Nordisk. OTHER: Conflict of interest: Authors have received grants and consultancy fees from different pharmaceutical companies.,commercial,21975753,published data only,2,2,0,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,665,"Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomise","Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Thomsen AB, Søndergaard RE, Davies M; 1860-LIRA-DPP-4 Study Group.",Lancet. 2010 Apr 24;375(9724):1447-56. doi: 10.1016/S0140-6736(10)60307-8.,Pratley RE,2010,9,3,0.4831581182,1,From Cochrane:NUMBERS: Assessed: 1302; randomised: 665,21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,0,,,dif,-0.6,0.0089725441,0,0
20484058,3,0,USA,Funding: NIH NIHR funding,non-commercial,25188210,published data only,2,1,0,0,1,0,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,109,"The effect of a diabetes education, coping skills training, and care intervention on physiological and psychosocial outcomes in black women with","D'Eramo Melkus G, Chyun D, Vorderstrasse A, Newlin K, Jefferson V, Langerman S.",Biol Res Nurs. 2010 Jul;12(1):7-19. doi: 10.1177/1099800410369825. Epub 2010 May 18.,D'Eramo Melkus G,2010,6,2,0.1948201735,1,Characteristics of included studies in Cochrane review does not report on number randomized; d'Eramo reports:  in 109 Black women (aged 48 + 10 years) with type 2 diabetes in primary care (PC),25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,7.32,1.41,52,7.35,1.71,57,-0.187820294,0.0207480061,0,0,,post,-0.03,0.0895326923,0,1
20484058,24,0,USA,Funding: NIH NIHR funding,non-commercial,25188210,published data only,2,1,0,0,1,0,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,109,"The effect of a diabetes education, coping skills training, and care intervention on physiological and psychosocial outcomes in black women with","D'Eramo Melkus G, Chyun D, Vorderstrasse A, Newlin K, Jefferson V, Langerman S.",Biol Res Nurs. 2010 Jul;12(1):7-19. doi: 10.1177/1099800410369825. Epub 2010 May 18.,D'Eramo Melkus G,2010,6,2,0.1948201735,1,Characteristics of included studies in Cochrane review does not report on number randomized; d'Eramo reports:  in 109 Black women (aged 48 + 10 years) with type 2 diabetes in primary care (PC),25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,7.2,2.15,52,8,2.41,57,-0.007984364,0.0223938166,0,0,,post,-0.8,0.190790722,0,1
20536952,2.01,0,Multi-countr,SOURCE OF FUNDING: Hoffmann-La Roche OTHER: Conflict of interest: Two authors have received consulting and advisory board honoraria from F. Hoffmann-La Roche as well as from other pharmaceutical companies developing incretin-based therapies whose products may be perceived as competitive to taspoglutide. One author has received consulting and research fees from F. Hoffman-La Roche and Ispen. Some authors are employees of F. Hoffman- La Roche.,commercial,21975753,published data only,2,1,2,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,129,"Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomi","Ratner R, Nauck M, Kapitza C, Asnaghi V, Boldrin M, Balena R.",Diabet Med. 2010 May;27(5):556-62. doi: 10.1111/j.1464-5491.2010.02990.x.,Ratner R,2010,6,4,0.5397965429,1,"From Cochrane:NUMBERS: Randomised: 133 (TAS 20 mg QW: 32, TAS 20/30 mg QW: 33; TAS 20/40 QW: 32; Placebo: 32);safety population: 129;",21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,1,,,dif,-0.7,0.01999396,0,0
20536952,2.02,0,Multi-countr,SOURCE OF FUNDING: Hoffmann-La Roche OTHER: Conflict of interest: Two authors have received consulting and advisory board honoraria from F. Hoffmann-La Roche as well as from other pharmaceutical companies developing incretin-based therapies whose products may be perceived as competitive to taspoglutide. One author has received consulting and research fees from F. Hoffman-La Roche and Ispen. Some authors are employees of F. Hoffman- La Roche.,commercial,21975753,published data only,2,1,2,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,129,"Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomi","Ratner R, Nauck M, Kapitza C, Asnaghi V, Boldrin M, Balena R.",Diabet Med. 2010 May;27(5):556-62. doi: 10.1111/j.1464-5491.2010.02990.x.,Ratner R,2010,6,4,0.5397965429,1,"From Cochrane:NUMBERS: Randomised: 133 (TAS 20 mg QW: 32, TAS 20/30 mg QW: 33; TAS 20/40 QW: 32; Placebo: 32);safety population: 129;",21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,1,,,dif,-0.7,0.01999396,0,0
20536952,2.03,0,Multi-countr,SOURCE OF FUNDING: Hoffmann-La Roche OTHER: Conflict of interest: Two authors have received consulting and advisory board honoraria from F. Hoffmann-La Roche as well as from other pharmaceutical companies developing incretin-based therapies whose products may be perceived as competitive to taspoglutide. One author has received consulting and research fees from F. Hoffman-La Roche and Ispen. Some authors are employees of F. Hoffman- La Roche.,commercial,21975753,published data only,2,1,2,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,129,"Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomi","Ratner R, Nauck M, Kapitza C, Asnaghi V, Boldrin M, Balena R.",Diabet Med. 2010 May;27(5):556-62. doi: 10.1111/j.1464-5491.2010.02990.x.,Ratner R,2010,6,4,0.5397965429,1,"From Cochrane:NUMBERS: Randomised: 133 (TAS 20 mg QW: 32, TAS 20/30 mg QW: 33; TAS 20/40 QW: 32; Placebo: 32);safety population: 129;",21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,1,,,dif,-0.4,0.0198424345,0,0
20541825,60,0,Multi-countr,"Funding source: Servier; ""Study data were collected and retained by the investigators and were not made available to the study sponsors.""",commercial,28594069,published and unpublished data,2,2,2,2,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,11140,The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial,"Zoungas S, Chalmers J, Kengne AP, Pillai A, Billot L, de Galan B, Marre M, Neal B, Harrap S, Poulter N, Patel A.",Diabetes Res Clin Pract. 2010 Aug;89(2):126-33. doi: 10.1016/j.diabres.2010.05.012. Epub 2010 Jun 11.,Zoungas S,2010,11,2,0.8632998369,1,from Cochrane: Number: treatment group (5128); control group (5123),28594069,,,Glucose targets for preventing diabetic kidney disease and its progression,Cochrane Database Syst Rev. 2017 Jun 8;6(6):CD010137. doi: 10.1002/14651858.CD010137.pub2.,Ruospo M,2017,6.53,0.91,4828,7.3,1.26,4741,-0.213955766,0.0002194193,0,0,,post,-0.77,0.0005063864,0,1
20580422,6.01,0,Multi-countr,SOURCE OF FUNDING: Amylin Pharmaceuticals and Eli Lilly,commercial,21975753,published data only,2,2,2,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,491,Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURA,"Bergenstal RM, Wysham C, Macconell L, Malloy J, Walsh B, Yan P, Wilhelm K, Malone J, Porter LE; DURATION-2 Study Group.",Lancet. 2010 Aug 7;376(9739):431-9. doi: 10.1016/S0140-6736(10)60590-9. Epub 2010 Jun 26.,Bergenstal RM,2010,9,3,0.7838870879,1,"From Cochrane:NUMBERS: Screened: 958; randomised: 514 (EX 2 mg: 170, SITA 100 mg: 172, PIO 45 mg: 172); evaluable patient: 387 (EX 2 mg: 122, SITA 100 mg: 137, PIO 45 mg: 128); ITT: 491 (EX 2 mg: 160, SITA 100 mg: 166, PIO 45 mg: 165)",21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,0,,,dif,-0.3,0.0162681242,0,0
20580422,6.02,0,Multi-countr,SOURCE OF FUNDING: Amylin Pharmaceuticals and Eli Lilly,commercial,21975753,published data only,2,2,2,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,491,Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURA,"Bergenstal RM, Wysham C, Macconell L, Malloy J, Walsh B, Yan P, Wilhelm K, Malone J, Porter LE; DURATION-2 Study Group.",Lancet. 2010 Aug 7;376(9739):431-9. doi: 10.1016/S0140-6736(10)60590-9. Epub 2010 Jun 26.,Bergenstal RM,2010,9,3,0.7838870879,1,"From Cochrane:NUMBERS: Screened: 958; randomised: 514 (EX 2 mg: 170, SITA 100 mg: 172, PIO 45 mg: 172); evaluable patient: 387 (EX 2 mg: 122, SITA 100 mg: 137, PIO 45 mg: 128); ITT: 491 (EX 2 mg: 160, SITA 100 mg: 166, PIO 45 mg: 165)",21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,0,,,dif,-0.6,0.0162686656,0,0
20587585,6,0,Multi-countr,COMMERCIAL FUNDING: Supported by Medtronic,commercial,22258980,published data only,2,1,1,2,,,,,,,,,,,,,,,,,,,,,1,2,,,,,,,,,,,485,Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes,"Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Peoples T, Perkins BA, Welsh JB, Willi SM, Wood MA; STAR 3 Study Group.",N Engl J Med. 2010 Jul 22;363(4):311-20. doi: 10.1056/NEJMoa1002853. Epub 2010 Jun 29.,Bergenstal RM,2010,12,2,0.1742801619,1,"From Cochrane: WHO PARTICIPATED: 485 patients, 329 adults and 156 children",22258980,,,Continuous glucose monitoring systems for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008101. doi: 10.1002/14651858.CD008101.pub2.,Langendam M,2012,7.46,0.81,244,8.03,0.88,241,,,0,,,dif,-0.57,0.0044510412,0,0
20587585,12,0,Multi-countr,COMMERCIAL FUNDING: Supported by Medtronic,commercial,22258980,published data only,2,1,1,2,,,,,,,,,,,,,,,,,,,,,1,2,,,,,,,,,,,485,Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes,"Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Peoples T, Perkins BA, Welsh JB, Willi SM, Wood MA; STAR 3 Study Group.",N Engl J Med. 2010 Jul 22;363(4):311-20. doi: 10.1056/NEJMoa1002853. Epub 2010 Jun 29.,Bergenstal RM,2010,12,2,0.1742801619,1,"From Cochrane: WHO PARTICIPATED: 485 patients, 329 adults and 156 children",22258980,,,Continuous glucose monitoring systems for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008101. doi: 10.1002/14651858.CD008101.pub2.,Langendam M,2012,,,,,,,,,0,,,dif,-0.6,0.0232051282,0,0
20587585,12.01,0,Multi-countr,COMMERCIAL FUNDING: Supported by Medtronic,commercial,22258980,published data only,2,1,1,2,,,,,,,,,,,,,,,,,,,,,1,2,,,,,,,,,,,485,Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes,"Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Peoples T, Perkins BA, Welsh JB, Willi SM, Wood MA; STAR 3 Study Group.",N Engl J Med. 2010 Jul 22;363(4):311-20. doi: 10.1056/NEJMoa1002853. Epub 2010 Jun 29.,Bergenstal RM,2010,12,2,0.1742801619,1,"From Cochrane: WHO PARTICIPATED: 485 patients, 329 adults and 156 children",22258980,,,Continuous glucose monitoring systems for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008101. doi: 10.1002/14651858.CD008101.pub2.,Langendam M,2012,7.49,0.86,244,8.09,0.97,241,,,0,,,dif,-0.6,0.0059839467,0,0
20587585,12.02,0,Multi-countr,COMMERCIAL FUNDING: Supported by Medtronic,commercial,22258980,published data only,2,1,1,2,,,,,,,,,,,,,,,,,,,,,1,2,,,,,,,,,,,485,Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes,"Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Peoples T, Perkins BA, Welsh JB, Willi SM, Wood MA; STAR 3 Study Group.",N Engl J Med. 2010 Jul 22;363(4):311-20. doi: 10.1056/NEJMoa1002853. Epub 2010 Jun 29.,Bergenstal RM,2010,12,2,0.1742801619,1,"From Cochrane: WHO PARTICIPATED: 485 patients, 329 adults and 156 children",22258980,,,Continuous glucose monitoring systems for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008101. doi: 10.1002/14651858.CD008101.pub2.,Langendam M,2012,,,,,,,,,0,,,dif,-0.6,0.0068781876,0,0
20609969,6,0,Multi-countr,"SOURCE OF FUNDING: Amylin and Eli Lilly. OTHER: Conflict of interest: First author is a consultant and speaker for Eli Lilly, Novo Nordisk, and Merck, Sharp and Dohme; and 10 lines of conflict",commercial,21975753,published data only,2,2,0,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,456,Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised t,"Diamant M, Van Gaal L, Stranks S, Northrup J, Cao D, Taylor K, Trautmann M.",Lancet. 2010 Jun 26;375(9733):2234-43. doi: 10.1016/S0140-6736(10)60406-0.,Diamant M,2010,7,2,0.1053739551,1,"From Cochrane:NUMBERS: Screened: 659; randomised: 456 (EX: 233, GLAR: 223)""",21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,0,,,dif,-0.2,0.006111257,0,0
20617348,3,0,Japan,Funding source: Sanwa Kagaku Kenkyusyo Co Ltd,commercial,27640062,published data only,1,1,,2,,1,1,,1,,1,1,,,,,,,,,,,,,,2,,2,1,,,,,,,,197,Efficacy of combined use of miglitol in Type 2 diabetes patients receiving insulin therapy-placebo-controlled double-blind comparative study,"Nemoto M, Tajima N, Kawamori R.",Acta Diabetol. 2011 Mar;48(1):15-20. doi: 10.1007/s00592-010-0206-4. Epub 2010 Jul 9.,Nemoto M,2011,3,2,0.2687882797,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Nemoto reports: Two hundred and seventy-six patients were enrolled, and 107 were randomly allocated to Group M and 100 to Group P.",27640062,,,Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control,Cochrane Database Syst Rev. 2016 Sep 18;9(9):CD006992. doi: 10.1002/14651858.CD006992.pub2.,Vos RC,2016,7.47,1.13,100,7.87,1.05,97,0.1254100423,0.0107764905,0,0,,dif,-0.39,0.0075889897,0,1
20628517,3,0,Spain,"Funding: ""This work was supported by grants from Fundacion para Estudios Metabolicos"".Declarations of interest: ""The authors declare that they have no conflicts of interest""",non-commercial,29081069,published data only,0,0,0,1,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,97,The outcomes of gestational diabetes mellitus after a telecare approach are not inferior to traditional outpatient clinic visits,"Pérez-Ferre N, Galindo M, Fernández MD, Velasco V, Runkle I, de la Cruz MJ, Martín Rojas-Marcos P, Del Valle L, Calle-Pascual AL.",Int J Endocrinol. 2010;2010:386941. doi: 10.1155/2010/386941. Epub 2010 Jun 10.,Pérez-Ferre N,2010,9,2,0.8764614313,1,from Cochrane:100 women randomised,29081069,,,Different methods and settings for glucose monitoring for gestational diabetes during pregnancy,Cochrane Database Syst Rev. 2017 Oct 29;10(10):CD011069. doi: 10.1002/14651858.CD011069.pub2.,Raman P,2017,5.3,0.4,49,5.4,0.4,48,0.0184695355,0.0217288948,0,0,,post,-0.1,0.0065986395,0,1
20634175,4,0,multi-countr,"COMMERCIAL FUNDING: Daiichi Sankyo, Inc",commercial,23235674,published data only,1,1,2,,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,286,Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes,"Rosenstock J, Fonseca VA, Garvey WT, Goldberg RB, Handelsman Y, Abby SL, Lai YL, Jin X, Misir S, Nagendran S, Jones MR.",Endocr Pract. 2010 Jul-Aug;16(4):629-40. doi: 10.4158/EP10130.OR.,Rosenstock J,2010,11,2,0.9999324536,1,From Cochrane: WHO PARTCIPATED: 286 patients with T2DM,23235674,,,Colesevelam for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2012 Dec 12;12(12):CD009361. doi: 10.1002/14651858.CD009361.pub2.,Ooi CP,2012,6.6,,138,6.7,,137,,,1,,,dif,-0.3,0.0083125782,0,0
20711715,6,0,Multi-countr,COMMERCIAL FUNDING: Medtronic Inc,commercial,22258980,published data only,1,1,2,2,,,,,,,,,,,,,,,,,,,,,1,2,,,,,,,,,,,154,Sensor-augmented pump therapy from the diagnosis of childhood type 1 diabetes: results of the Paediatric Onset Study (ONSET) after 12 months of t,"Kordonouri O, Pankowska E, Rami B, Kapellen T, Coutant R, Hartmann R, Lange K, Knip M, Danne T.",Diabetologia. 2010 Dec;53(12):2487-95. doi: 10.1007/s00125-010-1878-6. Epub 2010 Aug 14.,Kordonouri O,2010,9,2,0.1042073516,1,From Cochrane: WHO PARTICIPATED: 160 patients with type 1 diabetes;  Kordonouri reports 154 patients in Table 2.,22258980,,,Continuous glucose monitoring systems for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008101. doi: 10.1002/14651858.CD008101.pub2.,Langendam M,2012,7,1,76,7.2,1.2,78,-0.153933721,0.0139581466,0,0,,dif,0.1,0.0889136302,0,1
20711715,12,0,Multi-countr,COMMERCIAL FUNDING: Medtronic Inc,commercial,22258980,published data only,1,1,2,2,,,,,,,,,,,,,,,,,,,,,1,2,,,,,,,,,,,154,Sensor-augmented pump therapy from the diagnosis of childhood type 1 diabetes: results of the Paediatric Onset Study (ONSET) after 12 months of t,"Kordonouri O, Pankowska E, Rami B, Kapellen T, Coutant R, Hartmann R, Lange K, Knip M, Danne T.",Diabetologia. 2010 Dec;53(12):2487-95. doi: 10.1007/s00125-010-1878-6. Epub 2010 Aug 14.,Kordonouri O,2010,9,2,0.1042073516,1,From Cochrane: WHO PARTICIPATED: 160 patients with type 1 diabetes;  Kordonouri reports 154 patients in Table 2.,22258980,,,Continuous glucose monitoring systems for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008101. doi: 10.1002/14651858.CD008101.pub2.,Langendam M,2012,7.4,1.2,76,7.6,1.4,78,-0.127264754,0.0141146004,0,0,,dif,0.1,0.0799662618,0,1
20714820,4,0,USA,Funding:This study was supported by grant #DK35524 from the National Institute of Diabetes and Digestive and Kidney Diseases.,non-commercial,23543567,published data only,2,1,1,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,463,Outcomes of minimal and moderate support versions of an internet-based diabetes self-management support program,"Glasgow RE, Kurz D, King D, Dickman JM, Faber AJ, Halterman E, Wooley T, Toobert DJ, Strycker LA, Estabrooks PA, Osuna D, Ritzwoller D.",J Gen Intern Med. 2010 Dec;25(12):1315-22. doi: 10.1007/s11606-010-1480-0. Epub 2010 Aug 17.,Glasgow RE,2010,12,3,0.4552013803,1,From Cochrane: Follow-up rates: Intervention: 130/169 = 77%. Control: 115/132 = 87%; discrepance due because Glasgow is a 3-arm study- cochrane abstracts 2 arms,23543567,,,Computer-based diabetes self-management interventions for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2013 Mar 28;2013(3):CD008776. doi: 10.1002/14651858.CD008776.pub2.,Pal K,2013,7.84,1.67,130,8,1.58,115,0.0750865703,0.0090187825,0,0,,post,-0.16,0.043160903,0,1
20722676,3.01,0,Multi-countr,SOURCE OF FUNDING: Hoffmann-La Roche. OTHER: Conflict of interest: Two authors have received consulting and advisory board honoraria from F. Hoffmann-La Roche as well as from other pharmaceutical companies developing incretin-based therapies whose products may be perceived as competitive to taspoglutide. One author has received consulting and research fees from F. Hoffman-La Roche and Ispen. Some authors are employees of F. Hoffman-La Roche.,commercial,21975753,published data only,2,2,2,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,542,Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metfor,"Ratner RE, Rosenstock J, Boka G; DRI6012 Study Investigators.",Diabet Med. 2010 Sep;27(9):1024-32. doi: 10.1111/j.1464-5491.2010.03020.x.,Ratner RE,2010,3,9,0.1168233974,1,From Cochrane: NUMBERS: Screened: 1466; randomised: 542,21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,1,,,dif,-0.69,,0,0
20722676,3.02,0,Multi-countr,SOURCE OF FUNDING: Hoffmann-La Roche. OTHER: Conflict of interest: Two authors have received consulting and advisory board honoraria from F. Hoffmann-La Roche as well as from other pharmaceutical companies developing incretin-based therapies whose products may be perceived as competitive to taspoglutide. One author has received consulting and research fees from F. Hoffman-La Roche and Ispen. Some authors are employees of F. Hoffman-La Roche.,commercial,21975753,published data only,2,2,2,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,542,Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metfor,"Ratner RE, Rosenstock J, Boka G; DRI6012 Study Investigators.",Diabet Med. 2010 Sep;27(9):1024-32. doi: 10.1111/j.1464-5491.2010.03020.x.,Ratner RE,2010,3,9,0.1168233974,1,From Cochrane: NUMBERS: Screened: 1466; randomised: 542,21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,1,,,dif,-0.57,,0,0
20722676,3.03,0,Multi-countr,SOURCE OF FUNDING: Hoffmann-La Roche. OTHER: Conflict of interest: Two authors have received consulting and advisory board honoraria from F. Hoffmann-La Roche as well as from other pharmaceutical companies developing incretin-based therapies whose products may be perceived as competitive to taspoglutide. One author has received consulting and research fees from F. Hoffman-La Roche and Ispen. Some authors are employees of F. Hoffman-La Roche.,commercial,21975753,published data only,2,2,2,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,542,Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metfor,"Ratner RE, Rosenstock J, Boka G; DRI6012 Study Investigators.",Diabet Med. 2010 Sep;27(9):1024-32. doi: 10.1111/j.1464-5491.2010.03020.x.,Ratner RE,2010,3,9,0.1168233974,1,From Cochrane: NUMBERS: Screened: 1466; randomised: 542,21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,1,,,dif,-0.6,,0,0
20722676,3.04,0,Multi-countr,SOURCE OF FUNDING: Hoffmann-La Roche. OTHER: Conflict of interest: Two authors have received consulting and advisory board honoraria from F. Hoffmann-La Roche as well as from other pharmaceutical companies developing incretin-based therapies whose products may be perceived as competitive to taspoglutide. One author has received consulting and research fees from F. Hoffman-La Roche and Ispen. Some authors are employees of F. Hoffman-La Roche.,commercial,21975753,published data only,2,2,2,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,542,Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metfor,"Ratner RE, Rosenstock J, Boka G; DRI6012 Study Investigators.",Diabet Med. 2010 Sep;27(9):1024-32. doi: 10.1111/j.1464-5491.2010.03020.x.,Ratner RE,2010,3,9,0.1168233974,1,From Cochrane: NUMBERS: Screened: 1466; randomised: 542,21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,1,,,dif,-0.47,,0,0
20722676,3.05,0,Multi-countr,SOURCE OF FUNDING: Hoffmann-La Roche. OTHER: Conflict of interest: Two authors have received consulting and advisory board honoraria from F. Hoffmann-La Roche as well as from other pharmaceutical companies developing incretin-based therapies whose products may be perceived as competitive to taspoglutide. One author has received consulting and research fees from F. Hoffman-La Roche and Ispen. Some authors are employees of F. Hoffman-La Roche.,commercial,21975753,published data only,2,2,2,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,542,Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metfor,"Ratner RE, Rosenstock J, Boka G; DRI6012 Study Investigators.",Diabet Med. 2010 Sep;27(9):1024-32. doi: 10.1111/j.1464-5491.2010.03020.x.,Ratner RE,2010,3,9,0.1168233974,1,From Cochrane: NUMBERS: Screened: 1466; randomised: 542,21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,1,,,dif,-0.58,,0,0
20722676,3.06,0,Multi-countr,SOURCE OF FUNDING: Hoffmann-La Roche. OTHER: Conflict of interest: Two authors have received consulting and advisory board honoraria from F. Hoffmann-La Roche as well as from other pharmaceutical companies developing incretin-based therapies whose products may be perceived as competitive to taspoglutide. One author has received consulting and research fees from F. Hoffman-La Roche and Ispen. Some authors are employees of F. Hoffman-La Roche.,commercial,21975753,published data only,2,2,2,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,542,Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metfor,"Ratner RE, Rosenstock J, Boka G; DRI6012 Study Investigators.",Diabet Med. 2010 Sep;27(9):1024-32. doi: 10.1111/j.1464-5491.2010.03020.x.,Ratner RE,2010,3,9,0.1168233974,1,From Cochrane: NUMBERS: Screened: 1466; randomised: 542,21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,1,,,dif,-0.51,,0,0
20722676,3.07,0,Multi-countr,SOURCE OF FUNDING: Hoffmann-La Roche. OTHER: Conflict of interest: Two authors have received consulting and advisory board honoraria from F. Hoffmann-La Roche as well as from other pharmaceutical companies developing incretin-based therapies whose products may be perceived as competitive to taspoglutide. One author has received consulting and research fees from F. Hoffman-La Roche and Ispen. Some authors are employees of F. Hoffman-La Roche.,commercial,21975753,published data only,2,2,2,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,542,Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metfor,"Ratner RE, Rosenstock J, Boka G; DRI6012 Study Investigators.",Diabet Med. 2010 Sep;27(9):1024-32. doi: 10.1111/j.1464-5491.2010.03020.x.,Ratner RE,2010,3,9,0.1168233974,1,From Cochrane: NUMBERS: Screened: 1466; randomised: 542,21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,1,,,dif,-0.32,,0,0
20722676,3.08,0,Multi-countr,SOURCE OF FUNDING: Hoffmann-La Roche. OTHER: Conflict of interest: Two authors have received consulting and advisory board honoraria from F. Hoffmann-La Roche as well as from other pharmaceutical companies developing incretin-based therapies whose products may be perceived as competitive to taspoglutide. One author has received consulting and research fees from F. Hoffman-La Roche and Ispen. Some authors are employees of F. Hoffman-La Roche.,commercial,21975753,published data only,2,2,2,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,542,Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metfor,"Ratner RE, Rosenstock J, Boka G; DRI6012 Study Investigators.",Diabet Med. 2010 Sep;27(9):1024-32. doi: 10.1111/j.1464-5491.2010.03020.x.,Ratner RE,2010,3,9,0.1168233974,1,From Cochrane: NUMBERS: Screened: 1466; randomised: 542,21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,1,,,dif,-0.29,,0,0
20739728,6,0,Netherland,Funding: Roche Diagnostics,commercial,22258959,published and unpublished data,2,2,0,0,2,,,,,,,,,,,,,,,,,,,,2,2,,,,,,,,,,,40,Self-monitoring of blood glucose in tablet-treated type 2 diabetic patients (ZODIAC),"Kleefstra N, Hortensius J, Logtenberg SJ, Slingerland RJ, Groenier KH, Houweling ST, Gans RO, van Ballegooie E, Bilo HJ.",Neth J Med. 2010 Aug;68(1):311-6.,Kleefstra N,2010,9,2,0.596579897,1,From Cochrane:Number of participants: 41,22258959,,,Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin,Cochrane Database Syst Rev. 2012 Jan 18;1:CD005060. doi: 10.1002/14651858.CD005060.pub3.,Malanda UL,2012,7.4,0.7,22,7.7,0.6,19,0.1898791733,0.0549907367,0,0,,dif,-0.25,0.0516545455,0,1
20739728,12,0,Netherland,Funding: Roche Diagnostics,commercial,22258959,published and unpublished data,2,2,0,0,2,,,,,,,,,,,,,,,,,,,,2,2,,,,,,,,,,,40,Self-monitoring of blood glucose in tablet-treated type 2 diabetic patients (ZODIAC),"Kleefstra N, Hortensius J, Logtenberg SJ, Slingerland RJ, Groenier KH, Houweling ST, Gans RO, van Ballegooie E, Bilo HJ.",Neth J Med. 2010 Aug;68(1):311-6.,Kleefstra N,2010,9,2,0.596579897,1,From Cochrane:Number of participants: 41,22258959,,,Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin,Cochrane Database Syst Rev. 2012 Jan 18;1:CD005060. doi: 10.1002/14651858.CD005060.pub3.,Malanda UL,2012,7.5,0.8,22,7.5,0.5,19,0.4658937485,0.0550155492,0,0,,dif,0,0.0723737374,0,1
20854384,3,0,UK,"No (non-)/commercial funding - Publication reports: ""This study was supported by the following: Thames Valley University UK; Jeffrey Kelson Diabetes and Endocrine Centre, Central Middlesex Hospital London; Brent NHS London; Department of Dietetics, Brent National Health Services, London; Research and Development Office, Brent National Health Services, London and Holland and Barrett Ltd, UK.",non-commercial,22972104,published data only,2,2,2,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,58,"Glycated haemoglobin and blood pressure-lowering effect of cinnamon in multi-ethnic Type 2 diabetic patients in the UK: a randomized, placebo-con","Akilen R, Tsiami A, Devendra D, Robinson N.",Diabet Med. 2010 Oct;27(10):1159-67. doi: 10.1111/j.1464-5491.2010.03079.x.,Akilen R,2010,4,2,0.0173134732,1,"From Cochrane:Participants: 58 adults randomised, 58 analysed (cinnamon = 30, placebo = 28).",22972104,,,Cinnamon for diabetes mellitus,Cochrane Database Syst Rev. 2012 Sep 12;2012(9):CD007170. doi: 10.1002/14651858.CD007170.pub2.,Leach MJ,2012,7.86,1.42,30,8.68,1.83,28,-0.155451555,0.0397175715,1,0,,post,-0.82,0.1868169048,0,1
20873243,12,0,Russia,Funding: not reported,not reported,32501595,published data only,1,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,182,[Capabilities of hypoglycemic therapy in women with decompensated type 2 diabetes mellitus],"Onuchin SG, Elsukova OS, Solov'ev OV, Onuchina EL.",Ter Arkh. 2010;82(8):34-41.,Onuchin SG,2010,4,4,0.6774688964,1,Characteristics of included studies in Cochrane review does not report on number randomized; Onuchin reports: 182 women …..,32501595,,,Metformin monotherapy for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Jun 5;6(6):CD012906. doi: 10.1002/14651858.CD012906.pub2.,Gnesin F,2020,7.1,0.6,46,8.1,0.9,45,-0.273888806,0.0234095723,0,0,,post,-1,0.025826087,0,1
20923485,6,0,Spain,Funding: Ministerio de Sanidad from Spain (Fondos de Cohesion 2008),non-commercial,22258959,published and unpublished data,1,1,0,0,1,,,,,,,,,,,,,,,,,,,,2,2,,,,,,,,,,,195,"Benefits of self-monitoring blood glucose in the management of new-onset Type 2 diabetes mellitus: the St Carlos Study, a prospective randomized","Durán A, Martín P, Runkle I, Pérez N, Abad R, Fernández M, Del Valle L, Sanz MF, Calle-Pascual AL.",J Diabetes. 2010 Sep;2(3):203-11. doi: 10.1111/j.1753-0407.2010.00081.x.,Durán A,2010,9,2,0.8450865938,1,From Cochrane:Number of participants: 195,22258959,,,Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin,Cochrane Database Syst Rev. 2012 Jan 18;1:CD005060. doi: 10.1002/14651858.CD005060.pub3.,Malanda UL,2012,6.1,0.43,99,6.8,0.84,62,-0.563979558,0.0137815419,0,1,3,dif,-0.8,0.0051058977,0,1
20923485,12,0,Spain,Funding: Ministerio de Sanidad from Spain (Fondos de Cohesion 2008),non-commercial,22258959,published and unpublished data,1,1,0,0,1,,,,,,,,,,,,,,,,,,,,2,2,,,,,,,,,,,195,"Benefits of self-monitoring blood glucose in the management of new-onset Type 2 diabetes mellitus: the St Carlos Study, a prospective randomized","Durán A, Martín P, Runkle I, Pérez N, Abad R, Fernández M, Del Valle L, Sanz MF, Calle-Pascual AL.",J Diabetes. 2010 Sep;2(3):203-11. doi: 10.1111/j.1753-0407.2010.00081.x.,Durán A,2010,9,2,0.8450865938,1,From Cochrane:Number of participants: 195,22258959,,,Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin,Cochrane Database Syst Rev. 2012 Jan 18;1:CD005060. doi: 10.1002/14651858.CD005060.pub3.,Malanda UL,2012,6.1,0.52,99,6.8,0.52,62,0.1055496185,0.0136529246,0,0,,dif,-0.7,0.0083317041,0,1
21076128,3,0,USA,"Funding: grants and awards from Center for Health Intervention and Prevention (University of Connecticut),NIH/NIDDK National Research Service Award, Diversity Supplement Award, NIH/NCMHD",non-commercial,25188210,published data only,1,1,0,0,2,0,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,91,A brief culturally tailored intervention for Puerto Ricans with type 2 diabetes,"Osborn CY, Amico KR, Cruz N, O'Connell AA, Perez-Escamilla R, Kalichman SC, Wolf SA, Fisher JD.",Health Educ Behav. 2010 Dec;37(6):849-62. doi: 10.1177/1090198110366004. Epub 2010 Nov 12.,Osborn CY,2010,8,2,0.6192133248,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Osborn reports:  Participants (n = 118) were recruited from an outpatient, primary care clinic at an urban hospital in the northeast United States.",25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,7.28,1.29,48,7.18,1.54,43,-0.192030288,0.0247776396,0,0,,post,0.1,0.0898222384,0,1
21114607,4,0,Multi-countr,SOURCE OF FUNDING: Novo Nordisk. OTHER: Conflict of interest: Two authors are employees of Novo Nordisk. Other authors have no competing interests.,commercial,21975753,published data only,1,1,2,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,929,Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pre,"Yang W, Chen L, Ji Q, Liu X, Ma J, Tandon N, Bhattacharyya A, Kumar A, Kim KW, Yoon KH, Bech OM, Zychma M.",Diabetes Obes Metab. 2011 Jan;13(1):81-8. doi: 10.1111/j.1463-1326.2010.01323.x.,Yang W,2011,12,4,0.2947209086,1,From Cochrane: NUMBERS: Randomised: 926; Exposed: 928 (LIR 1.2 mg: 233; LIR 1.8 mg: 233; GLIM: 231); per-protocol set: 562 (LIR 1.2 mg: 179; LIR 1.8 mg: 172; GLIM: 211),21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,0,,,dif,-0.06,0.0074403097,0,0
21114680,3,0,Greece,Funding source: European National Fund and National Resources (EPEAEK 2 PYTHAGORAS),non-commercial,35420698,published and unpublished data,2,2,0,0,1,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,60,"A randomized, controlled trial on the effect of non-surgical periodontal therapy in patients with type 2 diabetes. Part I: effect on periodontal","Koromantzos PA, Makrilakis K, Dereka X, Katsilambros N, Vrotsos IA, Madianos PN.",J Clin Periodontol. 2011 Feb;38(2):142-7. doi: 10.1111/j.1600-051X.2010.01652.x. Epub 2010 Nov 29.,Koromantzos PA,2011,6,2,0.1915674419,1,"From Cochrane:Number randomised: 60 Number evaluated: 60 (4 lost to follow-up in Gp A, 3 in Gp B)",26545069,35420698,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,7.14,0.54,30,7.41,0.48,30,0.1548753014,0.0360023818,0,0,,post,-0.27,0.0174,0,1
21114680,6,0,Greece,Funding source: European National Fund and National Resources (EPEAEK 2 PYTHAGORAS),non-commercial,35420698,published and unpublished data,2,2,0,0,1,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,60,"A randomized, controlled trial on the effect of non-surgical periodontal therapy in patients with type 2 diabetes. Part I: effect on periodontal","Koromantzos PA, Makrilakis K, Dereka X, Katsilambros N, Vrotsos IA, Madianos PN.",J Clin Periodontol. 2011 Feb;38(2):142-7. doi: 10.1111/j.1600-051X.2010.01652.x. Epub 2010 Nov 29.,Koromantzos PA,2011,6,2,0.1915674419,1,"From Cochrane:Number randomised: 60 Number evaluated: 60 (4 lost to follow-up in Gp A, 3 in Gp B)",26545069,35420698,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,7.16,0.69,30,7.46,0.72,30,-0.001513712,0.0362919829,0,0,,post,-0.3,0.03315,0,1
21146881,6,0,USA,Funding: non-commercial funding,non-commercial,33166419,published data only,1,1,1,2,1,2,,0,,1,2,1,2,,0,,,,,,,,,,0,0,0,0,,0,,,,,,,85,"Insulin glargine compared to NPH among insulin-naïve, U.S. inner city, ethnic minority type 2 diabetic patients","Hsia SH,",Diabetes Res Clin Pract. 2011 Mar;91(3):293-9. doi: 10.1016/j.diabres.2010.11.028. Epub 2010 Dec 13.,Hsia SH,2011,1,3,0.2385374488,1,Characteristics of included studies in Cochrane review does not report on number randomized; Hsia reports: Eighty-five subjects were randomized to 26 weeks of open-label,33166419,,,(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Nov 9;11(11):CD005613. doi: 10.1002/14651858.CD005613.pub4.,Semlitsch T,2020,7.9,1.4,25,7.9,1.5,30,-0.065428157,0.0419967491,0,0,,dif,0.1,0.1539333333,0,1
21206443,3,0,Iran,"Non-commercial funding: grant from the Department of Research, Kermanshah University of Medical Sciences",non-commercial,23235661,published data only,2,1,1,2,0,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,40,Treatment of depression in type 2 diabetes with Fluoxetine or Citalopram?,"Khazaie H, Rahimi M, Tatari F, Rezaei M, Najafi F, Tahmasian M.",Neurosciences (Riyadh). 2011 Jan;16(1):42-5.,Khazaie H,2011,6,2,0.7990493195,1,Characteristics of included studies in Cochrane review does not report on number randomized; Khazaie reports: were randomly assigned to 2 groups (n=20 per group) in a randomized controlled trial method.,23235661,,,Psychological and pharmacological interventions for depression in patients with diabetes mellitus and depression,Cochrane Database Syst Rev. 2012 Dec 12;12:CD008381. doi: 10.1002/14651858.CD008381.pub2.,Baumeister H,2012,5.74,1.06,20,6.65,1.6,20,-0.263982416,0.0600068907,0,0,,post,-0.91,0.18418,0,1
21213091,6,0,USA,"Funding: National Heart, Lung and Blood Institute",non-commercial,25188210,published data only,2,1,0,0,2,0,,,,,,,,,,,,,,,,,,,2,2,,,,,,,,,,,280,Outcomes from a multiple risk factor diabetes self-management trial for Latinas: ¡Viva Bien!,"Toobert DJ, Strycker LA, Barrera M Jr, Osuna D, King DK, Glasgow RE.",Ann Behav Med. 2011 Jun;41(3):310-23. doi: 10.1007/s12160-010-9256-7.,Toobert DJ,2011,6,2,0.9998650315,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Toobert reports:Random assignment of 280 Latinas with type 2 diabetes to usual care only or to usual care+¡Viva Bien!,",25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,7.9,1.7,142,8.3,1.6,138,0.1098854299,0.0078429968,0,0,,post,-0.4,0.0389028373,0,1
21213091,12,0,USA,"Funding: National Heart, Lung and Blood Institute",non-commercial,25188210,published data only,2,1,0,0,2,0,,,,,,,,,,,,,,,,,,,2,2,,,,,,,,,,,280,Outcomes from a multiple risk factor diabetes self-management trial for Latinas: ¡Viva Bien!,"Toobert DJ, Strycker LA, Barrera M Jr, Osuna D, King DK, Glasgow RE.",Ann Behav Med. 2011 Jun;41(3):310-23. doi: 10.1007/s12160-010-9256-7.,Toobert DJ,2011,6,2,0.9998650315,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Toobert reports:Random assignment of 280 Latinas with type 2 diabetes to usual care only or to usual care+¡Viva Bien!,",25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,8.3,1.9,142,8.3,1.6,138,0.1716968459,0.0078859392,0,0,,post,0,0.0439732598,0,1
21216855,3,0,Netherlands,Non-commercial funding: Dutch Diabetes Research Foundation,non-commercial,23235661,published and unpublished data,2,2,0,2,0,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,255,"Web-based depression treatment for type 1 and type 2 diabetic patients: a randomized, controlled trial","van Bastelaar KM, Pouwer F, Cuijpers P, Riper H, Snoek FJ.",Diabetes Care. 2011 Feb;34(2):320-5. doi: 10.2337/dc10-1248. Epub 2011 Jan 7.,van Bastelaar KM,2011,5,2,0.9808593218,1,Characteristics of included studies in Cochrane review does not report on number randomized;Van Bastelaar reports: A randomized controlled trial was in the Netherlands in 255 adult diabetic patients,23235661,,,Psychological and pharmacological interventions for depression in patients with diabetes mellitus and depression,Cochrane Database Syst Rev. 2012 Dec 12;12:CD008381. doi: 10.1002/14651858.CD008381.pub2.,Baumeister H,2012,7.6,1.5,125,7.2,1.1,130,0.2561779522,0.0084620371,0,0,,post,0.4,0.0273076923,0,1
21226754,3,0,Netherlands,Non-commercial funding: The Netherlands Organization for Health Research and Development (Zon-Mw),non-commercial,23235661,published and unpublished data,2,2,0,2,0,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,208,Treating depression in diabetes patients: does a nurse-administered minimal psychological intervention affect diabetes-specific quality of life a,"Lamers F, Jonkers CC, Bosma H, Knottnerus JA, van Eijk JT.",J Adv Nurs. 2011 Apr;67(4):788-99. doi: 10.1111/j.1365-2648.2010.05540.x. Epub 2011 Jan 12.,Lamers F,2011,5,2,0.1798151138,1,Characteristics of included studies in Cochrane review does not report on number randomized; Lamers reports: with usual care among 208 Dutch primary care patients of 60 years with type 2 diabetes and co-occurring minor to moderate depression,23235661,,,Psychological and pharmacological interventions for depression in patients with diabetes mellitus and depression,Cochrane Database Syst Rev. 2012 Dec 12;12:CD008381. doi: 10.1002/14651858.CD008381.pub2.,Baumeister H,2012,7.8,1,26,7.4,1,23,-0.055290105,0.0459869993,0,0,,post,0.4,0.0819397993,0,1
21226754,6,0,Netherlands,Non-commercial funding: The Netherlands Organization for Health Research and Development (Zon-Mw),non-commercial,23235661,published and unpublished data,2,2,0,2,0,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,208,Treating depression in diabetes patients: does a nurse-administered minimal psychological intervention affect diabetes-specific quality of life a,"Lamers F, Jonkers CC, Bosma H, Knottnerus JA, van Eijk JT.",J Adv Nurs. 2011 Apr;67(4):788-99. doi: 10.1111/j.1365-2648.2010.05540.x. Epub 2011 Jan 12.,Lamers F,2011,5,2,0.1798151138,1,Characteristics of included studies in Cochrane review does not report on number randomized; Lamers reports: with usual care among 208 Dutch primary care patients of 60 years with type 2 diabetes and co-occurring minor to moderate depression,23235661,,,Psychological and pharmacological interventions for depression in patients with diabetes mellitus and depression,Cochrane Database Syst Rev. 2012 Dec 12;12:CD008381. doi: 10.1002/14651858.CD008381.pub2.,Baumeister H,2012,7.4,1,26,7.5,1,23,0.0107310383,0.0460361884,0,0,,post,-0.1,0.0819397993,0,1
21226754,12,0,Netherlands,Non-commercial funding: The Netherlands Organization for Health Research and Development (Zon-Mw),non-commercial,23235661,published and unpublished data,2,2,0,2,0,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,208,Treating depression in diabetes patients: does a nurse-administered minimal psychological intervention affect diabetes-specific quality of life a,"Lamers F, Jonkers CC, Bosma H, Knottnerus JA, van Eijk JT.",J Adv Nurs. 2011 Apr;67(4):788-99. doi: 10.1111/j.1365-2648.2010.05540.x. Epub 2011 Jan 12.,Lamers F,2011,5,2,0.1798151138,1,Characteristics of included studies in Cochrane review does not report on number randomized; Lamers reports: with usual care among 208 Dutch primary care patients of 60 years with type 2 diabetes and co-occurring minor to moderate depression,23235661,,,Psychological and pharmacological interventions for depression in patients with diabetes mellitus and depression,Cochrane Database Syst Rev. 2012 Dec 12;12:CD008381. doi: 10.1002/14651858.CD008381.pub2.,Baumeister H,2012,7.3,1,26,7.8,1,23,0.0635185591,0.0459972195,0,0,,post,-0.5,0.0819397993,0,1
21251180,4.01,0,USA,"SOURCE OF FUNDING: Eli Lilly and Company. OTHER: First author has received research support from different pharmaceutical companies and has acted as a consultant for some of the companies. Another author has served on advisory boards and received honorarium or consulting fees from different pharmaceutical companies. He has also received research grants from some of these companies. Two authors are employees and shareholders of Eli Lilly and Company. One author was a shareholder, and during the conduct of the study and preparation of the paper, an employee, of Eli Lilly and Company.",commercial,21975753,published data only,2,1,2,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,263,"The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/o","Umpierrez GE, Blevins T, Rosenstock J, Cheng C, Anderson JH, Bastyr EJ 3rd; EGO Study Group.",Diabetes Obes Metab. 2011 May;13(5):418-25. doi: 10.1111/j.1463-1326.2011.01366.x. Epub 2011 Jan 19.,Umpierrez GE,2011,6,4,0.6190393862,1,From Cochrane: NUMBERS: LY 0.5/1.0 QW: 66; LY 1.0/1.0 QW: 65; LY 1.0/2.0 QW: 65; Placebo: 66,21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,1,,,dif,-1.14,0.0285121212,0,0
21251180,4.02,0,USA,"SOURCE OF FUNDING: Eli Lilly and Company. OTHER: First author has received research support from different pharmaceutical companies and has acted as a consultant for some of the companies. Another author has served on advisory boards and received honorarium or consulting fees from different pharmaceutical companies. He has also received research grants from some of these companies. Two authors are employees and shareholders of Eli Lilly and Company. One author was a shareholder, and during the conduct of the study and preparation of the paper, an employee, of Eli Lilly and Company.",commercial,21975753,published data only,2,1,2,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,263,"The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/o","Umpierrez GE, Blevins T, Rosenstock J, Cheng C, Anderson JH, Bastyr EJ 3rd; EGO Study Group.",Diabetes Obes Metab. 2011 May;13(5):418-25. doi: 10.1111/j.1463-1326.2011.01366.x. Epub 2011 Jan 19.,Umpierrez GE,2011,6,4,0.6190393862,1,From Cochrane: NUMBERS: LY 0.5/1.0 QW: 66; LY 1.0/1.0 QW: 65; LY 1.0/2.0 QW: 65; Placebo: 66,21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,1,,,dif,-1.08,0.0285121212,0,0
21251180,4.03,0,USA,"SOURCE OF FUNDING: Eli Lilly and Company. OTHER: First author has received research support from different pharmaceutical companies and has acted as a consultant for some of the companies. Another author has served on advisory boards and received honorarium or consulting fees from different pharmaceutical companies. He has also received research grants from some of these companies. Two authors are employees and shareholders of Eli Lilly and Company. One author was a shareholder, and during the conduct of the study and preparation of the paper, an employee, of Eli Lilly and Company.",commercial,21975753,published data only,2,1,2,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,263,"The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/o","Umpierrez GE, Blevins T, Rosenstock J, Cheng C, Anderson JH, Bastyr EJ 3rd; EGO Study Group.",Diabetes Obes Metab. 2011 May;13(5):418-25. doi: 10.1111/j.1463-1326.2011.01366.x. Epub 2011 Jan 19.,Umpierrez GE,2011,6,4,0.6190393862,1,From Cochrane: NUMBERS: LY 0.5/1.0 QW: 66; LY 1.0/1.0 QW: 65; LY 1.0/2.0 QW: 65; Placebo: 66,21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,,,,,,,,,1,,,dif,-1.35,0.0285121212,0,0
21270188,6,0,South Korea,"Funding: ""This study was supported by a grant of the Korea Healthcare technology R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea (A090001), a research grant (02-2008-036) from the SNUBH  and the Korea Science and Engineering Foundation grants funded by the Ministry of Science and Technology (M10642140004-06N4214-00410)""",non-commercial,23543567,published data only,1,1,0,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,154,"Improved glycemic control without hypoglycemia in elderly diabetic patients using the ubiquitous healthcare service, a new medical information sy","Lim S, Kang SM, Shin H, Lee HJ, Won Yoon J, Yu SH, Kim SY, Yoo SY, Jung HS, Park KS, Ryu JO, Jang HC.",Diabetes Care. 2011 Feb;34(2):308-13. doi: 10.2337/dc10-1447.,Lim S,2011,12,3,0.3327757382,1,From Cochrane:2/51 (3.9%) dropout rate in the intervention group and 4/52 (7.3%) dropout rate in the control group.,23543567,,,Computer-based diabetes self-management interventions for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2013 Mar 28;2013(3):CD008776. doi: 10.1002/14651858.CD008776.pub2.,Pal K,2013,7.4,1,49,7.8,1,48,0.0524069745,0.0222135653,0,0,,post,-0.4,0.0412414966,0,1
21294770,3,0,Multi-countr,COMMERCIAL FUNDING: Medtronic,commercial,22258980,published data only,2,2,2,2,,,,,,,,,,,,,,,,,,,,,1,2,,,,,,,,,,,83,Sensor-augmented pump therapy lowers HbA(1c) in suboptimally controlled Type 1 diabetes; a randomized controlled trial,"Hermanides J, Nørgaard K, Bruttomesso D, Mathieu C, Frid A, Dayan CM, Diem P, Fermon C, Wentholt IM, Hoekstra JB, DeVries JH.",Diabet Med. 2011 Oct;28(10):1158-67. doi: 10.1111/j.1464-5491.2011.03256.x.,Hermanides J,2011,11,2,0.6502552332,1,"FromCochrane: WHO PARTICIPATED: 83 adults, randomised to 44 in the CGM group and 39 in the control group. 78 patients completed the study",22258980,,,Continuous glucose monitoring systems for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008101. doi: 10.1002/14651858.CD008101.pub2.,Langendam M,2012,7.29,0.71,41,8.55,1.21,36,-0.375306156,0.028294248,0,0,,dif,-1.13,0.0358978997,0,1
21294770,6,0,Multi-countr,COMMERCIAL FUNDING: Medtronic,commercial,22258980,published data only,2,2,2,2,,,,,,,,,,,,,,,,,,,,,1,2,,,,,,,,,,,83,Sensor-augmented pump therapy lowers HbA(1c) in suboptimally controlled Type 1 diabetes; a randomized controlled trial,"Hermanides J, Nørgaard K, Bruttomesso D, Mathieu C, Frid A, Dayan CM, Diem P, Fermon C, Wentholt IM, Hoekstra JB, DeVries JH.",Diabet Med. 2011 Oct;28(10):1158-67. doi: 10.1111/j.1464-5491.2011.03256.x.,Hermanides J,2011,11,2,0.6502552332,1,"FromCochrane: WHO PARTICIPATED: 83 adults, randomised to 44 in the CGM group and 39 in the control group. 78 patients completed the study",22258980,,,Continuous glucose monitoring systems for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008101. doi: 10.1002/14651858.CD008101.pub2.,Langendam M,2012,7.23,0.65,41,8.46,1.04,36,-0.314567883,0.0281234029,0,0,,dif,-1.1,0.0335915989,0,1
21307137,6.03,0,USA,SOURCE OF FUNDING: Amylin Pharmaceuticals,commercial,21975753,published data only,2,1,0,,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,252,DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type,"Blevins T, Pullman J, Malloy J, Yan P, Taylor K, Schulteis C, Trautmann M, Porter L.",J Clin Endocrinol Metab. 2011 May;96(5):1301-10. doi: 10.1210/jc.2010-2081. Epub 2011 Feb 9.,Blevins T,2011,8,2,0.5204531721,1,"From Cochrane:NUMBERS: EX 10 Pg BID: 123; EX 2 mg QW: 129""",21975753,,,Glucagon-like peptide analogues for type 2 diabetes mellitus,Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2.,Shyangdan DS,2011,7.7,1.11,123,7.1,1.14,129,,,0,,,dif,0.7,0.0200914918,0,0
21335621,6,0,Multi-countr,COMMERCIAL FUNDING: Abbott Diabetes Care and various other pharmaceutical companies NON-COMMERCIAL FUNDING: Slovenian National Research Agency Grants,both,22258980,published data only,2,2,1,2,,,,,,,,,,,,,,,,,,,,,1,2,,,,,,,,,,,120,Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes,"Battelino T, Phillip M, Bratina N, Nimri R, Oskarsson P, Bolinder J.",Diabetes Care. 2011 Apr;34(4):795-800. doi: 10.2337/dc10-1989. Epub 2011 Feb 19.,Battelino T,2011,6,2,0.0487350312,1,From Cochrane: WHO PARTICIPATED: 120 patients; 62 in the CGM group and 58 in the CGM group,22258980,,,Continuous glucose monitoring systems for type 1 diabetes mellitus,Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008101. doi: 10.1002/14651858.CD008101.pub2.,Langendam M,2012,6.686,0.55,62,6.95,0.57,58,,,0,,,dif,-0.297,0.0142547275,0,0
21342243,6,0,Italy,Funding: Unconditionally support by LifeScan Inc. Clinical Research Management and Monitoring,commercial,22258959,published data only,2,2,0,0,0,,,,,,,,,,,,,,,,,,,,2,2,,,,,,,,,,,62,ROSES: role of self-monitoring of blood glucose and intensive education in patients with Type 2 diabetes not receiving insulin. A pilot randomize,"Franciosi M, Lucisano G, Pellegrini F, Cantarello A, Consoli A, Cucco L, Ghidelli R, Sartore G, Sciangula L, Nicolucci A; ROSES Study Group.",Diabet Med. 2011 Jul;28(7):789-96. doi: 10.1111/j.1464-5491.2011.03268.x.,Franciosi M,2011,10,2,0.034241726,1,From Cochrane:Number of participants: 62,22258959,,,Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin,Cochrane Database Syst Rev. 2012 Jan 18;1:CD005060. doi: 10.1002/14651858.CD005060.pub3.,Malanda UL,2012,6.7,0.678,46,7.2,0.8,16,,,0,,,dif,-0.6,0.0499931304,0,0
21342412,17,0,Germany,Funding: commercial funding (Bristol-Myers Squibb and AstraZeneca),commercial,32501595,published data only,2,2,2,2,2,2,2,2,2,2,2,,,,,,,,,,,,,,0,0,0,0,0,0,0,0,0,,,,1306,Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks,"Pfützner A, Paz-Pacheco E, Allen E, Frederich R, Chen R; CV181039 Investigators.",Diabetes Obes Metab. 2011 Jun;13(6):567-76. doi: 10.1111/j.1463-1326.2011.01385.x.,Pfützner A,2011,5,4,0.4535942672,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Pfutner reports: 1306 patients 18–77 years of age (HbA1c 8.0–12.0%) were randomized to saxagliptin 5 mg + 500 mg metformin, saxagliptin 10 mg + 500 mg metformin, saxagliptin 10 mg + placebo or 500 mg metformin + placebo.",32501595,,,Metformin monotherapy for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Jun 5;6(6):CD012906. doi: 10.1002/14651858.CD012906.pub2.,Gnesin F,2020,,,,,,,,,0,,,dif,-0.24,0.0112930256,0,0
21378213,4,0,USA,"Funding: National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases Grant",non-commercial,25188210,published data only,2,1,0,0,2,0,,,,,,,,,,,,,,,,,,,2,2,,,,,,,,,,,252,"Randomized trial of a literacy-sensitive, culturally tailored diabetes self-management intervention for low-income latinos: latinos en control","Rosal MC, Ockene IS, Restrepo A, White MJ, Borg A, Olendzki B, Scavron J, Candib L, Welch G, Reed G.",Diabetes Care. 2011 Apr;34(4):838-44. doi: 10.2337/dc10-1981. Epub 2011 Mar 4.,Rosal MC,2011,10,2,0.9413954825,1,Characteristics of included studies in Cochrane review does not report on number randomized; Rosal reports: A total of 252 patients recruited from community health centers were randomized to the Latinos en Control intervention or to usual care.,25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,7.96,1.79,128,8.76,1.818,124,0.0800936345,0.0088086448,0,0,,dif,-0.53,0.0500852098,0,1
21378213,12,0,USA,"Funding: National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases Grant",non-commercial,25188210,published data only,2,1,0,0,2,0,,,,,,,,,,,,,,,,,,,2,2,,,,,,,,,,,252,"Randomized trial of a literacy-sensitive, culturally tailored diabetes self-management intervention for low-income latinos: latinos en control","Rosal MC, Ockene IS, Restrepo A, White MJ, Borg A, Olendzki B, Scavron J, Candib L, Welch G, Reed G.",Diabetes Care. 2011 Apr;34(4):838-44. doi: 10.2337/dc10-1981. Epub 2011 Mar 4.,Rosal MC,2011,10,2,0.9413954825,1,Characteristics of included studies in Cochrane review does not report on number randomized; Rosal reports: A total of 252 patients recruited from community health centers were randomized to the Latinos en Control intervention or to usual care.,25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,8.39,2.045,128,8.92,2.107,124,0.031252958,0.0089804145,0,0,,dif,-0.26,0.0540337738,0,1
21503128,3,0,China,"Funding source: National Key Project of Science and Technical Supporting Programs of China, National Natural Science Foundation of China, ""211"" Project Foundation, Mega-projects of Science for the  10th 5-year Plan",non-commercial,35420698,published data only,1,1,0,0,1,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,66,[Effect of community periodontal care intervention on periodontal health and glycemic control in type 2 diabetic patients with chronic periodonti,"Li Z, Sha YQ, Zhang BX, Zhu L, Kang J.",Beijing Da Xue Xue Bao Yi Xue Ban. 2011 Apr 18;43(2):285-9.,Li Z,2011,5,3,0.3783349189,1,From Cochrane:Number randomised: 66; Number evaluated: not reported,26545069,35420698,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,7.44,1.48,22,7.23,0.94,19,0.4208629143,0.0569546587,0,0,,post,0.21,0.1460688995,0,1
21503128,6,0,China,"Funding source: National Key Project of Science and Technical Supporting Programs of China, National Natural Science Foundation of China, ""211"" Project Foundation, Mega-projects of Science for the  10th 5-year Plan",non-commercial,35420698,published data only,1,1,0,0,1,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,66,[Effect of community periodontal care intervention on periodontal health and glycemic control in type 2 diabetic patients with chronic periodonti,"Li Z, Sha YQ, Zhang BX, Zhu L, Kang J.",Beijing Da Xue Xue Bao Yi Xue Ban. 2011 Apr 18;43(2):285-9.,Li Z,2011,5,3,0.3783349189,1,From Cochrane:Number randomised: 66; Number evaluated: not reported,26545069,35420698,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,7.08,1.15,22,7.14,1.33,19,-0.140632895,0.0572921467,0,0,,post,-0.06,0.1532136364,0,1
21587283,49,0,Netherlands,Funding: non-commercial funding (Netherlands Organisation for Scientific Research (ZonMW:940-35-034) and the Dutch Diabetes Research Foundation (DFN: 98.901),non-commercial,29205264,published data only,1,1,2,,,2,2,,,,,,,2,,,2,2,,,,,,,2,,,0,0,,,,,,,,114,Predictors of lifestyle intervention outcome and dropout: the SLIM study,"Roumen C, Feskens EJ, Corpeleijn E, Mensink M, Saris WH, Blaak EE.",Eur J Clin Nutr. 2011 Oct;65(10):1141-7. doi: 10.1038/ejcn.2011.74. Epub 2011 May 18.,Roumen C,2011,6,2,0.5954793641,1,"from cochrane - no info on # randomized found; from Roumen: In the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht, 147 Caucasian IGT subjects were randomized to an intervention group (INT: n=74; 38 male, 36 female) and control group (CON: n=73; 37 male, 36 female).  Baseline values (sample size shown here taken from Mensink cited as primary in Hemmingsen Cochrane review.",29205264,,,"Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus",Cochrane Database Syst Rev. 2017 Dec 4;12(12):CD003054. doi: 10.1002/14651858.CD003054.pub4.,Hemmingsen B,2017,6.27,0.79,57,6.19,0.72,58,0.0800744851,0.01852568,0,0,,post,0.08,0.0198870538,0,1
21640424,18,0,UK,Funding source: government,non-commercial,28594069,published data only,1,1,1,2,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,189,Multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: the Microalbuminuria Education and Medication Optimisation,"Crasto W, Jarvis J, Khunti K, Skinner TC, Gray LJ, Brela J, Troughton J, Daly H, Lawrence IG, McNally PG, Carey ME, Davies MJ.",Diabetes Res Clin Pract. 2011 Sep;93(3):328-36. doi: 10.1016/j.diabres.2011.05.008. Epub 2011 Jun 2.,Crasto W,2011,12,2,0.6062753812,1,From Cochrane:Number: treatment group (95); control group (95),28594069,,,Glucose targets for preventing diabetic kidney disease and its progression,Cochrane Database Syst Rev. 2017 Jun 8;6(6):CD010137. doi: 10.1002/14651858.CD010137.pub2.,Ruospo M,2017,7.1,1,89,7.8,1.4,89,-0.242373746,0.0120777239,0,0,,post,-0.7,0.033258427,0,1
21680932,6.01,0,USA,Nothing mentioned,not reported,25188210,published and unpublished data,1,1,0,0,2,0,,,,,,,,,,,,,,,,,,,2,2,,,,,,,,,,,164,Effectiveness of a community health worker intervention among African American and Latino adults with type 2 diabetes: a randomized controlled tr,"Spencer MS, Rosland AM, Kieffer EC, Sinco BR, Valerio M, Palmisano G, Anderson M, Guzman JR, Heisler M.",Am J Public Health. 2011 Dec;101(12):2253-60. doi: 10.2105/AJPH.2010.300106. Epub 2011 Jun 16.,Spencer MS,2011,9,2,0.9842707414,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Spencer reports: We used a randomized, 6-month delayed control group design among 164 African American and Latino adult participants recruited from 2 health systems in Detroit, Michigan.",25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,,,,,,,,,0,,,dif,-1.5,0.1387179487,1,0
21680932,6.02,0,USA,Nothing mentioned,not reported,25188210,published and unpublished data,1,1,0,0,2,0,,,,,,,,,,,,,,,,,,,2,2,,,,,,,,,,,164,Effectiveness of a community health worker intervention among African American and Latino adults with type 2 diabetes: a randomized controlled tr,"Spencer MS, Rosland AM, Kieffer EC, Sinco BR, Valerio M, Palmisano G, Anderson M, Guzman JR, Heisler M.",Am J Public Health. 2011 Dec;101(12):2253-60. doi: 10.2105/AJPH.2010.300106. Epub 2011 Jun 16.,Spencer MS,2011,9,2,0.9842707414,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Spencer reports: We used a randomized, 6-month delayed control group design among 164 African American and Latino adult participants recruited from 2 health systems in Detroit, Michigan.",25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,,,,,,,,,0,,,dif,-0.2,0.1416666667,0,0
21751889,3,0,Macedonia,Funding: Macedonion Ministry of Health and the Health Care Fund of Macedonia.,non-commercial,31120549,published data only,1,1,2,2,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,25,Is there a difference in pregnancy and glycemic outcome in patients with type 1 diabetes on insulin pump with constant or intermittent glucose mo,"Petrovski G, Dimitrovski C, Bogoev M, Milenkovic T, Ahmeti I, Bitovska I.",Diabetes Technol Ther. 2011 Nov;13(11):1109-13. doi: 10.1089/dia.2011.0081. Epub 2011 Jul 13.,Petrovski G,2011,6,2,0.9999970167,1,from Cochrane: Number randomised: 25.,24782359,28602020,31120549,Techniques of monitoring blood glucose during pregnancy for women with pre-existing diabetes,Cochrane Database Syst Rev. 2019 May 23;5(5):CD009613. doi: 10.1002/14651858.CD009613.pub4.,Jones LV,2019,6.52,1.3,12,6.82,0.7,13,0.6665609113,0.0988547678,0,1,4,post,-0.3,0.178525641,0,1
21751889,9,0,Macedonia,Funding: Macedonion Ministry of Health and the Health Care Fund of Macedonia.,non-commercial,31120549,published data only,1,1,2,2,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,25,Is there a difference in pregnancy and glycemic outcome in patients with type 1 diabetes on insulin pump with constant or intermittent glucose mo,"Petrovski G, Dimitrovski C, Bogoev M, Milenkovic T, Ahmeti I, Bitovska I.",Diabetes Technol Ther. 2011 Nov;13(11):1109-13. doi: 10.1089/dia.2011.0081. Epub 2011 Jul 13.,Petrovski G,2011,6,2,0.9999970167,1,from Cochrane: Number randomised: 25.,24782359,28602020,31120549,Techniques of monitoring blood glucose during pregnancy for women with pre-existing diabetes,Cochrane Database Syst Rev. 2019 May 23;5(5):CD009613. doi: 10.1002/14651858.CD009613.pub4.,Jones LV,2019,6.14,0.9,12,6.23,0.6,13,0.4232660836,0.0972314751,0,0,,post,-0.09,0.0951923077,0,1
21775748,4,0,USA,"Funding: National Institute of Diabetes and Digestive Kidney Diseases Grant, National Center for Research Resources Grant and a grant from Lifescan and Johnson and Johnson",both,25188210,published data only,2,1,0,1,1,1,,,,,,,,,,,,,,,,,,,0,1,,,,,,,,,,,207,Peer-led diabetes education programs in high-risk Mexican Americans improve glycemic control compared with standard approaches: a Project Dulce p,"Philis-Tsimikas A, Fortmann A, Lleva-Ocana L, Walker C, Gallo LC.",Diabetes Care. 2011 Sep;34(9):1926-31. doi: 10.2337/dc10-2081. Epub 2011 Jul 20.,Philis-Tsimikas,2011,5,2,0.396458879,1,Characteristics of included studies in Cochrane review does not report on number randomized; Philis-Tsiminakis reports: total of 207 Mexican-American patients recruited from federally funded community health centers in San Diego County,25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,9,1.9,64,9.1,1.9,81,0.0126572547,0.0156255647,0,0,,post,-0.1,0.1009741512,0,1
21775748,10,0,USA,"Funding: National Institute of Diabetes and Digestive Kidney Diseases Grant, National Center for Research Resources Grant and a grant from Lifescan and Johnson and Johnson",both,25188210,published data only,2,1,0,1,1,1,,,,,,,,,,,,,,,,,,,0,1,,,,,,,,,,,207,Peer-led diabetes education programs in high-risk Mexican Americans improve glycemic control compared with standard approaches: a Project Dulce p,"Philis-Tsimikas A, Fortmann A, Lleva-Ocana L, Walker C, Gallo LC.",Diabetes Care. 2011 Sep;34(9):1926-31. doi: 10.2337/dc10-2081. Epub 2011 Jul 20.,Philis-Tsimikas,2011,5,2,0.396458879,1,Characteristics of included studies in Cochrane review does not report on number randomized; Philis-Tsiminakis reports: total of 207 Mexican-American patients recruited from federally funded community health centers in San Diego County,25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,9.1,2,56,9.7,2.3,74,-0.073720273,0.0178223271,0,0,,post,-0.6,0.1429150579,0,1
21782948,3.01,0,USA,"Funding source: Columbia University Office of Clinical Trials Pilot Award and National Institute of Dental and Craniofacial Research Award DE 00449 (SE). Collagenex Pharmaceutical Inc. provided subantimicrobial doxycycline doses (brand name: Periostat; Gp A) and placebos (Gps B+C), and Columbia University Medical Center Research Pharmacy provided visually indistinguishable antimicrobial doxycyline doses (Gp B). Conflict of interests: ""The authors disclosed no conflicts of interest""",non-commercial,26545069,published data only,2,2,2,1,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,45,Sub-antimicrobial doxycycline for periodontitis reduces hemoglobin A1c in subjects with type 2 diabetes: a pilot study,"Engebretson SP, Hey-Hadavi J.",Pharmacol Res. 2011 Dec;64(6):624-9. doi: 10.1016/j.phrs.2011.06.024. Epub 2011 Jul 19.,Engebretson SP,2011,2,3,0.9716673724,1,From Cochrane:Number randomised: 45;Number evaluated: 34,26545069,,,Treatment of periodontal disease for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2015 Nov 6;2015(11):CD004714. doi: 10.1002/14651858.CD004714.pub3.,Simpson TC,2015,7.9666667,2.1684975,15,7.44,1.9245778,15,0.0506934001,0.0859531675,0,0,,post,0.5266667,0.5604254077,0,1
21782948,3.02,0,USA,"Funding source: Columbia University Office of Clinical Trials Pilot Award and National Institute of Dental and Craniofacial Research Award DE 00449 (SE). Collagenex Pharmaceutical Inc. provided subantimicrobial doxycycline doses (brand name: Periostat; Gp A) and placebos (Gps B+C), and Columbia University Medical Center Research Pharmacy provided visually indistinguishable antimicrobial doxycyline doses (Gp B). Conflict of interests: ""The authors disclosed no conflicts of interest""",non-commercial,26545069,published data only,2,2,2,1,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,45,Sub-antimicrobial doxycycline for periodontitis reduces hemoglobin A1c in subjects with type 2 diabetes: a pilot study,"Engebretson SP, Hey-Hadavi J.",Pharmacol Res. 2011 Dec;64(6):624-9. doi: 10.1016/j.phrs.2011.06.024. Epub 2011 Jul 19.,Engebretson SP,2011,2,3,0.9716673724,1,From Cochrane:Number randomised: 45;Number evaluated: 34,26545069,,,Treatment of periodontal disease for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2015 Nov 6;2015(11):CD004714. doi: 10.1002/14651858.CD004714.pub3.,Simpson TC,2015,7.7033334,2.0322373,30,8.3133333,2.4313038,15,-0.119864645,0.0641421949,0,0,,post,-0.6099999,0.531748826,0,1
21788632,12,0,USA,"Funding: This study was funded through a contract between the University of Maryland Baltimore and WellDoc in addition to contributions by WellDoc, CareFirst Blue Cross/Blue Shield of Maryland, LifeScan, and Sprint. Additional funding was provided by the Maryland Industrial Partnerships program through the University of Maryland, an initiative of the A. James Clark School of Engineering’s Maryland Technology Enterprise Institute.",commercial,23543567,published data only,1,1,0,,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,163,Cluster-randomized trial of a mobile phone personalized behavioral intervention for blood glucose control,"Quinn CC, Shardell MD, Terrin ML, Barr EA, Ballew SH, Gruber-Baldini AL.",Diabetes Care. 2011 Sep;34(9):1934-42. doi: 10.2337/dc11-0366. Epub 2011 Jul 25.,Quinn CC,2011,6,4,0.0042469285,1,"From Cochrane: Follow-up rates: Intervention: 13/15 = 87%. Control: 13/15 = 87%.; unclear why Cochrane reports these numbers - Quinn double checked:""A total of 163 patients were enrolled and""",23543567,,,Computer-based diabetes self-management interventions for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2013 Mar 28;2013(3):CD008776. doi: 10.1002/14651858.CD008776.pub2.,Pal K,2013,7.7,1,21,8.5,1.8,51,-0.473902758,0.0381331637,0,0,,post,-0.8,0.1111484594,0,1
21804283,3,0,China,"Funding source: grants from public research organisations: Zhejiang Science and Technology Projects (2009C33168), Natural Science Foundation of Zhejiang Province (Y2100077), Zhejiang Education Committee Projects (Y201017607), National Natural Science Foundation of China (30872884), and Zhejiang Health Bureau Fund (2009A104)",non-commercial,35420698,published data only,1,1,0,0,0,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,157,"Inflammatory cytokines, adiponectin, insulin resistance and metabolic control after periodontal intervention in patients with type 2 diabetes and","Sun WL, Chen LL, Zhang SZ, Wu YM, Ren YZ, Qin GM.",Intern Med. 2011;50(15):1569-74. doi: 10.2169/internalmedicine.50.5166. Epub 2011 Aug 1.,Sun WL,2011,6,2,0.0003299067,1,From Cochrane:Number randomised: 190; Number evaluated: 157,26545069,35420698,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,8.25,0.72,82,8.56,0.69,75,0.0788595618,0.0132766385,0,0,,post,-0.31,0.0126699512,0,1
21806617,3,0,Brazil,"Funding source: Sao Paulo State Research Foundation (# 2008/09687-0; # 2008/04280-0). ""Conflict of interests: Not reported""",non-commercial,26545069,published and unpublished data,2,1,0,0,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,34,Partial- and full-mouth scaling and root planing in type 2 diabetic subjects: a 12-mo follow-up of clinical parameters and levels of cytokines an,"Santos VR, Ribeiro FV, Lima JA, Miranda TS, Feres M, Bastos MF, Duarte PM.",J Periodontal Res. 2012 Feb;47(1):45-54. doi: 10.1111/j.1600-0765.2011.01403.x. Epub 2011 Aug 2.,Santos VR,2012,7,2,0.4514973009,1,From Cochrane:Number randomised: 34; Number evaluated: 34,26545069,,,Treatment of periodontal disease for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2015 Nov 6;2015(11):CD004714. doi: 10.1002/14651858.CD004714.pub3.,Simpson TC,2015,10.1,2.5,17,9.3,1.9,17,0.1913414228,0.0724750193,0,0,,post,0.8,0.58,0,1
21806617,6,0,Brazil,"Funding source: Sao Paulo State Research Foundation (# 2008/09687-0; # 2008/04280-0). ""Conflict of interests: Not reported""",non-commercial,26545069,published and unpublished data,2,1,0,0,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,34,Partial- and full-mouth scaling and root planing in type 2 diabetic subjects: a 12-mo follow-up of clinical parameters and levels of cytokines an,"Santos VR, Ribeiro FV, Lima JA, Miranda TS, Feres M, Bastos MF, Duarte PM.",J Periodontal Res. 2012 Feb;47(1):45-54. doi: 10.1111/j.1600-0765.2011.01403.x. Epub 2011 Aug 2.,Santos VR,2012,7,2,0.4514973009,1,From Cochrane:Number randomised: 34; Number evaluated: 34,26545069,,,Treatment of periodontal disease for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2015 Nov 6;2015(11):CD004714. doi: 10.1002/14651858.CD004714.pub3.,Simpson TC,2015,9.7,2,17,10.2,2.9,17,-0.32017461,0.0736763747,0,0,,post,-0.5,0.73,0,1
21859323,3,0,China,"Funding source: 2 grants – both government sponsored: 1) Key Projects in the National Science and Technology Pillar Program (11th 5-year plan periods), Beijing, China and 2) Technology Planning  Project of Guangdong Province, China (grant 2010B031600117)",non-commercial,35420698,published data only,2,1,0,0,1,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,126,"Effects of non-surgical periodontal treatment on clinical response, serum inflammatory parameters, and metabolic control in patients with type 2","Chen L, Luo G, Xuan D, Wei B, Liu F, Li J, Zhang J.",J Periodontol. 2012 Apr;83(4):435-43. doi: 10.1902/jop.2011.110327. Epub 2011 Aug 22.,Chen L,2012,7,3,0.7792369202,1,"From Cochrane:Number randomised: 134; Number evaluated: 126 (loss to follow-up Gp A 3, Gp B 2, Gp C 3)",26545069,35420698,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,7.36576,1.50763,85,7.59,1.54,41,0.0024538118,0.0203333349,0,0,,post,-0.22424,0.0845844697,0,1
21859323,6,0,China,"Funding source: 2 grants – both government sponsored: 1) Key Projects in the National Science and Technology Pillar Program (11th 5-year plan periods), Beijing, China and 2) Technology Planning  Project of Guangdong Province, China (grant 2010B031600117)",non-commercial,35420698,published data only,2,1,0,0,1,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,126,"Effects of non-surgical periodontal treatment on clinical response, serum inflammatory parameters, and metabolic control in patients with type 2","Chen L, Luo G, Xuan D, Wei B, Liu F, Li J, Zhang J.",J Periodontol. 2012 Apr;83(4):435-43. doi: 10.1902/jop.2011.110327. Epub 2011 Aug 22.,Chen L,2012,7,3,0.7792369202,1,"From Cochrane:Number randomised: 134; Number evaluated: 126 (loss to follow-up Gp A 3, Gp B 2, Gp C 3)",26545069,35420698,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,6.97871,1.23206,85,7.38,1.57,41,-0.192657548,0.0203069366,0,0,,post,-0.40129,0.0779780045,0,1
21900148,2,0,Australia,"Cochrane does not appear to report on funding sources or conflict of interest - Acknowledgments This study was funded by Australian National Health and Medical Research Council Project grant ID632889. J.C.B. M. is a coauthor of The New Glucose Revolution book series, the director of a not for- profit GI-based food endorsement program in Australia, and manages the University of Sydney GI testing service. The authors thank Roche Diagnostics Australia for donation of glucose meters. No other potential conflicts ofinterest relevant to this article were reported.",both,28236296,published and unpublished data,2,2,2,0,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,92,A randomized controlled trial investigating the effects of a low-glycemic index diet on pregnancy outcomes in gestational diabetes mellitus,"Louie JC, Markovic TP, Perera N, Foote D, Petocz P, Ross GP, Brand-Miller JC.",Diabetes Care. 2011 Nov;34(11):2341-6. doi: 10.2337/dc11-0985. Epub 2011 Sep 6.,Louie JC,2011,7,2,0.7520617452,1,From Cochrane: 99 women.,28236296,,,Different types of dietary advice for women with gestational diabetes mellitus,Cochrane Database Syst Rev. 2017 Feb 25;2(2):CD009275. doi: 10.1002/14651858.CD009275.pub3.,Han S,2017,5.48,0.38,43,5.41,0.32,41,0.1583857653,0.0251978771,0,0,,post,0,0.01085173,0,1
22127826,3.01,0,USA,Funding: Agency for Healthcare Research and Quality,non-commercial,25188210,published and unpublished data,2,1,0,0,1,0,,,,,,,,,,,,,,,,,,,2,2,,,,,,,,,,,129,A diabetes education multimedia program in the waiting room setting,"Khan MA, Shah S, Grudzien A, Onyejekwe N, Banskota P, Karim S, Jin J, Kim Y, Gerber BS.",Diabetes Ther. 2011 Sep;2(3):178-88. doi: 10.1007/s13300-011-0007-y. Epub 2011 Aug 22.,Khan MA,2011,9,2,0.4231261684,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Kahn reports: In this randomized, controlled trial, 129 participants either viewed a computer multimedia education program (intervention group) or read an educational brochure (control group) while in the waiting room",25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,7.7,1.6,29,9,2.3,22,-0.21211378,0.0479011807,0,0,,post,-1.3,0.3287304075,0,1
22127826,3.02,0,USA,Funding: Agency for Healthcare Research and Quality,non-commercial,25188210,published and unpublished data,2,1,0,0,1,0,,,,,,,,,,,,,,,,,,,2,2,,,,,,,,,,,129,A diabetes education multimedia program in the waiting room setting,"Khan MA, Shah S, Grudzien A, Onyejekwe N, Banskota P, Karim S, Jin J, Kim Y, Gerber BS.",Diabetes Ther. 2011 Sep;2(3):178-88. doi: 10.1007/s13300-011-0007-y. Epub 2011 Aug 22.,Khan MA,2011,9,2,0.4231261684,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Kahn reports: In this randomized, controlled trial, 129 participants either viewed a computer multimedia education program (intervention group) or read an educational brochure (control group) while in the waiting room",25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,8.1,2.7,12,7.7,2.1,11,0.1948765279,0.1206735975,0,0,,post,0.4,1.0084090909,0,1
22369555,3,0,Iran,Funding source: grant from Mashhad University of Medical Sciences,non-commercial,35420698,published data only,2,1,0,0,1,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,40,Non-surgical periodontal therapy affects metabolic control in diabetics: a randomized controlled clinical trial,"Moeintaghavi A, Arab HR, Bozorgnia Y, Kianoush K, Alizadeh M.",Aust Dent J. 2012 Mar;57(1):31-7. doi: 10.1111/j.1834-7819.2011.01652.x.,Moeintaghavi A,2012,5,2,0.5270908072,1,From Cochrane:Number randomised: 40; Number evaluated: 40,26545069,35420698,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,7.41,1.18,22,8.97,1.82,18,-0.247301851,0.0595282299,0,0,,post,-1.56,0.2473131313,1,1
22420871,3,0,India,"Funding source: Not reported. States Simvastatin (SMV) sample was provided by Aurobindo Pharma, Hyderabad, Andhra Pradesh, India (www.aurobindo.com/). Conflict of interests: Authors declare no conflict of interests",not reported,26545069,published data only,2,2,2,1,,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,35,Efficacy of subgingivally delivered simvastatin in the treatment of patients with type 2 diabetes and chronic periodontitis: a randomized double-,"Pradeep AR, Rao NS, Bajaj P, Kumari M.",J Periodontol. 2013 Jan;84(1):24-31. doi: 10.1902/jop.2012.110721. Epub 2012 Mar 16.,Pradeep AR,2013,4,2,0.6031544902,1,From Cochrane:Number randomised: 38 (Gp A n = 19 (36 sites); Gp B n = 19 (34 sites));mNumber evaluated: 35 (Gp A n = 17 (29 sites); Gp B n = 18 (29 sites)),26545069,,,Treatment of periodontal disease for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2015 Nov 6;2015(11):CD004714. doi: 10.1002/14651858.CD004714.pub3.,Simpson TC,2015,6.64,0.12,17,6.68,0.12,18,0.0078436174,0.0643821343,0,0,,post,-0.04,0.0016470588,0,1
22420871,6,0,India,"Funding source: Not reported. States Simvastatin (SMV) sample was provided by Aurobindo Pharma, Hyderabad, Andhra Pradesh, India (www.aurobindo.com/). Conflict of interests: Authors declare no conflict of interests",not reported,26545069,published data only,2,2,2,1,,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,35,Efficacy of subgingivally delivered simvastatin in the treatment of patients with type 2 diabetes and chronic periodontitis: a randomized double-,"Pradeep AR, Rao NS, Bajaj P, Kumari M.",J Periodontol. 2013 Jan;84(1):24-31. doi: 10.1902/jop.2012.110721. Epub 2012 Mar 16.,Pradeep AR,2013,4,2,0.6031544902,1,From Cochrane:Number randomised: 38 (Gp A n = 19 (36 sites); Gp B n = 19 (34 sites));mNumber evaluated: 35 (Gp A n = 17 (29 sites); Gp B n = 18 (29 sites)),26545069,,,Treatment of periodontal disease for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2015 Nov 6;2015(11):CD004714. doi: 10.1002/14651858.CD004714.pub3.,Simpson TC,2015,6.65,0.12,17,6.68,0.13,18,-0.073702396,0.0643851891,0,0,,post,-0.03,0.0017859477,0,1
22443183,6,0,South Korea,Funding source: non commercial; National Research Foundation,non-commercial,27640062,published data only,1,1,,0,,0,0,,0,,0,0,,,,,,,,,,,,,,2,,2,2,,,,,,,,124,Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study,"Hong ES, Khang AR, Yoon JW, Kang SM, Choi SH, Park KS, Jang HC, Shin H, Walford GA, Lim S.",Diabetes Obes Metab. 2012 Sep;14(9):795-802. doi: 10.1111/j.1463-1326.2012.01600.x. Epub 2012 Apr 18.,Hong ES,2012,10,2,0.8678152268,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Hong reports: Subjects were randomly assigned to either the sitagliptin adding (100 mg daily, n = 70) or an insulin-increasing arm (?10% at week 12 and ?10% at week 24, n = 70) while continuing other medications.",27640062,,,Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control,Cochrane Database Syst Rev. 2016 Sep 18;9(9):CD006992. doi: 10.1002/14651858.CD006992.pub2.,Vos RC,2016,8.5,1.1,61,9,1.3,63,-0.109598539,0.0172726291,0,0,,dif,-0.41,0.0678932084,0,1
22505499,6,0,Brazil,Funding: no details,not reported,28120427,published data only,2,2,0,1,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,200,Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus,"Silva JC, Fachin DR, Coral ML, Bertini AM.",J Perinat Med. 2012 Jan 10;40(3):225-8. doi: 10.1515/jpm-2011-0175.,Silva JC,2012,4,2,0.9876949953,1,"From Cochrane: ""200 women. Mean age in metformin group 32.6 ± 5.6 years and for glyburide group 31.3 ± 5.4 years""",28120427,,,Oral anti-diabetic pharmacological therapies for the treatment of women with gestational diabetes,Cochrane Database Syst Rev. 2017 Jan 25;1(1):CD011967. doi: 10.1002/14651858.CD011967.pub2.,Brown J,2017,5.51,0.78,104,5.62,0.85,96,-0.06656138,0.0106510759,0,0,,post,-0.11,0.0133760417,0,1
22621750,3,0,Poland,"Funding source: Medical University of Silesia, Katowice, Poland. Conflict of interests: Not reported",non-commercial,26545069,published and unpublished data,2,2,2,2,,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,34,Efficacy of short-term adjunctive subantimicrobial dose doxycycline in diabetic patients--randomized study,"Gilowski L, Kondzielnik P, Wiench R, Pocica I, Strojek K, Krzemiski TF.",Oral Dis. 2012 Nov;18(8):763-70. doi: 10.1111/j.1601-0825.2012.01943.x. Epub 2012 May 23.,Gilowski L,2012,6,2,0.5746869879,1,From Cochrane:Number randomised: 34;Number evaluated: Assumed 34,26545069,,,Treatment of periodontal disease for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2015 Nov 6;2015(11):CD004714. doi: 10.1002/14651858.CD004714.pub3.,Simpson TC,2015,6.9,1.3,17,6.8,1.7,17,-0.282068573,0.0721797026,0,0,,post,0.1,0.2694117647,0,1
23148885,1,0,Iran,"Cochrane does not appear to report on funding sources or conflict of interest-Asemi reports: The present study was supported by a grant (no. 9013) from the Vice-chancellor for Research, KUMS, Kashan, Iran.",non-commercial,28236296,published data only,2,1,2,2,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,34,Favourable effects of the Dietary Approaches to Stop Hypertension diet on glucose tolerance and lipid profiles in gestational diabetes: a randomi,"Asemi Z, Tabassi Z, Samimi M, Fahiminejad T, Esmaillzadeh A.",Br J Nutr. 2013 Jun;109(11):2024-30. doi: 10.1017/S0007114512004242. Epub 2012 Nov 13.,Asemi Z,2013,5,2,0.9120342377,1,"From Cochrane:""40 women.""(n = 20 randomised; 17 analysed) for each group",28236296,,,Different types of dietary advice for women with gestational diabetes mellitus,Cochrane Database Syst Rev. 2017 Feb 25;2(2):CD009275. doi: 10.1002/14651858.CD009275.pub3.,Han S,2017,4.2,0.7,17,4.45,0.8,17,-0.075578252,0.0699445056,0,0,,post,-0.25,0.0664705882,0,1
23305133,3,0,Brazil,"Funding source: Sao Paulo Research Foundation (#2008/09687-0 2008/11419-4). ""Conflict of interests: Authors declare no conflict of interests exists""",non-commercial,26545069,published data only,2,2,2,2,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,38,Full-mouth disinfection as a therapeutic protocol for type-2 diabetic subjects with chronic periodontitis: twelve-month clinical outcomes: a rand,"Santos VR, Lima JA, Miranda TS, Gonçalves TE, Figueiredo LC, Faveri M, Duarte PM.",J Clin Periodontol. 2013 Feb;40(2):155-62. doi: 10.1111/jcpe.12040.,Santos VR,2013,7,2,0.8012844237,1,"From Cochrane:Number randomised: 38; Number evaluated: 3 months = 37, 6 months = 37, 12 months = 33",26545069,,,Treatment of periodontal disease for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2015 Nov 6;2015(11):CD004714. doi: 10.1002/14651858.CD004714.pub3.,Simpson TC,2015,9.3,2.75,19,9.7,2.9,18,-0.012450476,0.0700534615,0,0,,post,-0.4,0.865248538,0,1
23305133,6,0,Brazil,"Funding source: Sao Paulo Research Foundation (#2008/09687-0 2008/11419-4). ""Conflict of interests: Authors declare no conflict of interests exists""",non-commercial,26545069,published data only,2,2,2,2,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,38,Full-mouth disinfection as a therapeutic protocol for type-2 diabetic subjects with chronic periodontitis: twelve-month clinical outcomes: a rand,"Santos VR, Lima JA, Miranda TS, Gonçalves TE, Figueiredo LC, Faveri M, Duarte PM.",J Clin Periodontol. 2013 Feb;40(2):155-62. doi: 10.1111/jcpe.12040.,Santos VR,2013,7,2,0.8012844237,1,"From Cochrane:Number randomised: 38; Number evaluated: 3 months = 37, 6 months = 37, 12 months = 33",26545069,,,Treatment of periodontal disease for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2015 Nov 6;2015(11):CD004714. doi: 10.1002/14651858.CD004714.pub3.,Simpson TC,2015,9.9,2.4,19,9.6,3.2,18,-0.318547864,0.0697526637,0,0,,post,0.3,0.8720467836,0,1
23349548,7,0,Denmark,"Funding: The real-time CGM monitors and links were supplied, and glucose sensors were offered at a reduced price by Medtronic.",both,24782359,published data only,2,2,2,2,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,154,The effect of real-time continuous glucose monitoring in pregnant women with diabetes: a randomized controlled trial,"Secher AL, Ringholm L, Andersen HU, Damm P, Mathiesen ER.",Diabetes Care. 2013 Jul;36(7):1877-83. doi: 10.2337/dc12-2360. Epub 2013 Jan 24.,Secher AL,2013,5,2,,1,From  Cochrane: Number randomised: 154.,24782359,,,Techniques of monitoring blood glucose during pregnancy for women with pre-existing diabetes,Cochrane Database Syst Rev. 2014 Apr 30;(4):CD009613. doi: 10.1002/14651858.CD009613.pub2.,Moy FM,2014,6,0.5417,76,6.1,0.7756,73,,,0,,,post,-0.1,0.0121015224,0,0
23450056,12,0,USA,Funding: commercial funding (GSK),commercial,32501595,published data only,2,2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,225,Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus,"Bilezikian JP, Josse RG, Eastell R, Lewiecki EM, Miller CG, Wooddell M, Northcutt AR, Kravitz BG, Paul G, Cobitz AR, Nino AJ, Fitzpatrick LA.",J Clin Endocrinol Metab. 2013 Apr;98(4):1519-28. doi: 10.1210/jc.2012-4018. Epub 2013 Feb 28.,Bilezikian JP,2013,12,2,0.0051289121,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Bilezikijan reports: A total of 226 patients were randomized, with 225 receiving at least 1 dose of study medication (Figure 1). Patients entered either the RSG arm (n114) or theMET arm (n  112).",32501595,,,Metformin monotherapy for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Jun 5;6(6):CD012906. doi: 10.1002/14651858.CD012906.pub2.,Gnesin F,2020,6.26,0.811,85,6.35,0.741,77,0.1039051849,0.0130630952,0,0,,post,-0.09,0.0148688162,0,1
23474741,3,0,Brazil,Funding source: Financial support from the State of Sao Paulo Research Foundation (FAPESP protocol number 06/04600-9). Conflict of interests: Not reported,non-commercial,26545069,published data only,2,1,1,1,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,30,"Additional effects of aPDT on nonsurgical periodontal treatment with doxycycline in type II diabetes: a randomized, controlled clinical trial","Macedo Gde O, Novaes AB Jr, Souza SL, Taba M Jr, Palioto DB, Grisi MF.",Lasers Med Sci. 2014 May;29(3):881-6. doi: 10.1007/s10103-013-1285-6. Epub 2013 Mar 10.,Macedo Gde O,2014,6,2,0.7455602735,1,From Cochrane:Number randomised: 30; Number evaluated: 30,26545069,,,Treatment of periodontal disease for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2015 Nov 6;2015(11):CD004714. doi: 10.1002/14651858.CD004714.pub3.,Simpson TC,2015,7.6,0.6,15,7.8,1.35,15,-0.784163965,0.0789452465,0,1,4,post,-0.2,0.1455,0,1
23816038,12,0,USA,"Funding: ""supported by grants from the Robert Wood Johnson Foundation Disparities Research for Change program and the Kate B. Reynolds Foundation”",non-commercial,25188210,published data only,2,2,0,0,1,0,,,,,,,,,,,,,,,,,,,2,2,,,,,,,,,,,359,"The Cholesterol, Hypertension, And Glucose Education (CHANGE) study: results from a randomized controlled trial in African Americans with diabete","Crowley MJ, Powers BJ, Olsen MK, Grubber JM, Koropchak C, Rose CM, Gentry P, Bowlby L, Trujillo G, Maciejewski ML, Bosworth HB.",Am Heart J. 2013 Jul;166(1):179-86. doi: 10.1016/j.ahj.2013.04.004. Epub 2013 May 17.,Crowley MJ,2013,11,2,0.8584472929,1,Characteristics of included studies in Cochrane review does not report on number randomized; Crowley reports: We randomized 359 African Americans with type 2 diabetes to receive usual care or a nurse telephone intervention.,25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,7.8,1.34,180,7.9,1.31,172,,,0,,,post,-0.1,0.0199528811,0,0
23863810,29,0,USA,"Funding: commercial, funded by Takeda Pharmaceuticals. Non-commercial by the University of Tennessee Health Science Center, the University of Southern California Keck School of Medicine, the Veterans Affairs institutions in Pho",both,33210751,published data only,2,2,2,,,,2,2,2,2,2,,2,2,,,,2,2,2,2,2,,2,1,,,,0,0,0,0,0,,0,,602,Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates,"Defronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Gastaldelli A, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Reaven PD; ACT NOW Study.",Diabetes. 2013 Nov;62(11):3920-6. doi: 10.2337/db13-0265. Epub 2013 Jul 17.,Defronzo RA,2013,15,2,0.6564817391,1,Characteristics of included studies in Cochrane review does not report on number randomized; ACT NOW 404 patients in analysis 2.29 in Cochrane; 602 patients from Defronzo supplement data Supplementary Table 1.  Baseline characteristics of the 602 IGT subjects who were randomized in ACT NOW,33210751,,,Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Nov 19;11(11):CD013516. doi: 10.1002/14651858.CD013516.pub2.,Ipsen EØ,2020,5.6,0.44,213,5.75,0.6,228,-0.283556437,0.0046587034,1,0,,dif,-0.21,0.0014563071,0,1
23947316,12,0,USA,Funding: National Institute for Diabetes and Digestive and Kidney Diseases,non-commercial,25188210,published data only,2,1,0,0,2,0,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,144,Mexican American trial of community health workers: a randomized controlled trial of a community health worker intervention for Mexican Americans,"Rothschild SK, Martin MA, Swider SM, Tumialán Lynas CM, Janssen I, Avery EF, Powell LH.",Am J Public Health. 2014 Aug;104(8):1540-8. doi: 10.2105/AJPH.2013.301439. Epub 2013 Aug 15.,Rothschild SK,2014,7,2,0.9715196535,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Rothchildreports: We recruited 144 Mexican Americans with type 2 diabetes between January 2006 and September 2008 into the single-blinded, randomized controlled Mexican American Trial of Community Health Workers (MATCH) and followed them for 2 years.",25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,7.87,1.24,73,8.42,1.23,71,,,0,,,post,-0.55,0.0423714644,0,0
23947316,24,0,USA,Funding: National Institute for Diabetes and Digestive and Kidney Diseases,non-commercial,25188210,published data only,2,1,0,0,2,0,,,,,,,,,,,,,,,,,,,1,1,,,,,,,,,,,144,Mexican American trial of community health workers: a randomized controlled trial of a community health worker intervention for Mexican Americans,"Rothschild SK, Martin MA, Swider SM, Tumialán Lynas CM, Janssen I, Avery EF, Powell LH.",Am J Public Health. 2014 Aug;104(8):1540-8. doi: 10.2105/AJPH.2013.301439. Epub 2013 Aug 15.,Rothschild SK,2014,7,2,0.9715196535,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Rothchildreports: We recruited 144 Mexican Americans with type 2 diabetes between January 2006 and September 2008 into the single-blinded, randomized controlled Mexican American Trial of Community Health Workers (MATCH) and followed them for 2 years.",25188210,,,Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.,Attridge M,2014,7.64,1.22,73,8.33,1.23,71,,,0,,,post,-0.69,0.0416974918,0,0
23949898,12,0,Multi-countr,Funding source: Bristol-Myers-Squibb and AstraZeneca,commercial,27640062,published data only,2,2,,2,,2,1,,1,,,,,,,,,,,,,,,,,0,,0,2,,,,,,,,455,Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy,"Barnett AH, Charbonnel B, Li J, Donovan M, Fleming D, Iqbal N.",Clin Drug Investig. 2013 Oct;33(10):707-17. doi: 10.1007/s40261-013-0107-8.,Barnett AH,2013,6,4,0.8785580629,1,Characteristics of included studies in Cochrane review does not report on number randomized; Barnett reports: Patients were stratified by metformin use and randomly assigned 2:1 to oral saxagliptin 5 mg (n = 304) or placebo (n = 151) once daily.,27640062,,,Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control,Cochrane Database Syst Rev. 2016 Sep 18;9(9):CD006992. doi: 10.1002/14651858.CD006992.pub2.,Vos RC,2016,,,,,,,,,0,,,dif,-0.37,0.0185639588,0,0
24040570,3.01,0,India,Funding source: none mentioned,not reported,35420698,published data only,1,1,0,0,2,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,60,Efficacy of nonsurgical periodontal therapy on glycaemic control in type II diabetic patients: a randomized controlled clinical trial,"Telgi RL, Tandon V, Tangade PS, Tirth A, Kumar S, Yadav V.",J Periodontal Implant Sci. 2013 Aug;43(4):177-82. doi: 10.5051/jpis.2013.43.4.177. Epub 2013 Aug 31.,Telgi RL,2013,6,3,0.0033119136,1,From Cochrane:Number randomised: 60 (20 per gp); Number evaluated: 60,35420698,,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,7.1,0.64,20,7.75,0.58,20,0.1859750186,0.056088094,0,0,,post,-0.65,0.0373,0,1
24040570,3.02,0,India,Funding source: none mentioned,not reported,35420698,published data only,1,1,0,0,2,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,60,Efficacy of nonsurgical periodontal therapy on glycaemic control in type II diabetic patients: a randomized controlled clinical trial,"Telgi RL, Tandon V, Tangade PS, Tirth A, Kumar S, Yadav V.",J Periodontal Implant Sci. 2013 Aug;43(4):177-82. doi: 10.5051/jpis.2013.43.4.177. Epub 2013 Aug 31.,Telgi RL,2013,6,3,0.0033119136,1,From Cochrane:Number randomised: 60 (20 per gp); Number evaluated: 60,35420698,,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,7.1,0.64,20,7.31,0.59,20,0.1104538529,0.0561337824,0,0,,post,-0.21,0.037885,0,1
24057294,12,0,USA,Funding: commercial funding: Takeda Global Research and Development Center,commercial,33210751,published data only,2,2,2,,,,2,2,2,2,2,,,2,,,,2,2,2,2,2,,,1,,,,0,1,0,1,1,,,,156,"Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind,","Bone HG, Lindsay R, McClung MR, Perez AT, Raanan MG, Spanheimer RG.",J Clin Endocrinol Metab. 2013 Dec;98(12):4691-701. doi: 10.1210/jc.2012-4096. Epub 2013 Sep 20.,Bone HG,2013,6,2,0.8400445218,1,Characteristics of included studies in Cochrane review does not report on number randomized; Bone reports: Postmenopausal women (n156) with impaired fasting glucose or impaired glucose tolerance participated in the study,33210751,,,Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Nov 19;11(11):CD013516. doi: 10.1002/14651858.CD013516.pub2.,Ipsen EØ,2020,,,,,,,,,1,,,dif,-0.09,0.0018001537,0,0
24346989,3,0,USA,Funding source: 2 NIH/NIDCR grants: U01 DE018902 (awarded to S Engebretson); U01 DE018886 (awarded to L Hyman),non-commercial,35420698,published data only,2,2,0,0,2,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,514,The effect of nonsurgical periodontal therapy on hemoglobin A1c levels in persons with type 2 diabetes and chronic periodontitis: a randomized cl,"Engebretson SP, Hyman LG, Michalowicz BS, Schoenfeld ER, Gelato MC, Hou W, Seaquist ER, Reddy MS, Lewis CE, Oates TW, Tripathy D, Katancik JA, Orlander PR, Paquette DW, Hanson NQ, Tsai MY.",JAMA. 2013 Dec 18;310(23):2523-32. doi: 10.1001/jama.2013.282431.,Engebretson SP,2013,16,2,0.2791163725,1,"From Cochrane:Number randomised: 514 (Gp A 257, Gp B 257)Number evaluated:ITT analysis (HbA1c outcome only):Baseline, 3 and 6 mths: Gp A 257, Gp B 257",26545069,35420698,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,7.9785992,0.9958749,257,7.8801556,1.0467748,257,-0.062258638,0.004050794,0,0,,post,0.0984436,0.0081225848,0,1
24346989,6,0,USA,Funding source: 2 NIH/NIDCR grants: U01 DE018902 (awarded to S Engebretson); U01 DE018886 (awarded to L Hyman),non-commercial,35420698,published data only,2,2,0,0,2,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,514,The effect of nonsurgical periodontal therapy on hemoglobin A1c levels in persons with type 2 diabetes and chronic periodontitis: a randomized cl,"Engebretson SP, Hyman LG, Michalowicz BS, Schoenfeld ER, Gelato MC, Hou W, Seaquist ER, Reddy MS, Lewis CE, Oates TW, Tripathy D, Katancik JA, Orlander PR, Paquette DW, Hanson NQ, Tsai MY.",JAMA. 2013 Dec 18;310(23):2523-32. doi: 10.1001/jama.2013.282431.,Engebretson SP,2013,16,2,0.2791163725,1,"From Cochrane:Number randomised: 514 (Gp A 257, Gp B 257)Number evaluated:ITT analysis (HbA1c outcome only):Baseline, 3 and 6 mths: Gp A 257, Gp B 257",26545069,35420698,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,8.0299611,1.2158448,257,7.9105058,1.1613261,257,0.0308859704,0.004094585,0,0,,post,0.1194553,0.0109998322,0,1
24629718,2,0,Thailand,Funding source: no details.Declarations of interest: no details.,not reported,28639706,published data only,1,1,1,1,,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,170,The effects of mindfulness eating and yoga exercise on blood sugar levels of pregnant women with gestational diabetes mellitus,"Youngwanichsetha S, Phumdoung S, Ingkathawornwong T.",Appl Nurs Res. 2014 Nov;27(4):227-30. doi: 10.1016/j.apnr.2014.02.002. Epub 2014 Feb 10.,Youngwanichsetha,2014,3,2,0.556336857,1,from Cochrane:180 women.,28639706,,,Exercise for pregnant women with gestational diabetes for improving maternal and fetal outcomes,Cochrane Database Syst Rev. 2017 Jun 22;6(6):CD012202. doi: 10.1002/14651858.CD012202.pub2.,Brown J,2017,5.23,1.4,85,5.68,1.4,85,,,0,,,post,-0.45,0.0461176471,0,0
24646172,3.01,0,Italy,Funding source: Regione Piemonte 2009.Declarations of interest: the authors report no conflicts of interest.,non-commercial,28639706,published data only,2,1,1,2,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,200,Simple lifestyle recommendations and the outcomes of gestational diabetes. A 2 × 2 factorial randomized trial,"Bo S, Rosato R, Ciccone G, Canil S, Gambino R, Poala CB, Leone F, Valla A, Grassi G, Ghigo E, Cassader M, Menato G.",Diabetes Obes Metab. 2014 Oct;16(10):1032-5. doi: 10.1111/dom.12289. Epub 2014 Apr 7.,Bo S,2014,12,4,4.4655249E-8,1,from publication: maternal/neonatal outcomes in 200 GDM patients.- From Cochrane: 200 women randomised.,28236296,28639706,,Exercise for pregnant women with gestational diabetes for improving maternal and fetal outcomes,Cochrane Database Syst Rev. 2017 Jun 22;6(6):CD012202. doi: 10.1002/14651858.CD012202.pub2.,Brown J,2017,4.6,0.5,51,5,0.4,50,0.3062692478,0.0209720249,0,0,,post,-0.4,0.0081019608,0,1
24646172,3.02,0,Italy,Funding source: Regione Piemonte 2009.Declarations of interest: the authors report no conflicts of interest.,non-commercial,28639706,published data only,2,1,1,2,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,200,Simple lifestyle recommendations and the outcomes of gestational diabetes. A 2 × 2 factorial randomized trial,"Bo S, Rosato R, Ciccone G, Canil S, Gambino R, Poala CB, Leone F, Valla A, Grassi G, Ghigo E, Cassader M, Menato G.",Diabetes Obes Metab. 2014 Oct;16(10):1032-5. doi: 10.1111/dom.12289. Epub 2014 Apr 7.,Bo S,2014,12,4,4.4655249E-8,1,from publication: maternal/neonatal outcomes in 200 GDM patients.- From Cochrane: 200 women randomised.,28236296,28639706,,Exercise for pregnant women with gestational diabetes for improving maternal and fetal outcomes,Cochrane Database Syst Rev. 2017 Jun 22;6(6):CD012202. doi: 10.1002/14651858.CD012202.pub2.,Brown J,2017,4.6,0.5,51,4.9,0.5,49,0.0627526524,0.0212778881,0,0,,post,-0.3,0.0100040016,0,1
24710641,12.01,0,Turkey,Funding: non-commercial funding (University),non-commercial,32501595,published data only,1,1,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,,,,,0,0,0,0,0,0,0,0,0,,,,57,"Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients wit","Erem C, Ozbas HM, Nuhoglu I, Deger O, Civan N, Ersoz HO.",Exp Clin Endocrinol Diabetes. 2014 May;122(5):295-302. doi: 10.1055/s-0034-1370989. Epub 2014 Apr 7.,Erem C,2014,6,3,0.8389422116,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Erem reports: A total of 57 patients were randomized into gliclazide-MR, metformin and pioglitazone groups",32501595,,,Metformin monotherapy for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Jun 5;6(6):CD012906. doi: 10.1002/14651858.CD012906.pub2.,Gnesin F,2020,6.4,0.7,19,6.98,0.5,19,0.4230433849,0.0595419053,0,0,,post,-0.58,0.0389473684,0,1
24710641,12.02,0,Turkey,Funding: non-commercial funding (University),non-commercial,32501595,published data only,1,1,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,,,,,0,0,0,0,0,0,0,0,0,,,,57,"Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients wit","Erem C, Ozbas HM, Nuhoglu I, Deger O, Civan N, Ersoz HO.",Exp Clin Endocrinol Diabetes. 2014 May;122(5):295-302. doi: 10.1055/s-0034-1370989. Epub 2014 Apr 7.,Erem C,2014,6,3,0.8389422116,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Erem reports: A total of 57 patients were randomized into gliclazide-MR, metformin and pioglitazone groups",32501595,,,Metformin monotherapy for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Jun 5;6(6):CD012906. doi: 10.1002/14651858.CD012906.pub2.,Gnesin F,2020,6.4,0.7,19,6.46,0.56,19,0.2323578208,0.0596673875,0,0,,post,-0.06,0.0422947368,0,1
24797222,4,0,USA,"Funding source: ""...funded by National Institutes of Health Clinical and Translational Award ULI RR024148 and KL2 RR024149 from the National Center For Research Resources""",non-commercial,35420698,published data only,2,2,0,0,1,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,126,The effect of periodontal therapy on glycaemic control in a Hispanic population with type 2 diabetes: a randomized controlled trial,"Gay IC, Tran DT, Cavender AC, Weltman R, Chang J, Luckenbach E, Tribble GD.",J Clin Periodontol. 2014 Jul;41(7):673-80. doi: 10.1111/jcpe.12268. Epub 2014 Jun 1.,Gay IC,2014,7,2,0.1382842262,1,"From Cochrane:Number randomised: 154 (Gp A 77, Gp B 77) Number evaluated: 126 (Gp A 66, Gp B 60)",26545069,35420698,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,8.4,1.9,66,8.1,1.8,60,0.0169412392,0.0180277323,0,0,,post,0.3,0.1086969697,0,1
24842985,6,0,Multi-countr,Funding: commercial funding (Eli Lilly and Company),commercial,32501595,published data only,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,,,,,0,0,0,0,0,0,0,0,0,,,,807,Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3),"Umpierrez G, Tofé Povedano S, Pérez Manghi F, Shurzinske L, Pechtner V.",Diabetes Care. 2014 Aug;37(8):2168-76. doi: 10.2337/dc13-2759. Epub 2014 May 19.,Umpierrez G,2014,5,3,0.1710033114,1,Characteristics of included studies in Cochrane review does not report on number randomized; Patients (N = 807) had HbA1c ‡6.5% (‡48 mmol/mol) and £9.5% (£80 mmol/mol) with diet and exercise alone or low-dose oral antihyperglycemic medication (OAM) monotherapy; OAMs were discontinued at beginning of lead-in period.,32501595,,,Metformin monotherapy for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Jun 5;6(6):CD012906. doi: 10.1002/14651858.CD012906.pub2.,Gnesin F,2020,,,,,,,,,0,,,dif,0.1149,0.0079244715,0,0
24930639,3,0,Brazil,"Funding source: São Paulo State Research Foundation (São Paulo, São Paulo, Brazil, # 2011/14872-4;2013/01072-5). Conflicts of interest: Authors declare no conflict of interest. All participants received Colgate Total toothpaste (attributed to Colgate Palmolive Co., São Paulo, SP, Brazil) for use throughout trial, but it isnot clear if products were donated by the company",non-commercial,26545069,published and unpublished data,2,2,2,2,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,56,Metronidazole and amoxicillin as adjuncts to scaling and root planing for the treatment of type 2 diabetic subjects with periodontitis: 1-year ou,"Miranda TS, Feres M, Perez-Chaparro PJ, Faveri M, Figueiredo LC, Tamashiro NS, Bastos MF, Duarte PM.",J Clin Periodontol. 2014 Sep;41(9):890-9. doi: 10.1111/jcpe.12282. Epub 2014 Jul 17.,Miranda TS,2014,8,2,0.3199871027,1,From Cochrane:Number randomised: 58 (Gp A: n = 29; Gp B: n = 29) Number evaluated: 56 (Gp A: n = 29; Gp B: n= 27 - 2 did not attend baseline visit),26545069,,,Treatment of periodontal disease for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2015 Nov 6;2015(11):CD004714. doi: 10.1002/14651858.CD004714.pub3.,Simpson TC,2015,8.6,2.01,29,8.94,1.71,27,0.1987768146,0.0417066854,0,0,,post,-0.34,0.2476137931,0,1
24930639,6,0,Brazil,"Funding source: São Paulo State Research Foundation (São Paulo, São Paulo, Brazil, # 2011/14872-4;2013/01072-5). Conflicts of interest: Authors declare no conflict of interest. All participants received Colgate Total toothpaste (attributed to Colgate Palmolive Co., São Paulo, SP, Brazil) for use throughout trial, but it isnot clear if products were donated by the company",non-commercial,26545069,published and unpublished data,2,2,2,2,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,56,Metronidazole and amoxicillin as adjuncts to scaling and root planing for the treatment of type 2 diabetic subjects with periodontitis: 1-year ou,"Miranda TS, Feres M, Perez-Chaparro PJ, Faveri M, Figueiredo LC, Tamashiro NS, Bastos MF, Duarte PM.",J Clin Periodontol. 2014 Sep;41(9):890-9. doi: 10.1111/jcpe.12282. Epub 2014 Jul 17.,Miranda TS,2014,8,2,0.3199871027,1,From Cochrane:Number randomised: 58 (Gp A: n = 29; Gp B: n = 29) Number evaluated: 56 (Gp A: n = 29; Gp B: n= 27 - 2 did not attend baseline visit),26545069,,,Treatment of periodontal disease for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2015 Nov 6;2015(11):CD004714. doi: 10.1002/14651858.CD004714.pub3.,Simpson TC,2015,8.49,2.17,29,9.07,1.69,27,0.314224851,0.0420072545,0,0,,post,-0.58,0.2681573436,0,1
24957785,8,0,Multi-countr,Funding: commercial funding (Sanofi),commercial,33166419,published data only,2,2,1,2,1,2,,0,,1,2,1,2,,0,,,,,,,,,,2,2,2,2,,2,,,,,,,701,Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in ins,"Home PD, Bolli GB, Mathieu C, Deerochanawong C, Landgraf W, Candelas C, Pilorget V, Dain MP, Riddle MC.",Diabetes Obes Metab. 2015 Jan;17(1):15-22. doi: 10.1111/dom.12329. Epub 2014 Jul 12.,Home PD,2015,9,2,0.5463425343,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Home reports: The efficacy population (n=701) had a mean age of 57 years,",33166419,,,(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Nov 9;11(11):CD005613. doi: 10.1002/14651858.CD005613.pub4.,Semlitsch T,2020,7.88,0.7903,694,8,0.7451,347,0.0732894872,0.0022112978,0,0,,dif,-0.1,0.0037844769,0,1
24965218,3,0,Malaysia,Funding source: 2 research grants from University of Malaya (P0027/2009B and RG/11HTM),non-commercial,35420698,published data only,2,1,0,0,1,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,32,Effect of nonsurgical periodontal therapy verses oral hygiene instructions on type 2 diabetes subjects with chronic periodontitis: a randomised c,"Raman RP, Taiyeb-Ali TB, Chan SP, Chinna K, Vaithilingam RD.",BMC Oral Health. 2014 Jun 25;14:79. doi: 10.1186/1472-6831-14-79.,Raman RP,2014,5,2,0.9651397057,1,From Cochrane:Number randomised: 40; Number evaluated: 32 (Gp A n = 15; Gp B n = 17),26545069,35420698,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,7.0733333,1.1961048,15,7.0705882,1.1888,17,0.0100802678,0.0750408319,0,0,,post,0.0027451,0.1785098642,0,1
25041182,3,0,Greece,"Funding source: Procter and Gamble Hellas (Koulourides 2011 Award for Dental Research, Greece). Conflicts of interest: Authors declare no conflict of interests",commercial,26545069,published data only,2,0,2,2,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,66,"Effects of doxycycline on clinical, microbiological and immunological parameters in well-controlled diabetes type-2 patients with periodontal dis","Tsalikis L, Sakellari D, Dagalis P, Boura P, Konstantinidis A.",J Clin Periodontol. 2014 Oct;41(10):972-80. doi: 10.1111/jcpe.12287. Epub 2014 Sep 3.,Tsalikis L,2014,5,2,0.9548992145,1,From Cochrane:Number randomised: 70; Number evaluated: 66 (Gp A: 31; Gp B: 35),26545069,,,Treatment of periodontal disease for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2015 Nov 6;2015(11):CD004714. doi: 10.1002/14651858.CD004714.pub3.,Simpson TC,2015,6.62,0.55,31,6.96,1.01,35,-0.555552941,0.0331851662,0,1,3,post,-0.34,0.0389037788,0,1
25041182,6,0,Greece,"Funding source: Procter and Gamble Hellas (Koulourides 2011 Award for Dental Research, Greece). Conflicts of interest: Authors declare no conflict of interests",commercial,26545069,published data only,2,0,2,2,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,66,"Effects of doxycycline on clinical, microbiological and immunological parameters in well-controlled diabetes type-2 patients with periodontal dis","Tsalikis L, Sakellari D, Dagalis P, Boura P, Konstantinidis A.",J Clin Periodontol. 2014 Oct;41(10):972-80. doi: 10.1111/jcpe.12287. Epub 2014 Sep 3.,Tsalikis L,2014,5,2,0.9548992145,1,From Cochrane:Number randomised: 70; Number evaluated: 66 (Gp A: 31; Gp B: 35),26545069,,,Treatment of periodontal disease for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2015 Nov 6;2015(11):CD004714. doi: 10.1002/14651858.CD004714.pub3.,Simpson TC,2015,6.48,0.71,31,6.8,0.87,35,-0.153025144,0.0332157611,0,0,,post,-0.32,0.0378870046,0,1
25222105,3,0,China,"Cochrane does not appear to report on funding sources or conflict of interest -This study was jointly supported by Science and Technology Program of Guangdong Province, China (grant number 2006B36005013).",non-commercial,28236296,published data only,2,0,0,1,,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,83,Intensive low-glycaemic-load dietary intervention for the management of glycaemia and serum lipids among women with gestational diabetes: a rando,"Ma WJ, Huang ZH, Huang BX, Qi BH, Zhang YJ, Xiao BX, Li YH, Chen L, Zhu HL.",Public Health Nutr. 2015 Jun;18(8):1506-13. doi: 10.1017/S1368980014001992. Epub 2014 Sep 15.,Ma WJ,2015,9,2,0.2371566314,1,From Cochrane: 95 women.,28236296,,,Different types of dietary advice for women with gestational diabetes mellitus,Cochrane Database Syst Rev. 2017 Feb 25;2(2):CD009275. doi: 10.1002/14651858.CD009275.pub3.,Han S,2017,5.68,0.54,41,5.67,0.28,42,0.6552411068,0.0255836015,0,1,4,post,0.01,0.0089788618,0,1
25819531,6,0,Canada,Funding: commercial funding (Sanofi Canada),commercial,33166419,published data only,1,1,,,,1,,0,,,,,1,,0,,,,,,,,,,,,,1,,1,,,,,,,66,Replacing Insulin Glargine with Neutral Protamine Hagedorn (NPH) Insulin in a Subpopulation of Study Subjects in the Action to Control Cardiovasc,"Berard L, Cameron B, Woo V, Stewart J.",Can J Diabetes. 2015 Aug;39(4):296-301. doi: 10.1016/j.jcjd.2014.12.008. Epub 2015 Mar 24.,Berard L,2015,4,2,0.9569651423,1,"Characteristics of included studies in Cochrane review does not report on number randomized; Berard reports: A single-site, open-label, randomized, 6-month comparative study of 66 patients",33166419,,,(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Nov 9;11(11):CD005613. doi: 10.1002/14651858.CD005613.pub4.,Semlitsch T,2020,,,32,,,24,,,0,,,dif,-0.33,0.0200472426,0,0
26039911,6,0,Brazil,"Funding source: ""supported by the Fundação de Amparo à Pesquisa do Estado de SãoPaulo – FAPESP,São Paulo, Brazil, under protocol numbers 2011/06982-4;10057-4;18618-5""",non-commercial,35420698,published data only,2,2,0,0,2,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,24,Supragingival biofilm control and systemic inflammation in patients with type 2 diabetes mellitus,"Artese HP, Longo PL, Gomes GH, Mayer MP, Romito GA.",Braz Oral Res. 2015;29:S1806-83242015000100266. doi: 10.1590/1807-3107BOR-2015.vol29.0071.,Artese HP,2015,5,2,0.6980718718,1,From Cochrane:Number randomised: 24; Number evaluated: 24 at 6 mths,35420698,,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,8.13,1.79,12,8.93,1.9,12,0.0340836031,0.1070009247,0,0,,post,-0.8,0.5678416667,0,1
26055391,6,1,Germany,Funding: commercial funding (Sanofi),commercial,33166419,published data only,1,2,1,2,,2,0,0,,1,2,,2,0,0,,,,,,,,,,2,2,,2,1,2,,,,,,,339,Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs. intermediate-acting basal insulin therapy in com,"Hermanns N, Kulzer B, Kohlmann T, Jacob S, Landgraf W, Theobald K, Haak T.",Health Qual Life Outcomes. 2015 Jun 9;13:77. doi: 10.1186/s12955-015-0279-4.,Hermanns N,2015,7,2,0.1254020467,1,Characteristics of included studies in Cochrane review does not report on number randomized; Hermanns reports: A total of 343 patients were randomized to either receive insulin glargine (n = 176; sequence A) or neutral protamine Hagedorn (NPH) insulin (n = 167; sequence B) in period 1 (weeks 1–24) and vice versa in period 2 (weeks 25–48).,33166419,,,(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Nov 9;11(11):CD005613. doi: 10.1002/14651858.CD005613.pub4.,Semlitsch T,2020,,,,,,,,,0,,,dif,0,0.0115737805,0,0
26369484,3,0,India,Funding source: none,not reported,35420698,published data only,1,1,0,0,2,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,100,Periodontal and glycemic effects of nonsurgical periodontal therapy in patients with type 2 diabetes stratified by baseline HbA1c,"Kaur PK, Narula SC, Rajput R, K Sharma R, Tewari S.",J Oral Sci. 2015 Sep;57(3):201-11. doi: 10.2334/josnusd.57.201.,Kaur PK,2015,5,2,0.8524677563,1,"From Cochrane:Number randomised: 100; Number evaluated: 3 mths 100, 6 mths 100",35420698,,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,7.49,1.83,50,7.96,2.65,50,-0.3088721,0.0242383697,0,0,,post,-0.47,0.207428,0,1
26369484,6,0,India,Funding source: none,not reported,35420698,published data only,1,1,0,0,2,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,100,Periodontal and glycemic effects of nonsurgical periodontal therapy in patients with type 2 diabetes stratified by baseline HbA1c,"Kaur PK, Narula SC, Rajput R, K Sharma R, Tewari S.",J Oral Sci. 2015 Sep;57(3):201-11. doi: 10.2334/josnusd.57.201.,Kaur PK,2015,5,2,0.8524677563,1,"From Cochrane:Number randomised: 100; Number evaluated: 3 mths 100, 6 mths 100",35420698,,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,7.29,1.61,50,8.06,2.72,50,-0.423336587,0.0240809311,0,0,,post,-0.77,0.19981,0,1
27245786,3,0,Australia,Funding source: the Perio-Cardio study was funded by the National Health and Medical Research Council: Project grant #627100. MRS is supported by a Future Leader Fellowship from the National Heart Foundation of Australia #100419. KK received a University of Adelaide Divisional Scholarship to participate in this research,non-commercial,35420698,published data only,2,2,0,0,0,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,62,Periodontal therapy and glycaemic control among individuals with type 2 diabetes: reflections from the PerioCardio study,"Kapellas K, Mejia G, Bartold PM, Skilton MR, Maple-Brown LJ, Slade GD, O'Dea K, Brown A, Celermajer DS, Jamieson LM.",Int J Dent Hyg. 2017 Nov;15(4):e42-e51. doi: 10.1111/idh.12234. Epub 2016 Jun 1.,Kapellas K,2017,10,2,0.1233291333,1,"From Cochrane:Number randomised: 62 (Gp A 35, Gp B 27); Number evaluated: 44 at 3 mths (Gp A 24, Gp B 20)",35420698,,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,8.2,4.2,24,7.39,3.85,20,-0.020251843,0.0750386704,0,0,,post,0.81,1.476125,0,1
28836285,6,0,China,Funding source: none,not reported,35420698,published data only,1,1,0,0,2,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,18,Periodontal treatment modulates gene expression of endothelial progenitor cells in diabetic patients,"Wang Y, Liu HN, Zhen Z, Yiu KH, Tse HF, Pelekos G, Tonetti M, Jin L.",J Clin Periodontol. 2017 Dec;44(12):1253-1263. doi: 10.1111/jcpe.12806. Epub 2017 Oct 24.,Wang Y,2017,8,2,0.0820959848,1,From Cochrane:Number randomised: 18 (from 41 recruits); Number evaluated: 18 at 6 mths,35420698,,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,8.81,1.06,11,8.35,1.37,6,-0.358582452,0.1808135608,0,0,,post,0.46,0.4149621212,0,1
28923465,6,0,Multi-countr,"Funding: the trial was funded by Juvenile Diabetes Research Foundation (JDRF) grants #17-2011-533,and grants under the JDRF Canadian Clinical Trial Network, a public-private partnership including JDRF and FedDev Ontario and supported by JDRF #80-2010-585. Metronic supplied the CGM sensors and CGM systems at reduced cost. HRM conducts independent research supported by the National Institute for Health Research (Career Development Fellowship, CDF-2013-06-035), and is supported by Tommy’s charity. The funders had no role in the trial design, data collection, data analysis, or data interpretation. Declarations of interest: 8 authors report grants from the Juvenile Diabetes Research Foundation during the conduct of the study. Two authors report personal fees from Novo Nordisk, Roche and Medtronic, outside the submitted work. 1 author reports personal fees from Abbott Diabetes Care and Medtronic (MiniMed Academia), outside the submitted work. 1 author sits",non-commercial,31120549,published data only,2,2,2,2,,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,325,Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial,"Feig DS, Donovan LE, Corcoy R, Murphy KE, Amiel SA, Hunt KF, Asztalos E, Barrett JFR, Sanchez JJ, de Leiva A, Hod M, Jovanovic L, Keely E, McManus R, Hutton EK, Meek CL, Stewart ZA, Wysocki T, O'Brien R, Ruedy K, Kollman C, Tomlinson G, Murphy HR; CONCEPTT Collaborative Group.",Lancet. 2017 Nov 25;390(10110):2347-2359. doi: 10.1016/S0140-6736(17)32400-5. Epub 2017 Sep 15.,Feig DS,2017,23,2,0.5432889003,1,"from cochrane: Number randomised: 325 (215 pregnant, 110 planning pregnancy). Baseline assessment only entered for pregnant",31120549,,,Techniques of monitoring blood glucose during pregnancy for women with pre-existing diabetes,Cochrane Database Syst Rev. 2019 May 23;5(5):CD009613. doi: 10.1002/14651858.CD009613.pub4.,Jones LV,2019,6.35,0.57,108,6.53,0.7,108,-0.177475947,0.0096141546,0,0,,post,-0.18,0.0075453704,0,1
29145468,3,0,Japan,"Funder: Japanese Ministry of Health, Labour and Welfare grant number 25110601",non-commercial,35420698,published data only,2,1,0,0,2,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,37,"The effects of non-surgical periodontal treatment on glycemic control, oxidative stress balance and quality of life in patients with type 2 diabe","Mizuno H, Ekuni D, Maruyama T, Kataoka K, Yoneda T, Fukuhara D, Sugiura Y, Tomofuji T, Wada J, Morita M.",PLoS One. 2017 Nov 16;12(11):e0188171. doi: 10.1371/journal.pone.0188171. eCollection 2017.,Mizuno H,2017,10,2,0.334926312,1,"From Cochrane:Number randomised: 40; Number evaluated: at 3 mths 37 (Gp A 20, Gp B 17) (complete data for 31: Gp A 17, Gp B 14); at 6 mths 28 (Gp A 15, Gp B 13)",35420698,,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,7.37,1.433472,20,7.6941176,1.1019702,17,0.3007615252,0.0640046312,0,0,,post,-0.3241176,0.1741737647,0,1
29145468,6,0,Japan,"Funder: Japanese Ministry of Health, Labour and Welfare grant number 25110601",non-commercial,35420698,published data only,2,1,0,0,2,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,37,"The effects of non-surgical periodontal treatment on glycemic control, oxidative stress balance and quality of life in patients with type 2 diabe","Mizuno H, Ekuni D, Maruyama T, Kataoka K, Yoneda T, Fukuhara D, Sugiura Y, Tomofuji T, Wada J, Morita M.",PLoS One. 2017 Nov 16;12(11):e0188171. doi: 10.1371/journal.pone.0188171. eCollection 2017.,Mizuno H,2017,10,2,0.334926312,1,"From Cochrane:Number randomised: 40; Number evaluated: at 3 mths 37 (Gp A 20, Gp B 17) (complete data for 31: Gp A 17, Gp B 14); at 6 mths 28 (Gp A 15, Gp B 13)",35420698,,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,7.44,1.2783213,20,7.6470588,1.0977919,17,0.1746310868,0.0635941189,0,0,,post,-0.2070588,0.1525962706,0,1
29185604,3,0,China,Funding source: Xiamen Health Bureau (grant number: WSK 2012-01) and the National Institute of Hospital Administration (the hierarchical medical treatment policy in diabetes project),non-commercial,35420698,published data only,2,2,0,0,0,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,39,Glycemic control and adipokines after periodontal therapy in patients with Type 2 diabetes and chronic periodontitis,"Wang S, Liu J, Zhang J, Lin J, Yang S, Yao J, Du M.",Braz Oral Res. 2017 Nov 27;31:e90. doi: 10.1590/1807-3107BOR-2017.vol31.0090.,Wang S,2017,7,2,0.1684563833,1,"From Cochrane:Number randomised: 44;Number evaluated: at 3 mths Gp A = 19, Gp B = 20",35420698,,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,6.99,0.77,19,7.41,1.32,20,-0.478710637,0.0592485981,0,0,,post,-0.42,0.1183252632,0,1
29265454,6,0,Spain,Funding source: partially funded by a research grant from SEPA and by a research grant from the University of Barcelona,non-commercial,35420698,published data only,2,1,0,0,2,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,90,Benefits of non-surgical periodontal treatment in patients with type 2 diabetes mellitus and chronic periodontitis: A randomized controlled trial,"Mauri-Obradors E, Merlos A, Estrugo-Devesa A, Jané-Salas E, López-López J, Viñas M.",J Clin Periodontol. 2018 Mar;45(3):345-353. doi: 10.1111/jcpe.12858. Epub 2018 Jan 19.,Mauri-Obradors E,2018,6,2,0.4750552091,1,"From Cochrane:Number randomised: 90; Number evaluated: 80 at 3 mths, 79 at 6 mths",35420698,,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,7.2085714,0.8692023,35,7.7613636,1.1089941,44,-0.166643245,0.0279163466,0,0,,post,-0.5527922,0.0495376189,0,1
29482543,3,0,Cameroon,Funding source: none,not reported,35420698,published data only,1,1,0,0,2,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,30,Effects of nonsurgical periodontal treatment on glycated haemoglobin on type 2 diabetes patients (PARODIA 1 study): a randomized controlled trial,"Tsobgny-Tsague NF, Lontchi-Yimagou E, Nana ARN, Tankeu AT, Katte JC, Dehayem MY, Bengondo CM, Sobngwi E.",BMC Oral Health. 2018 Feb 26;18(1):28. doi: 10.1186/s12903-018-0479-5.,Tsobgny-Tsague N,2018,8,2,0.2579746739,1,From Cochrane:Number randomised: 34; Number evaluated: 30 at 3 mths (evaluations also at 6 wks),35420698,,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,6.7333333,1.9092507,15,8.12,2.5481646,15,-0.100800062,0.0884919036,0,0,,post,-1.3866667,0.6758920709,0,1
30136741,3,0,France,Funding source: French Ministry of Health Clinical Research Program 2008. Equipment by Acteon Group and Oral–B France endowment for part–time staff.,both,35420698,published data only,1,1,0,0,0,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,91,The effects of periodontal treatment on diabetic patients: The DIAPERIO randomized controlled trial,"Vergnes JN, Canceill T, Vinel A, Laurencin-Dalicieux S, Maupas-Schwalm F, Blasco-Baqué V, Hanaire H, Arrivé E, Rigalleau V, Nabet C, Sixou M, Gourdy P, Monsarrat P; DIAPERIO Group.",J Clin Periodontol. 2018 Oct;45(10):1150-1163. doi: 10.1111/jcpe.13003. Epub 2018 Sep 14.,Vergnes JN,2018,13,2,0.1650150736,1,"From Cochrane:Number randomised: 91 (T1DM = 67, T2DM = 24) Number evaluated: 88 at 3 mths (T1DM = 65, T2DM = 23)",35420698,,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,7.86,0.73,44,7.77,0.66,44,0.0892722268,0.0241567018,0,0,,post,0.09,0.0220113636,0,1
30472992,6,0,UK,Funding source: Diabetes UK and UK NIHR,non-commercial,35420698,published data only,2,1,0,0,0,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,264,"Systemic effects of periodontitis treatment in patients with type 2 diabetes: a 12 month, single-centre, investigator-masked, randomised trial","D'Aiuto F, Gkranias N, Bhowruth D, Khan T, Orlandi M, Suvan J, Masi S, Tsakos G, Hurel S, Hingorani AD, Donos N, Deanfield JE; TASTE Group.",Lancet Diabetes Endocrinol. 2018 Dec;6(12):954-965. doi: 10.1016/S2213-8587(18)30038-X. Epub 2018 Oct 24.,D'Aiuto F,2018,12,2,0.1162746825,1,"From Cochrane:Number randomised: 264; Number evaluated: 264 at 2, 6, and 12 mths",35420698,,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,8,2.29,131,8.1,2.31,133,0.0037780977,0.0089296943,0,0,,post,-0.1,0.0801523503,0,1
30472992,12,0,UK,Funding source: Diabetes UK and UK NIHR,non-commercial,35420698,published data only,2,1,0,0,0,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,264,"Systemic effects of periodontitis treatment in patients with type 2 diabetes: a 12 month, single-centre, investigator-masked, randomised trial","D'Aiuto F, Gkranias N, Bhowruth D, Khan T, Orlandi M, Suvan J, Masi S, Tsakos G, Hurel S, Hingorani AD, Donos N, Deanfield JE; TASTE Group.",Lancet Diabetes Endocrinol. 2018 Dec;6(12):954-965. doi: 10.1016/S2213-8587(18)30038-X. Epub 2018 Oct 24.,D'Aiuto F,2018,12,2,0.1162746825,1,"From Cochrane:Number randomised: 264; Number evaluated: 264 at 2, 6, and 12 mths",35420698,,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,7.8,2.29,131,8.3,2.31,133,0.0534565574,0.0089330701,0,0,,post,-0.5,0.0801523503,0,1
31383366,6,0.68,Brazil,Funding: non-commercially (University of Sao Paulo General Hospital),non-commercial,33166419,published data only,1,1,1,2,1,1,,0,,1,2,1,1,,0,,,,,,,,,,2,2,2,2,,2,,,,,,,34,Insulin Glargine U100 Improved Glycemic Control and Reduced Nocturnal Hypoglycemia in Patients with Type 2 Diabetes Mellitus and Chronic Kidney D,"Betônico CC, Titan SMO, Lira A, Pelaes TS, Correa-Giannella MLC, Nery M, Queiroz M.",Clin Ther. 2019 Oct;41(10):2008-2020.e3. doi: 10.1016/j.clinthera.2019.07.011. Epub 2019 Aug 2.,Betônico CC,2019,7,2,0.4644160857,1,Characteristics of included studies in Cochrane review does not report on number randomized; Betonico reports: Thirty-four patients were randomly assigned to glargine U100 or NPH insulin after a 2- way crossover open-label design.,33166419,,,(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus,Cochrane Database Syst Rev. 2020 Nov 9;11(11):CD005613. doi: 10.1002/14651858.CD005613.pub4.,Semlitsch T,2020,7.95,1.07,31,8.47,1.32,29,-0.146508084,0.0234513459,0,0,,dif,-1.14,0.0282133333,0,1
31834660,3,0,Egypt,Funding source: “funded by the authors”,not reported,35420698,published data only,2,1,0,0,2,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,88,The effects of non-surgical periodontal therapy on glycemic control in diabetic patients: A randomized controlled trial,"El-Makaky Y, Shalaby HK.",Oral Dis. 2020 May;26(4):822-829. doi: 10.1111/odi.13256. Epub 2020 Feb 27.,El-Makaky Y,2020,2,2,0.0016499571,1,From Cochrane:Number randomised: total 88 (44 per gp) Number evaluated: 88 at 3 mths (44 per gp),35420698,,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,7.27,0.5,44,8.34,0.64,44,-0.109539986,0.0240380007,0,0,,post,-1.07,0.0149909091,0,1
32381843,3.01,0,India,Funding source: nil,not reported,35420698,published data only,1,1,0,0,1,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,51,Adjunctive Effect of Doxycycline with Conventional Periodontal Therapy on Glycemic Level for Chronic Periodontitis with Type 2 Diabetes Mellitus,"Das AC, Das SJ, Panda S, Sharma D, Taschieri S, Fabbro MD.",J Contemp Dent Pract. 2019 Dec 1;20(12):1417-1423.,Das AC,2019,6,3,0.9986959923,1,From Cochrane:Number randomised: total 51 (17 per gp);Number evaluated: 51 at 3 mths (17 per gp),35420698,,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,6.9705882,0.8636874,17,8.4117647,0.9026921,17,0.1436482205,0.0679873826,0,0,,post,-1.4411765,0.0918122913,1,1
32381843,3.02,0,India,Funding source: nil,not reported,35420698,published data only,1,1,0,0,1,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,51,Adjunctive Effect of Doxycycline with Conventional Periodontal Therapy on Glycemic Level for Chronic Periodontitis with Type 2 Diabetes Mellitus,"Das AC, Das SJ, Panda S, Sharma D, Taschieri S, Fabbro MD.",J Contemp Dent Pract. 2019 Dec 1;20(12):1417-1423.,Das AC,2019,6,3,0.9986959923,1,From Cochrane:Number randomised: total 51 (17 per gp);Number evaluated: 51 at 3 mths (17 per gp),35420698,,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,7.4882353,1.1351665,17,8.4117647,0.9026921,17,0.3451140281,0.0684366065,0,0,,post,-0.9235294,0.1237327065,0,1
32395387,3,0,South Korea,"Funding source: supported by the Health Promotion Fund, Ministry of Health and Welfare, Republic of Korea (#13-15)",non-commercial,35420698,published data only,1,1,0,0,1,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,60,Efficacy of non-surgical treatment accompanied by professional toothbrushing in the treatment of chronic periodontitis in patients with type 2 di,"Lee JY, Choi YY, Choi Y, Jin BH.",J Periodontal Implant Sci. 2020 Apr 23;50(2):83-96. doi: 10.5051/jpis.2020.50.2.83. eCollection 2020 Apr.,Lee JY,2020,4,3,0.0054611178,1,From Cochrane:Number randomised: 75 (25 per gp); Number evaluated: 60 at 3 mths (20 per gp),35420698,,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,6.45,0.34119,40,6.98,0.51,20,-0.336399221,0.0411869984,0,0,,post,-0.53,0.0159152654,0,1
33804123,6,0,Italy,Funding source: no external funding,not reported,35420698,published data only,2,1,0,0,1,,,,,,,,,,,,,,,,,,,,2,,,,,,,,,,,,180,Inflammatory Status and Glycemic Control Level of Patients with Type 2 Diabetes and Periodontitis: A Randomized Clinical Trial,"Rapone B, Ferrara E, Corsalini M, Qorri E, Converti I, Lorusso F, Delvecchio M, Gnoni A, Scacco S, Scarano A.",Int J Environ Res Public Health. 2021 Mar 15;18(6):3018. doi: 10.3390/ijerph18063018.,Rapone B,2021,10,2,1,1,"From Cochrane:Number randomised: total 187 (Gp A 93, Gp B 94);Number evaluated: 6 mths 180 (90 per group)",35420698,,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,7.2,0.95,90,7.3,0.95,90,,,0,,,post,-0.1,0.0200555556,0,0
33980234,3.01,0,Pakistan,Funding source: Higher Education Commission of Pakistan through their National Research Program for Universities (NRPU) Grants [Grant No.: 7143] Research protocol registered with the Protocol Registration and Results System at ClinicalTrials.gov (NCT 03343366) on 17 November 2017,non-commercial,35420698,published data only,2,2,0,0,2,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,150,Clinical efficacy of scaling and root planing with and without metronidazole on glycemic control: three-arm randomized controlled trial,"Qureshi A, Bokhari SAH, Haque Z, Baloch AA, Zaheer S.",BMC Oral Health. 2021 May 12;21(1):253. doi: 10.1186/s12903-021-01620-1.,Qureshi A,2021,5,3,0.0495495105,1,From Cochrane:Number randomised: 150; Number evaluated: 97 at 3 mths; 74 at 6 mths,35420698,,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,7.80333,1.25582,24,9.03125,1.2315,24,0.1655438248,0.0472234074,0,0,,post,-1.22792,0.1289031718,0,1
33980234,3.02,0,Pakistan,Funding source: Higher Education Commission of Pakistan through their National Research Program for Universities (NRPU) Grants [Grant No.: 7143] Research protocol registered with the Protocol Registration and Results System at ClinicalTrials.gov (NCT 03343366) on 17 November 2017,non-commercial,35420698,published data only,2,2,0,0,2,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,150,Clinical efficacy of scaling and root planing with and without metronidazole on glycemic control: three-arm randomized controlled trial,"Qureshi A, Bokhari SAH, Haque Z, Baloch AA, Zaheer S.",BMC Oral Health. 2021 May 12;21(1):253. doi: 10.1186/s12903-021-01620-1.,Qureshi A,2021,5,3,0.0495495105,1,From Cochrane:Number randomised: 150; Number evaluated: 97 at 3 mths; 74 at 6 mths,35420698,,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,8.05115,1.29318,26,9.03125,1.2315,24,0.1618993207,0.0452521204,0,0,,post,-0.9801,0.1275111327,0,1
33980234,6.01,0,Pakistan,Funding source: Higher Education Commission of Pakistan through their National Research Program for Universities (NRPU) Grants [Grant No.: 7143] Research protocol registered with the Protocol Registration and Results System at ClinicalTrials.gov (NCT 03343366) on 17 November 2017,non-commercial,35420698,published data only,2,2,0,0,2,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,150,Clinical efficacy of scaling and root planing with and without metronidazole on glycemic control: three-arm randomized controlled trial,"Qureshi A, Bokhari SAH, Haque Z, Baloch AA, Zaheer S.",BMC Oral Health. 2021 May 12;21(1):253. doi: 10.1186/s12903-021-01620-1.,Qureshi A,2021,5,3,0.0495495105,1,From Cochrane:Number randomised: 150; Number evaluated: 97 at 3 mths; 74 at 6 mths,35420698,,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,7.47125,1.19996,24,9.65792,1.85995,24,-0.18131014,0.0479905519,0,0,,post,-2.18667,0.2041382502,1,1
33980234,6.02,0,Pakistan,Funding source: Higher Education Commission of Pakistan through their National Research Program for Universities (NRPU) Grants [Grant No.: 7143] Research protocol registered with the Protocol Registration and Results System at ClinicalTrials.gov (NCT 03343366) on 17 November 2017,non-commercial,35420698,published data only,2,2,0,0,2,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,150,Clinical efficacy of scaling and root planing with and without metronidazole on glycemic control: three-arm randomized controlled trial,"Qureshi A, Bokhari SAH, Haque Z, Baloch AA, Zaheer S.",BMC Oral Health. 2021 May 12;21(1):253. doi: 10.1186/s12903-021-01620-1.,Qureshi A,2021,5,3,0.0495495105,1,From Cochrane:Number randomised: 150; Number evaluated: 97 at 3 mths; 74 at 6 mths,35420698,,,Treatment of periodontitis for glycaemic control in people with diabetes mellitus,Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714. doi: 10.1002/14651858.CD004714.pub4.,Simpson TC,2022,7.81731,1.43537,26,9.65792,1.85995,24,-0.049303962,0.0463283855,0,0,,post,-1.84061,0.2233840592,1,1
